Methods and reagents for inducing immunity

ABSTRACT

Methods and reagents for treating tumors, metastases, and infectious lesions by co-administration of antigen presenting cells and immunostimulatory cytokines or nucleic acid encoding an immunostimulatory cytokine into or near the site of the tumor or infectious lesion are described.

RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application Ser. No. 60/418,865, filed Oct. 15, 2002, the entire disclosure of which is incorporated herein by reference.

GOVERNMENT LICENSE RIGHTS

[0002] Certain work described herein was supported, in part, by Federal Grant No. PO1 CA59371, awarded by the National Cancer Institute of the National Institutes of Health. The Government may have certain rights in the invention.

FIELD OF THE INVENTION

[0003] The invention is directed to the field of immunology. In particular, the invention is directed to the use of co-administration of antigen presenting cells and immunostimulatory cytokines to treat tumors or infections.

BACKGROUND OF THE INVENTION

[0004] Antigen presenting cells (APCs), such as dendritic cells, perform a number of closely linked functions that result in the activation of T lymphocytes, including antigen processing, during which large antigen moieties, cells or proteins are degraded to fragments more recognizable by T cells. (Steinman (1991) Annu. Rev. Immunol. 9:271-296; Macatonia et al. (1989) J. Exp. Med. 169:1255-1264). For example, activated dendritic cells take up soluble antigen and apoptotic bodies, migrate to the paracortical T cell-rich areas of lymph nodes, and initiate a series of interactions leading to the selection of antigen-specific T cells and the release of the dendritic cell cytokines interferon-α (IFN-α) and interleukin-12 (IL-12).

[0005] Administration of dendritic cells pulsed with synthetic tumor-associated peptides have been used as therapeutic anti-tumor vaccines to induce an anti-tumor immune response in vitro and in mice following adoptive transfer (Mayordomo et al. (1995) Nature Med. 1: 1297-1302; Zitvogel et al. (1996) J. Exp. Med. 183:87-97; Porgador and Gilboa (1995) J. Exp. Med. 182:255-260; Porgador et al. (1996) J. Immunol. 156:2918-2926). However, tumor-associated antigens have been identified for only a limited number of human tumors. Several approaches to overcoming this problem, including pulsing dendritic cells with acid-eluted bulk tumor peptides (Zitvogel et al. (1996) supra), tumor extracts and RNA (Flamand et al. (1994) Eur. J. Immunol. 24:605-610; Ashley et al. (1997) J. Exp. Med. 186:1177-1182; Boczkowski et al. (1996) J. Exp. Med. 184:465-472), or fusing of tumor cells with dendritic cells (Gong et al. (1997) Nature Med. 3:558-561), have been employed in dendritic cell-based vaccination strategies against tumors. However, the preparation of clinical samples from human solid tumors is time consuming and problematic. For example, tumor samples are not always available or in an accessible location in the body for obtaining a surgical biopsy. In addition, the technical expertise for obtaining, maintaining and processing such tumor samples may not be available at certain medical centers. Further, handling of a tumor sample ex vivo may introduce contamination into the tumor sample. Still further, the full repertoire of natural effector cells, e.g., DCs, natural killer (NK) cells and T cells, and cytokines recruited from the host that participate in the activation of the DCs may not be available to the full extent or in the appropriate signaling sequence or concentration as is found in vivo and simulating such events ex vivo is cumbersome.

[0006] Immunostimulatory cytokines have also been used as therapeutics for eliciting or regulating an immune response. For example, interleukin 18 (IL-18) induces the synthesis of high levels of IFN-γ by natural killer (NK), T cells, B cells, and cells of the monocyte lineage (Okamura et al. (1995a) Nature 378: 88-91; Okamura et al. (1995b) Infect. Immun. 63:3966-72). IL-18 also plays an important role in T cell proliferation (Okamura et al. (1995a) supra), cytotoxic T lymphocyte (CTL) activation (Okamoto et al. (1999) J. Immunol. 162: 3202-11) and enhancement of NK cell activity (Okamura et al. (1995b) supra; Dao et al. (1998) J. Immunol. 161: 2217-22; Hashimoto et al. (1999) J. Immunol. 163: 583-9). IL-18 also induces Th2 cytokines, including IL-13, IL-4, and IL-10, in synergy with IL-2 (Hoshino et al. (1999) J. Immunol. 162: 5070-7; Hoshino et al. (2000) Eur. J. Immunol. 30: 1998-2006; Leite-De-Moraes et al. (2001) J. Immunol. 166: 945-51). Systemic administration of recombinant IL-18 (rIL-18) is associated with significant in vivo anti-tumor effects which appears to be mediated by NK cells as primary effector cells (Osaki et al. (1998) J. Immunol. 160: 1742-49; Micallef et al. (1997) Cancer Immunol. Immunother. 43: 361-67). Further, established subcutaneous tumors can be successfully treated by intratumoral (i.t.) injection of recombinant adenoviral vectors expressing biologically active mIL-18 (Ad.PTH.IL-18) (Osaki et al. (1999) Gene Ther. 6: 808-15). However, administration of such immunostimulatory cytokines alone result in only a modest biological response and high dosages are often needed to produce an effect in an animal, which may be toxic or produce deleterious side effects. A need therefore remains for more effective and safe therapies that can elicit a strong immune response against specific tumor-associated antigens or pathogens.

SUMMARY OF THE INVENTION

[0007] The instant invention relates to methods and reagents for treating a tumor or infection by administering an immunostimulatory cytokine, or a nucleic acid encoding an immunostimulatory cytokine, in combination with antigen presenting cells into or near a tumor or infectious lesion. In a preferred embodiment, the invention relates to the anti-tumor effects associated with intratumor (i.t.) injection of an IL-18-expressing adenovirus in combination with dendritic cells. Intratumor injection of a combination of IL-18-expressing adenovirus and dendritic cells was associated with potent anti-tumor effects not only on the treated tumor lesion but also on distant lesions (e.g., metastases).

[0008] In one aspect, the invention provides methods for preventing or treating a primary tumor. In another aspect, the invention provides methods for preventing or treating a metastasis. In yet another aspect, the invention provides methods for preventing or treating an infection. The method comprises administering to a subject an effective amount of an antigen presenting cell and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine. In an embodiment, the nucleic acid is operatively linked to an expression vector. The methods of the invention can be used to stop tumor growth or to reduce tumor size. The methods of the invention can also be used to inhibit or neutralize an infectious pathogen. In a preferred embodiment, the tumor or infectious lesion is injected, and the size of the tumor or infectious lesion, or other indicia of the tumor or infectious lesion, is monitored. In another embodiment, a subject is injected with antigen presenting cells and a cytokine or cytokine nucleic acid at a site adjacent the tumor or infectious lesion, e.g., within the same organ site of the tumor or infectious lesion.

[0009] In still another aspect, the invention provides reagents for inhibiting or treating tumor growth, metastasis, or infection. A therapeutic composition comprising an antigen presenting cell combined with an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine is provided. The antigen presenting cell and immunostimulatory cytokine or nucleic acid encoding an immunostimulatory cytokine may be administered together as an admixture or may be administered separately or sequentially.

[0010] In an embodiment, the antigen presenting cell is a dendritic cell. Exemplary dendritic cells are CD34+-derived dendritic cells, bone marrow-derived dendritic cells, monocyte-derived dendritic cells, splenocyte derived dendritic cells, skin-derived dendritic cells, follicular dendritic cells, and germinal center dendritic cells, for example. The dendritic cell may be, for example, a CD34+-derived dendritic cell cultured in the presence of granulocyte colony stimulating factor, granulocyte macrophage colony stimulatory factor, tumor necrosis factor α, interleukin 4, the Flt-3 ligand, and/or the kit ligand. In another embodiment, the antigen presenting cell is a Langherhans' cell, an interdigitating cell, a B cell, or a macrophage, or other cell that presents antigen and synthesizes the appropriate co-stimulatory molecules (e.g., cytokines).

[0011] In an embodiment, the immunostimulatory cytokine is interleukin-1α (IL-1α or IL-1f1), interleukin-1β (IL-1β or IL-1f2), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-12 (IL-12), other members of the IL-12 family, (e.g., IL-23, and IL-27), interleukin-18 (IL-18 or IL-1f4), interleukin-19 (IL-19), interleukin-20 (IL-20), other IL-1 family members, such as IL-1f3, IL-1 f5, IL-1 f6, IL-1f7, IL-1f8, IL-1f9, and IL-1f10; interferon-α (INF-α), interferon-β (IFN-β), interferon-γ (IFN-γ), tumor necrosis factor α (TNFα), transforming growth factor-β (TGFβ), granulocyte colony stimulating factor (GCSF), macrophage colony stimulating factor (MCSF), granulocyte-macrophage colony stimulating factor (GMCSF), the Flt-3 ligand, or the kit ligand, for example. In a preferred embodiment, the cytokine is interleukin-18, however any factor or cytokine made by a cell acting on another cell to elicit an immune response may be used.

[0012] In an embodiment, the expression vector used in the methods of the invention is a viral vector, such as, for example, an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a herpes virus, a vaccinia virus, lentivirus, etc., or other exogenous plasmid.

[0013] The methods of the invention may be used to treat melanoma, hepatoma, adenocarcinoma, colorectal cancer, basal cell cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, bladder cancer, head and neck cancer, renal cell cancer, pancreatic cancer, pulmonary cancer, cervical cancer, ovarian cancer, esophageal cancer, gastric cancer, prostate cancer, testicular cancer, or breast cancer, for example.

[0014] The methods of the invention may also be used to treat an infection caused by a pathogen such as a virus, bacteria, parasite, prion, yeast, or fungus, for example.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The foregoing and other objects, features and advantages of the present invention, as well as the invention itself, will be more fully understood from the following description of preferred embodiments when read together with the accompanying drawings, in which:

[0016]FIG. 1 shows that intratumoral (i.t.) injection of Ad.PTH.IL-18 inhibited the growth of MCA205 tumors in wild type (WT) mice, but not in gld mice, and in turn enhanced CTL activity. FIG. 1 (A and B) shows the anti-tumor effects of Ad.PTH.IL-18 injection alone. WT mice and gld mice (five mice per group) received 1×10⁵ of MCA205 cells i.d. inoculation in the right flank on day 0. The animals were treated by i.t. injection of HBSS, Ad.EGFP, or Ad.PTH.IL-18 on day 7 and day 10. Data represent the mean±S.D. of tumor area. The i.t. injection of Ad.PTH.IL-18 was associated with a significant anti-tumor effect in WT animals (p=0.003; WT/Ad.PTH.IL-18 vs. WT/Ad.EGFP,p=0.003; WT/Ad.PTH.IL-18 vs WT/HBSS) (A), but not in gld mice (>0.05; gld/Ad.PTH.IL-18 vs gld/Ad.EGFP or gld/HBSS) (B). **;p<0.01, n.s.; not significant (C) CTL activities after treatment; Data represent the mean±S.D. of cytotoxic activity in the duplicate culture cells from regional lymph nodes cells obtained from two mice in each group. On day 7 and day 10 Ad.PTH.IL-18, Ad.EGFP or HBSS was administered, two in each group were sacrificed for the in vitro assay on day 14. After 5 days co-cultured with irradiated MCA205 cells, cytotoxic activity was assessed against MCA205 cells (A) and YAC-1 cells (B). There is a statistically significant difference between WT/Ad.PTH.IL-18 vs WT/Ad.EGFP (p=0.013) and WT/Ad.PTH.IL-18 vs gld/Ad.PTH.IL-18 (p=0.021). n.s., not significant.

[0017]FIG. 2 shows that coinjection of Ad.PTH.IL-18 and DC induced potent anti-tumor effect against not only injected MCA205 tumor but also non-injected tumor at the distant site. On day 0, mice received 1×10⁵ MCA205 cells on both the right and left flanks. On day 7 and 10, mice received 1×10⁶ DC and 3×10⁸ plaque forming units (p.fu.) of adenoviral vector, or HBSS. Data represent the mean±S.D. of tumor area of (A) injected and (B) non-injected tumor area of the animals. (C) Data represent the mean±S.D. of cytolytic activity of the cells cultured from regional lymph nodes or spleen harvested from treated animals. On day 7 and day 10, Ad.PTH.IL-18, Ad.EGFP or HBSS and DC were administered; two in each group were sacrificed for the in vitro assay on day 14. After 5 days of co-culture with irradiated MCA205 cells, cytotoxic activity was assessed against MCA205 cells and YAC-1 cells.

[0018]FIG. 3 shows that CTL induced by i.t. coinjection of Ad.PTH.IL-18 and DC are tumor specific and MHC class I restricted. In FIG. 3(A), cytolytic activity was assessed against MCA205 cells, MC38 cells, EL-4 cells, B16 cells, and YAC-1 cells at various effector: target (E:T) ratios. Data represent the mean±S.D. of cytotoxicity. There is a significant difference between cytolytic activity against MCA205 cells and those against other targets (p<0.01 for all). In FIG. 3(B), effector cells were treated with anti-H2K^(b) antibody, anti-H2K^(d) antibody, or no antibody at various E:T ratios. Data represent the mean±S.D. of cytotoxicity. There was a statistically significant difference between cytotoxicity of the anti-H2K^(b) treated group and that of the non-treated or anti-H2K^(d) treated group (*: p<0.05).

[0019]FIG. 4 shows the involvement of endogenous IL-12 in the anti-tumor effects mediated by AD.PTH-IL-18 and DCs using DCs cultured from IL-12 gene deficient (IL-12 GKO) mice. Coinjection of Ad.PTH.IL-18 and DC from IL-12 GKO mice was associated with significantly less anti-tumor effects when compared with that of the treatment with DCs from immunocompetent animals.

[0020]FIG. 5 shows a table of IL-1 homologs.

[0021]FIG. 6 shows an alignment of IL-1 homologs.

DETAILED DESCRIPTION OF THE INVENTION

[0022] The present invention relates to the discovery that co-administration of antigen-presenting cells (APCs) with an immunostimulatory cytokine, or nucleic acid encoding an immunostimulatory cytokine, into or near a tumor or infectious lesion induces a specific immunological response against antigens associated with the tumor or infectious lesion without pre-loading or pulsing the APCs with the antigens. For example, APCs such as dendritic cells (DCs) may be co-injected with IL-18 or an expression vector expressing IL-18, into or near the site of a tumor or infectious lesion to induce a specific immune response against antigens associated with the tumor or infectious lesion. Injection of dendritic cells and IL-18 can cause tumor regression both at the site of injection and at distant sites, such as metastases.

[0023] The below examples demonstrate the in vivo anti-tumor effects of intratumoral (i.t.) administration of an adenoviral vector expressing functional mouse interleukin-18 (Ad.PTH.IL-18) using murine tumor systems. Potent anti-tumor effects were observed when an established MCA205 fibrosarcoma was treated in syngeneic immunocompetent mice with i.t. injection of Ad.PTH.IL-18 (p=0.0025 vs. control vector treatment), and potent cytotoxic T lymphocytes (CTLs) were generated in culture. In contrast, this in vivo anti-tumor effect was absent, and cytotoxic activity was significantly less (p=0.021) in Fas ligand-deficient gld mice. Co-injection of an MCA205 fibrosarcoma and an MC38 adenocarcinoma with both Ad.PTH.IL-18 and dendritic cells inhibited growth of the injected tumors. Further, an anti-tumor effect was also observed on a distant tumor inoculated intradermally (i.d.) in the contralateral flank of a mouse. In vitro analysis showed that the induced cytolytic activity was tumor-specific and MHC class I restricted. These studies suggest that cancer patients with multiple distant metastasis could be treated using this strategy.

[0024] Choice and Isolation of Antigen Presenting Cell

[0025] The present invention employs antigen presenting cells preferably professional antigen presenting cells, more preferably, dendritic cells CD(s), particularly CD34+-derived DCs (CD34+-DCs) harvested from mobilized peripheral blood, and bone marrow-derived dendritic cells (BM-DCs), harvested from bone marrow. Other DCs that may be useful in the invention include monocyte-derived DCs harvested from blood, CD34+-DCs harvested from bone marrow, splenocyte derived DCs harvested from the spleen, skin-derived DCs, follicular dendritic cells, and germinal center dendritic cells. Methods of isolating these dendritic cells from the tissues in which they arise and/or localize are well known in the art. For example, methods for isolating BM-DCs are described in Inaba et al. ((1992), J. Exp. Med. 176:1693-1702). Alternatively, CD34+progenitor cells may be obtained from human umbilical cord or adult blood, and may be stimulated with cytokines to differentiate into dendritic cells (see, e.g., Caux et al. (1996) J. Exp. Med. 184:695-706; Romani et al. (1994) J. Exp. Med. 180:83-93). The effectiveness of the Flt-3 ligand in generating dendritic cells is described in, e.g., Shurin et al. (1997) Cell Immunol. 179:174-184. BM-DCs or CD34+-DCs cultured with GM-CSF and IL-4 for several (e.g., 5 days) are particularly preferred. TNF-α and the kit ligand are also effective at increasing the yield of DCs grown in culture (see, e.g., Mayordomo et al. (1997) Stem Cells 15:94-103, and references cited therein), and may be used to obtain the DCs of the present invention. A majority of such DCs may display the immature phenotype as determined by flow cytometry and mixed lymphocyte reaction assay in accordance with previous reports (Pierre et al. (1997), Nature 388:787-792; Inaba et al. (1993), J. Exp. Med. 178:479-488).

[0026] Preferably, the original source of the APCs is the subject to be treated, such that the APCs are autologous. Allogeneic APCs, obtained from other individuals, may also be employed in the present invention, but preferably the APCs are derived from histocompatible or syngeneic individuals so as to provide proper MHC presentation to the cognate, antigen-specific T cell receptors of the subject. In addition, genetically engineered animals, such as mice or pigs, may be created which express human or humanized MHC proteins, and optionally co-stimulatory molecules, and may be used as a renewable source of APCs capable of proper MHC presentation to the cognate, antigen-specific T cell receptors of the subject.

[0027] The number of antigen presenting cells to be introduced into a subject depends upon a number of factors, including the number of sites at which the cells are to be administered (e.g., injected), the number of administrations that are to be performed over time, the size of the tumor or infectious lesion, and the nature of the tumor or infectious lesion. Although the number of cells to be used will vary with such factors, it is presently expected that up to about 109, preferably about 104 to about 108, more preferably about 105 to about 107, cells are administered per site, per treatment.

[0028] The antigen presenting cells may be clonally expanded prior to administration by standard techniques of cell culture that are well known in the art. If the antigen presenting cells are autologous to the subject, the steps of obtaining and, optionally, clonally expanding the antigen presenting cells is preferably performed as closely as possible to the time of administration. If, however, heterologous but syngeneic antigen presenting cells are used, the cells may be obtained and, optionally, clonally expanded far in advance of administration, and may be maintained indefinitely prior to use.

[0029] Choice of Cytokine

[0030] The immunostimulatory cytokine of the invention is a soluble molecule that mediates interactions among immune system cells or that causes an activation/increase or deactivation/decrease in an immune response against an antigenic peptide presented by an APC. Immunostimulatory cytokines include, but are not limited to, interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-18 (IL-18), interleukin-19 (IL-19), interleukin-20 (IL-20), ), interleukin-23 (IL-23), interleukin-27 (IL-27), IL-1f3, IL-1f5, IL-1f6, IL-1f7, IL-1f8, IL-1f9, and IL-1f10, interferon-α (IFN-α), interferon-β (IFN-β), interferon-γ (IFN-γ), tumor necrosis factor α (TNF-α), transforming growth factor-β (TGF-β), granulocyte colony stimulating factor (GCSF), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), the Flt-3 ligand, and the kit ligand. The sequences for these immunostimulatory cytokines are known in the art and can be found, e.g,. in Genbank ((http://www.ncbi.nlm.nih.gov/), e.g., a Genbank accession number for IL-1a is NM000575; a Genbank accession number for IL-1 is X65019; a Genbank accession number for IL-2 is AF359939; a Genbank accession number for IL-3 is NM000588; a Genbank accession number for IL-4 is NM000589; a Genbank accession number for IL-6 is NM000600; a Genbank accession number for IL-8 is M2130; a Genbank accession number for IL-9 is M86593; a Genbank accession number for IL-10 is AF295024; a Genbank accession number for IL-12 is AF101062; a Genbank accession number for IL-18 is E17135; a Genbank accession number for IL-19 is NM013371; a Genbank accession number for IL-20 is AF212311; a Genbank accession number for IL-23 is NM016584; a Genbank accession number for IL-27 is AY099296; a Genbank accession number for IFN-α is M28586; a Genbank accession number for IFN-β is M28622; a Genbank accession number for IFN-γ is U10360; a Genbank accession number for TNF-α is NM000594; a Genbank accession number for TGF-β is AY149344; a Genbank accession number for GCSF Ml 7706; a Genbank accession number for M-CSF is M27087; a Genbank accession number for GM-CSF is M11734; a Genbank accession number for Flt-3 ligand is U03858; and a Genbank accession number for kit ligand is NM003994. See also Sims et al. (2001) Trends Immunol. 22:536, and sequences cited therein. See also FIGS. 5 and 6.

[0031] References to any of these cytokines are intended to embrace human homologs and variants and any other mammalian homologs or variants having activity in humans that is substantially similar to the human protein. The amino acid sequences of these cytokines are well known in the art. An amino acid sequence of IL-4 may be found in, for example, Arai et al. (1989) J. Immunol. 142(1):274-282; an amino acid sequence of interleukin-6 may be found in, for example, Yasukawa et al. (1987) EMBO J. 6(10):2939-2945; amino acid sequences of the p35 and p40 subunits of IL-12 may be found in, for example, Wolf et al. (1991) J. Immunol. 146(9):3074-3081; amino acid sequences of various IFN-α subtypes may be found in, for example, Gren et al. (1984) J. Interferon Res. 4(4):609-617, and Weismann et al. (1982) Princess Takamatsu Symp. 12:1-22; an amino acid sequence of TNF may be found in, for example, Pennica et al. (1984) Nature 312:724-729; an amino acid sequence of G-CSF may be found in, for example, Hirano et al. (1986) Nature 324:73-76; and an amino acid sequence of GM-CSF may be found in, for example, Cantrell et al. (1985) Proc. Natl. Acad. Sci. (USA) 82(18):6250-6254.

[0032] One of ordinary skill in the art may choose to use a vector comprising an isolated naturally occurring nucleic acid sequence that encodes the immunostimulatory cytokine (e.g., a genomic DNA, cDNA or RNA sequence) or may, utilizing the degeneracy of the genetic code, design and produce a vector comprising a non-naturally occurring sequence that still encodes a functional cytokine. In addition, a cytokine having amino acid sequence variations that do not adversely alter the activity or function of the cytokine may also be useful in the invention. For example, variations in the amino acid sequence of a cytokine that do not alter the residues that are conserved among humans and other mammals may be used. In the case of heterodimeric immunostimulatory cytokines (e.g., IL-12), nucleic acids that encode both subunits of the cytokine molecule must be either present in the expression vector or present on different expression vectors and co-administered. The expression vectors may contain any sequences know in the art required for expression of the operatively linked cytokine nucleic acid sequence, such as promoters, enhancers, etc.

[0033] In one embodiment of the invention, the cytokine nucleic acids are linked to an appropriate replicative cloning vector, a number of which are well known in the art. For expression, the subject nucleic acids can be operably linked to a transcriptional regulatory sequence, e.g., at least one of a transcriptional promoter (e.g., for constitutive expression or inducible expression) or transcriptional enhancer sequence. Such regulatory sequences in conjunction with a cytokine nucleic acid molecule can provide a useful vector for gene expression. This invention also comtemplates the use of host cells transfected with the cytokine expression vector.

[0034] Any vector capable of transporting and expressing the cytokine nucleic acid may be used. One type of vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of “plasmids” which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. However, the invention is intended to include such other forms of expression vectors, including RNA vectors, which serve equivalent functions and which become known in the art subsequently hereto.

[0035] However, it may be difficult to achieve expression of sufficient intracellular concentrations of the cytokine in certain instances. Therefore a preferred approach utilizes a recombinant DNA construct in which the cytokine nucleic acid is placed under the control of a strong pol III or pol II promoter. The use of such a construct results in the transcription of sufficient amounts of cytokine mRNA. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an cytokine RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired cytokine mRNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the cytokine mRNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive and can include but not be limited to: the SV40 early promoter region, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene, etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the cytokine expression vector that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g., systematically).

[0036] Variants of the immunostimulatory cytokines may also be administered. For example, for those cytokines having both pro-forms and mature forms (e.g., before and after cleavage of a signal peptide, or before and after limited proteolysis to yield an active fragment), either the pro- or mature form may be administered with the antigen presenting cells. Other variants, such as fusion proteins between an active fragment of a cytokine and a heterologous sequence (e.g., a heterologous signal peptide), may also be administered. Species variants may also be employed to the extent that they retain activity in a human subject. Thus, for example, murine, bovine, equine, ovine, feline, canine, non-human primate or other mammalian variant of a human cytokine may be used in the methods of the invention if these species variants retain activity that is substantially similar to their human homologs.

[0037] “Homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid molecules and can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are identical at that position. A degree of homology or similarity or identity between nucleic acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. An “unrelated” or “non-homologous” sequence shares less than about 40% identity, though preferably less than about 25% identity. Percent identity, homology or similarity are determined using a sequence alignment software such as BLAST. Alternatively percent identity, homology or similarity are determined by the number of nucleotide or amino acid differences in a sequence of a certain length. For example, a 100 residue sequence with 20 residue differences is defined as 80% identical, wherein a difference means a different residue or lack of residue. “Homologous” refers to the evolutionary relatedness of two nucleic acid or protein sequences. “Identity” refers to the degree to which nucleic acids or amino acids are the same between two sequences. “Similarity” refers to the degree to which nucleic acids or amino acids are the same, but includes neutral amino acid substitutions that do not significantly change the function of the protein as is well known in the art. Similarity also refers to neutral degenerate nucleic acids that may be substituted within a codon without changing the amino acid identity of the codon, as is well known in the art.

[0038] Subjects for treatment with the methods of the present invention include cancer patients and patients having an infection. Because it is preferred that the APCs and immunostimulatory cytokines or immunostimulatory cytokine nucleic acids can be administered directly into or near (e.g., within the same organ site(s)) of a tumor or infectious lesion, the present methods are useful in subjects having at least one physically well-defined tumor or infectious lesion. In addition, administration of the APCs and cytokines of the invention into one site at which a tumor or infectious lesion is present can lead to the development of a systemic immune response. The methods of the invention are therefore effective in treating diffuse or highly metastasized cancers or secondary infections if at least one site of a tumor or infectious lesion can be identified at which the APCs and immunostimulatory cytokine or immunostimulatory cytokine nucleic acid can be administered and can effectively load tumor or pathogen-associated antigen(s).

[0039] The methods of the invention may be used to treat patients that have solid tumors, into which the APCs and immunostimulatory cytokines or immunostimulatory cytokine expression vectors of the invention may be directly administered (e.g., injected). Appropriate solid tumors include melanomas, hepatomas, colorectal cancers, adenocarcinomas, basal cell cancers, oral cancers, nasopharyngeal cancers, laryngeal cancers, bladder cancers, head and neck cancers, renal cell cancers, pancreatic cancers, pulmonary cancers, cervical cancers, ovarian cancers, esophageal cancers, gastric cancers, prostate cancers, testicular cancers, and breast cancers, for example. For many of these cancers, an association between DC infiltration and prognosis has been established.

[0040] The methods of the invention may be used to treat patients that have an infectious lesion, to which the APCs and immunostimulatory cytokines or immunostimulatory cytokine nucleic acids of the invention may be directly administered. The infectious lesion may be caused by a pathogen such as a virus, bacteria, parasite, prion, fungus, or yeast, for example.

[0041] The antigen presenting cells and immunostimulatory cytokines of the invention may be administered by any of a number of methods. In a preferred embodiment, the APCs and immunostimulatory cytokines or immunostimulatory cytokine nucleic acids are injected using standard sterile techniques for intratumoral, subcutaneous, intradermal, transdermal, intramuscular, intraperitoneal, or other forms of injection.

[0042] The cells and cytokines or expression vectors may be administered together as a combined therapeutic or may be administered separately or sequentially. The cells and cytokines may be administered in a physiologically acceptable solution or buffer and may be administered in combination with other agents such as proteins, peptides, small molecules, antibodies, antibody fragments, or lipids, particularly cytokines such as G-CSF or IL-12, which may promote the ability of the antigen presenting cells to survive, load antigen, traffic to the draining lymph nodes or spleen, and present antigen to activate an immune response.

[0043] It is contemplated that the antigen presenting cells and immunostimulatory cytokines or cytokine nucleic acids encoding an immunostimulatory cytokine may be incorporated into any suitable carrier prior to use. More specifically, the dose, mode of administration, and use of suitable carrier will depend upon the location, size and type of tumor or infectious lesion.

[0044] The present invention provides for both prophylactic and therapeutic methods of treating a subject having a tumor, metastasis, or infectious lesion. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the tumor, metastasis, or infectious lesion such that it is prevented or, alternatively, delayed in its progression. The prophylactic agent may also be administered during remission of a tumor or infection, to prevent regrowth of the tumor or further infectious episodes. Administration of a therapeutic agent can occur during tumor growth or infection, to reduce the size, extent, or spread of the tumor or infection.

[0045] Toxicity and therapeutic efficacy of DCs and cytokines or nucleic acids encoding cytokines can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the Ld₅₀ (the dose lethal to 50% of the population) and the Ed₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit large therapeutic indices are preferred. Care should be taken to design a delivery system that targets such DCs and cytokines or nucleic acids encoding a cytokine to the site of affected tissue in order to minimize potential damage to uninfected cells and to reduce side effects.

[0046] The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such DCs and cytokines or nucleic acids encoding a cytokine lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any DC and cytokine or nucleic acid encoding a cytokine used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the DC and cytokine or nucleic acid encoding a cytokine that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0047] It is contemplated that with regard to mammalian recipients, the DCs and cytokines or nucleic acids encoding a cytokine of interest may be administered by any conventional approach known and/or used in the art. Thus, as appropriate, administration can be oral or parenteral, including intravenous and intraperitoneal routes of administration. In addition, administration can be by periodic injections of a bolus (e.g., directly into the tumor or infectious lesion), or can be made more continuous by intravenous or intraperitoneal administration from a reservoir which is external (e.g., an intravenous bag). Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the cytokine or nucleic acid encoding a cytokine may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. In certain embodiments, the compounds of the invention can be therapeutic-grade. That is, certain embodiments comply with standards of purity and quality control required for administration to humans. Veterinary applications are also within the intended meaning as used herein.

[0048] The formulations, both for veterinary and for human medical use, of the DCs and cytokines or nucleic acids encoding a cytokine according to the present invention typically include such drugs in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients or cells of the formulations and not deleterious to the recipient thereof. Pharmaceutically acceptable carriers, in this regard, are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with an active compound, use thereof in the DCs and cytokines or nucleic acids encoding a cytokine compositions is contemplated. Supplementary active compounds also can be incorporated into the compositions. The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy/microbiology. In general, some formulations are prepared by bringing the DCs and cytokines or nucleic acids encoding a cytokine into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

[0049] A pharmaceutical composition of the invention should be formulated to be compatible with its intended route of administration. Examples of routes of administration include oral or parenteral, e.g., intravenous, intraarterial, intradermal, intratumoral, inhalation, transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. In a preferred embodiment, the DCs and cytokines or nucleic acids encoding a cytokine are administered in AIM5 medium or other medium compatible with the viability and activity of the DCs.

[0050] Useful solutions for oral or parenteral administration can be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Sciences, (Gennaro, A., ed.), Mack Pub., (1990). Formulations for parenteral administration can also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or cutric acid for vaginal administration. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Suppositories for rectal administration also can be prepared by mixing the DCs and cytokines or nucleic acids encoding a cytokine with a non-irritating excipient such as cocoa butter, other glycerides, or other compositions which are solid at room temperature and liquid at body temperatures. Formulations also can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. Formulations for direct administration can include glycerol and other compositions of high viscosity. Other potentially useful parenteral carriers for these drugs include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration can contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Retention enemas also can be used for rectal delivery.

[0051] Formulations of the present invention suitable for oral administration may be in the form of discrete units such as capsules, gelatin capsules, sachets, tablets, troches, or lozenges, each containing a predetermined amount of the cytokine or nucleic acid encoding a cytokine; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The cytokines or nucleic acids encoding a cytokine may also be administered in the form of a bolus, electuary or paste. A tablet may be made by compressing or moulding the cytokine or nucleic acids encoding a cytokine optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the drug in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active or dispersing agent. Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered cytokine or nucleic acid encoding a cytokine and suitable carrier moistened with an inert liquid diluent.

[0052] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fimgi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0053] Formulations suitable for topical administration, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops. Formulations for topical administration to the skin surface can be prepared by dispersing the cytokine or nucleic acid encoding a cytokine with a dermatologically acceptable carrier such as a lotion, cream, ointment or soap. Particularly useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal. For topical administration to internal tissue surfaces, the DCs and cytokine or nucleic acid encoding a cytokine can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface. For example, hydroxypropylcellulose or fibrinogen/thrombin solutions can be used to advantage. Alternatively, tissue-coating solutions, such as pectin-containing formulations can be used.

[0054] For inhalation treatments, inhalation of powder (self-propelling or spray formulations) dispensed with a spray can, a nebulizer, or an atomizer can be used. Such formulations can be in the form of a fine powder for pulmonary administration from a powder inhalation device or self-propelling powder-dispensing formulations. In the case of self-propelling solution and spray formulations, the effect may be achieved either by choice of a valve having the desired spray characteristics (i.e., being capable of producing a spray having the desired particle size) or by incorporating the cytokine as a suspended powder in controlled particle size. For administration by inhalation, the compounds also can be delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0055] Systemic administration also can be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants generally are known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and filsidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active DCs and cytokine or nucleic acid encoding a cytokine compounds typically are formulated into ointments, salves, gels, or creams as generally known in the art. A wash solution can be used locally to treat an injury or inflammation to accelerate healing.

[0056] The active compounds may be prepared with carriers that will protect the DCs and cytokine or nucleic acid encoding a cytokine against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials also can be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811. Microsomes and microparticles also can be used.

[0057] In addition to the formulations described previously, the DCs and cytokine or nucleic acid encoding a cytokine may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the cytokine or nucleic acid encoding a cytokine may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Other suitable delivery systems include microspheres, which offer the possibility of local noninvasive delivery of DCs and cytokine or nucleic acid encoding a cytokine over an extended period of time. This technology utilizes microspheres of precapillary size that can be injected via a coronary catheter into any selected part of the body, e.g., the eye, or other organs without causing inflammation or ischemia. The administered DCs and cytokine or nucleic acid encoding a cytokine therapeutic is slowly released from these microspheres and taken up by surrounding tissue cells.

[0058] Where the drug comprises part of a tissue or organ preservation solution, any commercially available preservation solution can be used to advantage. For example, useful solutions known in the art include Collins solution, Wisconsin solution, Belzer solution, Eurocollins solution, and lactated Ringer's solution.

[0059] The effective concentration of the DCs and cytokine or nucleic acid encoding a cytokine to be delivered in a therapeutic composition will vary depending upon a number of factors, including the final desired dosage of the DCs and cytokine or nucleic acid encoding a cytokine to be administered and the route of administration. The preferred dosage to be administered also is likely to depend on such variables as the type and extent of tumor or infection to be treated, the overall health status of the particular patient, the relative biological efficacy of the DCs and cytokine or nucleic acid encoding a cytokine delivered, the formulation of the DCs and cytokine or nucleic acid encoding a cytokine, the extent to which regulatory sequences in an expression vector encoding a cytokine cause expression of the cytokine (e.g., high vs. low expression) the presence and types of excipients in the formulation, the level of endogenous expression of the cytokine in vivo and the route of administration. In general terms, the therapy of this invention can be provided to an individual using typical dose units deduced from the earlier-described mammalian studies using non-human primates and rodents.

[0060] Active immunostimulatory cytokines used in the methods of the invention also include precursors of the active cytokines. The term precursors refers to a pharmacologically inactive (or partially inactive) derivative of a parent molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active cytokines. Precursors are variations or derivatives of the cytokines of the invention which have groups cleavable under metabolic conditions. Precursors become the active cytokines of the invention that are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Precursor forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, Calif. (1992).

[0061] In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of cytokine therapeutics can lead to severe toxicity or therapeutic failure by altering the relationship between dose and blood concentration of the pharmacologically active cytokine(s). Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a cytokine as well as tailoring the dosage and/or therapeutic regimen of treatment with the cytokine.

[0062] With regard to mammals, it is contemplated that the effective dose of a cytokine will be in the range of about 0.01 to about 50 mg/kg, preferably about 0.1 to about 10 mg/kg of body weight, administered in single or multiple doses. Typically, the cytokine may be administered to a human recipient in need of treatment at a daily dose range of about 1 to about 2000 mg per patient.

[0063] The DC and immunostimulatory cytokine or nucleic acid encoding an immunostimulatory cytokine therapeutic may be administered alone or in combination with other molecules known to have a beneficial effect on stimulating the immune system, including molecules capable of tissue repair and regeneration and/or inhibiting inflammation. Examples of useful cofactors include basic fibroblast growth factor (bFGF), ciliary neurotrophic factor (CNTF), axokine (a mutein of CNTF), leukemia inhibitory factor (LIF), neutrotrophin 3 (NT-3), neurotrophin-4 (NT-4), nerve growth factor (NGF), insulin-like growth factor II, prostaglandin E2, 30 kD survival factor, taurine, and vitamin A. Other useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral, antifungal agents, analgesics, and anesthetics.

[0064] The DC and immunostimulatory cytokine or nucleic acid encoding an immunostimulatory cytokine therapeutics also may be associated with means for targeting the therapeutic to a desired tissue. Alternatively, an antibody or other binding protein that interacts specifically with a surface molecule on the desired target tissue cells also may be used. Such targeting molecules further may be covalently associated to the cytokine therapeutic, e.g., by chemical crosslinking, or by using standard genetic engineering means to create, for example, an acid labile bond such as an Asp-Pro linkage. Useful targeting molecules may be designed, for example, using the simple chain binding site technology disclosed, for example, in U.S. Pat. No. 5,091,513.

[0065] The present invention is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all references cited throughout this application (including literature references, issued patents, and published patent applications) are hereby expressly incorporated by reference.

EXEMPLIFICATION Example 1 Materials and Methods

[0066] Preparation of Adenoviral Vectors: Construction of the IL-18 vector was described previously (Osaki et al. (1999) supra). Briefly, the fragment encoding the prepro leader peptide of human parathyroid hormone (Ghivizzani et al. (1997) J. Immunol. 159: 3604-12) (Genbank numbers) was fused to the sequence encoding mature IL-18 cDNA, termed PTH.IL-18 (Genbank numbers). The PTH.IL-18 fragment was inserted into a shuttle plasmid (Hardy et al. (1997) J. Virol. 71: 1842-49), termed pAdlox, to make an E1 and E3-substituted recombinant adenoviral vector designated Adlox.PTH.IL-18 (FIG. 1A). A recombinant adenoviral vector encoding PTH.IL-18 was generated through Cre-lox recombination as previously described (Hardy et al. (1997) supra), and was termed Ad.PTH.IL-18. An adenoviral vector expressing enhanced green fluorescent protein (EGFP) (Ad.EGFP) was created in the same manner by subcloning the respective fragments obtained from pEGFP-N1 (Clontech, Palo Alto, Calif.) (Cormack et al. (1996) Gene 177: 33-38) (FIG. 1B). Expression of mIL-18 was determined in an mIL-18 ELISA using MCA205 sarcoma cells (ATCC number) infected at different multiplicities of infection (m.o.i) with Ad.PTH.IL-18 (FIG. 1C), and biological activity was confirmed as described previously (Osaki et al. (1999) supra).

[0067] Recombinant cytokines: Murine rIL-18 was obtained from Hayashibara Biochemical Laboratories (Okayama, Japan). Murine rIL-4 and murine GM-CSF were obtained from Schering-Plough Research Institute. rhIL-2 was obtained from Chiron, Emeryville, Calif.

[0068] Tumor cell lines, dendritic cells and animal experiments: MCA205, a methylcholanthrene-induced murine fibrosarcoma cell line (ATCC), and MC38, a murine adenocarcinoma cell line (ATCC), were obtained from the National Cancer Institute, Bethesda, Md. YAC-1 cells were obtained from the University of Pittsburgh, Pittsburgh, Pa. (ATCC). These cell lines were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 mg/ml streptimycin, 100 IU/ml penicillin, and 5×10⁻⁵ M 2-mercaptoethanol (Life Technologies, Inc., Grand Island, N.Y.), referred to hereinafter as complete medium (CM) (Nishioka (1999) Cancer Res. 59: 4035-41). Bone-marrow derived dendritic cells (BM-DCs) cultured with GM-CSF and IL-4 for 6 days were prepared as previously described (Nishioka (1999) supra). Phenotypic analysis with flow cytometry was performed on all preparations as described below to ensure the quality of the cell preparations. Wild type (WT) C57BL/6 mice were obtained from Taconic Farms (Germantown, N.Y.) and gld (FasL deficient) mice were obtained from the Jackson Laboratory (Bar Harbor, Mass. and used for experiments when they were 7 to 12 weeks old. All the animals were ear-tagged, randomized before experiments, and treated and examined in a blinded fashion, 7 animals per treatment group. 1×10⁵ MCA205 tumor cells were injected i.d. into the flank(s) of mice on day 0. In some experiments, mice received 1×10⁹ plaque forming units (p.f.u.) of adenoviral vector or HBSS as a control on day 7 and day 10. In other experiments, mice received 3×10⁸ p.f.u. of adenoviral vector or HBSS and 1×10⁶ of DC. Tumor size was measured every 3-4 days and expressed as the product of the perpendicular diameters of the individual tumors. On day 14, two animals in each group were sacrificed to harvest samples to be tested in vitro. Each animal experiment was repeated at least twice. Representative results are shown.

[0069] Flow cytometry: DCs were stained with phycoerythrin (PE-) or fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies against murine cell surface molecules CD11c, CD80, CD86, Gr-1, H-2 Kb, I-Ab and appropriate isotype controls (all from PharMingen, San Diego, Calif.). Lymphoid cells harvested from lymph nodes were stained with CD4 and CD8. Cells were examined with the FACScan (Becton Dickinson, Sunnyvale, Calif.).

[0070] Cytokine release or CTL assay in vitro: Lymphoid cells were obtained from groin lymph nodes harvested from the mice that had received i.t. injection of adenoviral vector or HBSS, or adenoviral vector or HBSS and DCs 7 days earlier. To examine the IFN-γ response of the lymphoid cells, contaminating erythrocytes were lysed with 0.83M NH4Cl buffer and 2×10⁶ lymphoid cells were co-cultured with 2×10⁵ irradiated (10000 rad) MCA205 cells in the presence of rhIL-2 (25 IU/ml) in 24-well plates for 40 hours. The resultant supernatant was collected and examined with an enzyme linked immunoabsorbent assay (ELISA) specific for mIFN-γ (PharMingen, San Diego, Calif.). To obtain CTLs from these cells, 2×10⁶ lymphoid cells were re-stimulated in vitro with 2×10⁵ irradiated (10000 rad) MCA205 cells in the presence of rhIL-2 (25 IU/ml) for 5 days. Cytotoxic activity was examined using lymphoid cells after co-culture. Viable lymphoid cells were counted using trypan blue-exclusion according to standard methods and used as effector cells for the standard 4 hour−⁵¹Cr release assay against the target cells. In brief, 10⁶ cells of each target were labeled with 100 μCi of Na₂ ⁵¹CrO₄ for 1 hour, rinsed twice, and plated with target cells at an appropriate E:T ratio in 96-well round bottom plates. The supernatant (100 μl) was collected after a 4 hour incubation and the radioactivity was counted with a y-counter. The percentage of the specific lysis was calculated using the following formula: % specific lysis=100×(experimental release−spontaneous release)/(maximal release−spontaneous release). Forty hours after the culture, 0.4 ml of supernatant was collected for ELISA analysis for IFN-γ (Pharmingen, San Diego, Calif.). The lower detection limit of these assays was 15 pg/ml. For cytolytic assay, cells were cultured for 4 days, collected and tested for cytotoxic activity.

[0071] Statistical evaluation: Statistical analyses were performed using the repeated measure ANOVA method when comparing the in vivo tumor growth and cytotoxic activity in an individual group. An unpaired two-tailed Student's t test was used to compare cytokine expression. Differences were considered significant when the p value was less than 0.05.

Example 2 Intratumoral Injection of an IL-18 Adenoviral Vector Induces Regression of Established MCA205 Sarcoma in WT Mice, But Not Gld Mice

[0072] To examine the anti-tumor effect of i.t., injection of Ad.PTH.IL-18, 1×10⁵ of MCA205 cells were inoculated intradermally (i.d.) in the right flank of mice on day 0. Each group, consisting of 5 mice, was treated with i.t. injection of HBSS, 1×10⁹ p.f.u. Ad.EGFP, or 1×10⁹ p.f.u. Ad.PTH.IL-18 on day 7 and day 10. Significant anti-tumor effects were observed in mice treated with Ad.PTH.IL-18 compared with mice injected with a control adenoviral vector, Ad.EGFP (p=0.0025), or HBSS (p=0.0033) (FIG. 1Ba). In contrast, when gld mice were treated with Ad.PTH.IL-18, no significant anti-tumor effects were observed (p=0.508 against mice treated with Ad.EGFP,p=0.273 against mice treated with HBSS) (FIG. 1Bb). Thus, the Fas-FasL pathway appears to be involved in the anti-tumor effects of Ad.PTH.IL-18.

Example 3 Intratumoral Delivery of Ad.PTH.IL-18 Enhances the Tumor Specific CTL Response in Regional Lymph Nodes of WT but Not of Gld Mice

[0073] The in vitro cytotoxic activity of lymphoid cells harvested from the regional lymph nodes of treated animals and the mechanism responsible for the anti-tumor effect of i.t. injection of Ad.PTH.IL-18 were examined. Animals were sacrificed 7 days after i.t. injection, and draining lymph nodes were harvested and processed to obtain lymphoid cells. These lymphoid cells were cultured in vitro with irradiated MCA205 cells to examine the IFN—Y response and in vitro cytolytic activity against MCA205 cells and YAC-1 cells. In immunocompetent mice, i.t. injection of Ad.PTH.IL-18 enhanced tumor specific IFN-γ responses (1102±129 pg/ml) and the cytolytic activity against MCA205 but not against YAC-1 cells (FIG. 1C). In gld mice, i.t. injection of Ad.PTH.IL-18 enhanced neither tumor specific IFN-γ responses (137±11 μg/ml) nor in vitro cytotoxic activity (FIG. 1C). These data suggest that the i.t. injection of Ad.PTH.IL-18 significantly enhanced the cellular immune response to MCA205 cells in WT mice, but not in gld mice.

Example 4 Intratumoral Injection of Both Ad.PTH.IL-18 and DC a Induces Strong Anti-Tumor Effect In Vivo

[0074] Tumor cells killed by IL-18-activated NK cells can serve as an antigen source for DCs to rapidly induce tumor specific CTL (Tanaka et al. (2000) Cancer Res. 60: 4838-44). Thus, the in vivo anti-tumor effect of i.t. injection of both Ad.PTH.IL-18 and DC against MCA205 fibrosarcoma cells was examined. Although the dose of 3×10⁸ p.f.u. of Ad.PTH.IL-18 alone could not achieve a significant anti-tumor effect on MCA205 cells, the tumors treated with Ad.PTH.IL-18 and DC were completely abrogated after day 18 (FIG. 2A). DC alone, Ad.PTH.IL-18 alone or DC plus control vector showed significant but modest anti-tumor effects.

[0075] In addition, un-injected tumor located at a distant site in the same animal was completely rejected only with the treatment consisting of DC plus Ad.PTH.IL-18 (FIG. 2B). Similar anti-tumor responses were observed in MC38 cells, another syngeneic mouse tumor system. Coinjection of Ad.PTH.IL-18 and DC therefore induces potent anti-tumor effects against not only the injected tumor but also against distant tumors such as metastases.

Example 5 The Cellular Immune Response Associated With the Treatment With Ad.PTH.IL-18 and DC is Specific for the Treated Tumor, MCA205, and is MHC Class-I Restricted

[0076] To investigate the nature of anti-tumor immune response, lymphoid cells were collected from lymph nodes and spleens of the Ad.PTH.IL-18 and DC treated animals and the specificity and MHC class-I restriction of effector cells against tumor cells was examined. The most potent cytolytic activity of those effector cells was generated against MCA205 cells when the animals were treated with Ad.PTH.IL-18 and DC. Treatment with DC alone, DC plus control vector, or Ad.IL-18 alone showed significant but modest increases of cytolysis (FIG. 2C). To analyze the specificity of effector cells generated from the lymphoid cells of the animals treated with Ad.PTH.IL-18 and DC, the cytolytic activity of effector cells was assayed against four different syngeneic tumor cell lines (MCA205, MC38, EL-4, B116), and YAC-1 cells (a NK sensitive cell line). The cytotoxicity of the effector cells was significantly enhanced only against MCA205 cells but not significantly against any other cell lines (p<0.01 for all) (FIG. 3A). Thus, the anti-tumor effects against the tumor at a distant site appeared to be mediated by the tumor-specific effector cells generated by the injection of both Ad.PTH.IL-18 and DC. When the effector cells were incubated with anti-MHC class I antibody, the cytolytic activity was significantly inhibited (FIG. 3B). These results strongly suggest that the cytolytic activity of the effector cells was MCA205-specific and MHC class I-restricted.

Example 6 Coinjection of Ad.PTH.IL-18 and DC Can be an Effective Treatment for Treatment Against Another Tumor Cell Line, the MC38 Adenocarcinoma Cell

[0077] The efficiency of i.t. injection of both Ad.PTH.IL-18 and DC on MC38 adenocarcinoma cells was analyzed. As shown in FIG. 3A, significant anti-tumor effects were observed on the injected tumor with i.t. coinjection of Ad.PTH.IL-18 and DC, and the effects were superior than those in mice treated with DC alone (p<0.001), DC plus control vector (p<0.001), or Ad.PTH.IL-18 alone (p<0.01). The anti-tumor effect was also observed against a non-injected distant tumor of the treated animals (FIG. 3B). These results suggest that i.t. coinjection using Ad.PTH.IL-18 and DC can be an effective therapy even against weakly immunogenic tumors such as MC38 adenocarcinoma.

[0078] These results suggest that the NK activity through the Fas-FasL system, which requires direct effector-target contact, plays an important role for the generation of potent CTLs specific to the tumor both in vitro and in vivo.

[0079] In the studies of coinjection of Ad.PTH.IL-18 and DC, ⅓ the amount of adenoviral vector achieved sufficient anti-tumor effect compared to adenoviral vector alone. Although a significantly lower dose (⅓) of adenoviral vector was injected with DCs, coinjection of Ad.PTH.IL-18 and DC was associated with more effective anti-tumor response when compared with that of Ad.PTH.IL-18 injection alone. There, DCs appear to play an important role as primary antigen-presenting cells to initiate and maintain T-cell responses acquiring tumor cells damaged with locally expressed IL-18 through enhanced NK cell activity (Hashimoto et al. (1999) J. Immunol. 163: 583-9; Osaki et al. (1998) J. Immunol. 160: 1742-49; Tanaka et al. (2000) supra). Not to be limited to any particular theory, inoculated immature DCs may acquire damaged tumor cells, become matured and express CCR on the surface (Hirao et al. (2000) Cancer Res. 60: 2209-17), and migrate into drainage lymph nodes. Then, DCs in the T cell area of the regional lymph nodes may activate and educate naïve T cells into tumor specific CTLs (Steinman (1991) Ann. Rev. Immunol. 9: 271-96; Mayordomo et al. (1995) Nature Med. 1: 1297-302; Zitvogel et al. (1996) J. Exp. Med. 183: 87-97; Porgador et al. (1996) J. Immunol. 156: 2918-26). This hypothesis is also consistent with previous reports of co-culture system using NK cells, DCs, T cells, live tumor cells, and IL-18 protein in vitro (Tanaka et al. (2000) supra).

[0080] To examine the involvement of endogenous IL-12 in the potent anti-tumor effects mediated by Ad.PTH.IL-18 and DC, DCs cultured from IL-12 gene deficient (IL-12 GKO) mice were used. Coinjection of Ad.PTH.IL-18 and DC from IL-12 GKO mice was associated with significantly less anti-tumor effects when compared with that of the treatment with DCs from immunocompetent animals (FIG. 5). This suggested that the anti-tumor effect induced with coinjection of Ad.PTH.IL-18 and DC plays important role for inducing adoptive immune response with the help of endogenous IL-12. This observation is consistent with the reported synergistic effect between IL-18 and IL-12 in the multiple systems including fungus infection (Zhang et al. (1997) Infect. Immun. 65: 3594-99), Toxoplasma gondii infection (Cai et al. (2000) Infect. Immun. 68: 6932-38), angiogenesis inhibition in a murine tumor model (Coughlin et al. (1998) J. Clin. Invest. 101: 1441-52) and effective activation of CD8 positive T cells (Okamoto et al. (1999) J. Immunol. 162: 3202-11).

Equivalents

[0081] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein.

1 87 1 1314 DNA Mus musculus 1 gggggggggg atttagagac ttgctcttgc actaccaaag ccacaaagca gccttgcaga 60 aaagagagct ccatcatgcc tggctcagca ctgctatgct gcctgctctt actgactggc 120 atgaggatca gcaggggcca gtacagccgg gaagacaata actgcaccca cttcccagtc 180 ggccagagcc acatgctcct agagctgcgg actgccttca gccaggtgaa gactttcttt 240 caaacaaagg accagctgga caacatactg ctaaccgact ccttaatgca ggactttaag 300 ggttacttgg gttgccaagc cttatcggaa atgatccagt tttacctggt agaagtgatg 360 ccccaggcag agaagcatgg cccagaaatc aaggagcatt tgaattccct gggtgagaag 420 ctgaagaccc tcaggatgcg gctgaggcgc tgtcatcgat ttctcccctg tgaaaataag 480 agcaaggcag tggagcaggt gaagagtgat tttaataagc tccaagacca aggtgtctac 540 aaggccatga atgaatttga catcttcatc aactgcatag aagcatacat gatgatcaaa 600 atgaaaagct aaaacacctg cagtgtgtat tgagtctgct ggactccagg acctagacag 660 agctctctaa atctgatcca gggatcttag ctaacggaaa caactccttg gaaaacctcg 720 tttgtacctc tctccgaaat atttattacc tctgatacct cagttcccat tctatttatt 780 cactgagctt ctctgtgaac tatttagaaa gaagcccaat attataattt tacagtattt 840 attattttta acctgtgttt aagctgtttc cattggggac actttatagt atttaaaggg 900 agattatatt atatgatggg aggggttctt ccttgggaag caattgaagc ttctattcta 960 aggctggcca cacttgagag ctgcagggcc ctttgctatg gtgtcctttc aattgctctc 1020 atccctgagt tcagagctcc taagagagtt gtgaagaaac tcatgggtct tgggaagaga 1080 aaccagggag atcctttgat gatcattcct gcagcagctc agagggttcc cctactgtca 1140 tcccccagcc gcttcatccc tgaaaactgt ggccagtttg ttatttataa ccacctaaaa 1200 ttagttctaa tagaactcat ttttaactag aagtaatgca attcctctgg gaatggtgta 1260 ttgtttgtct gcctttgtag cagcatctaa ttttgaataa atggatctta ttcg 1314 2 178 PRT Mus musculus 2 Met Pro Gly Ser Ala Leu Leu Cys Cys Leu Leu Leu Leu Thr Gly Met 1 5 10 15 Arg Ile Ser Arg Gly Gln Tyr Ser Arg Glu Asp Asn Asn Cys Thr His 20 25 30 Phe Pro Val Gly Gln Ser His Met Leu Leu Glu Leu Arg Thr Ala Phe 35 40 45 Ser Gln Val Lys Thr Phe Phe Gln Thr Lys Asp Gln Leu Asp Asn Ile 50 55 60 Leu Leu Thr Asp Ser Leu Met Gln Asp Phe Lys Gly Tyr Leu Gly Cys 65 70 75 80 Gln Ala Leu Ser Glu Met Ile Gln Phe Tyr Leu Val Glu Val Met Pro 85 90 95 Gln Ala Glu Lys His Gly Pro Glu Ile Lys Glu His Leu Asn Ser Leu 100 105 110 Gly Glu Lys Leu Lys Thr Leu Arg Met Arg Leu Arg Arg Cys His Arg 115 120 125 Phe Leu Pro Cys Glu Asn Lys Ser Lys Ala Val Glu Gln Val Lys Ser 130 135 140 Asp Phe Asn Lys Leu Gln Asp Gln Gly Val Tyr Lys Ala Met Asn Glu 145 150 155 160 Phe Asp Ile Phe Ile Asn Cys Ile Glu Ala Tyr Met Met Ile Lys Met 165 170 175 Lys Ser 3 674 DNA Homo sapiens 3 gatccaaaca tgagccgcct gcccgtcctg ctcctgctcc aactcctggt ccgccccgga 60 ctccaagctc ccatgaccca gacaacgtcc ttgaagacaa gctgggttaa ctgctctaac 120 atgatcgatg aaattataac acacttaaag cagccacctt tgcctttgct ggacttcaac 180 aacctcaatg gggaagacca agacattctg atggaaaata accttcgaag gccaaacctg 240 gaggcattca acagggctgt caagagttta cagaacgcat cagcaattga gagcattctt 300 aaaaatctcc tgccatgtct gcccctggcc acggccgcac ccacgcgaca tccaatccat 360 atcaaggacg gtgactggaa tgaattccgg aggaaactga cgttctatct gaaaaccctt 420 gagaatgcgc aggctcaaca gacgactttg agcctcgcga tcttttagtc caacgtccag 480 ctcgttctct gggccttctc accacagcgc ctcgggacat caaaaacagc agaacttctg 540 aaacctctgg gtcatctctc acacattcca ggaccagaag catttcacct tttcctgcgg 600 catcagatga attgttaatt atctaatttc tgaaatgtgc agctcccatt tggccttgtg 660 cggttgtgtt ctca 674 4 152 PRT Homo sapiens 4 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro 1 5 10 15 Gly Leu Gln Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp 20 25 30 Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln 35 40 45 Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln 50 55 60 Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe 65 70 75 80 Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile 85 90 95 Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr 100 105 110 Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg 115 120 125 Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln 130 135 140 Thr Thr Leu Ser Leu Ala Ile Phe 145 150 5 614 DNA Homo sapiens 5 gatcgttagc ttctcctgat aaactaattg cctcacattg tcactgcaaa tcgacaccta 60 ttaatgggtc tcacctccca actgcttccc cctctgttct tcctgctagc atgtgccggc 120 aactttgtcc acggacacaa gtgcgatatc accttacagg agatcatcaa aactttgaac 180 agcctcacag agcagaagac tctgtgcacc gagttgaccg taacagacat ctttgctgcc 240 tccaagaaca caactgagaa ggaaaccttc tgcagggctg cgactgtgct ccggcagttc 300 tacagccacc atgagaagga cactcgctgc ctgggtgcga ctgcacagca gttccacagg 360 cacaagcagc tgatccgatt cctgaaacgg ctcgacagga acctctgggg cctggcgggc 420 ttgaattcct gtcctgtgaa ggaagccaac cagagtacgt tggaaaactt cttggaaagg 480 ctaaagacga tcatgagaga gaaatattca aagtgttcga gctgaatatt ttaatttatg 540 agtttttgat agctttattt tttaagtatt tatatattta taactcatca taaaataaag 600 tatatataga atct 614 6 153 PRT Homo sapiens 6 Met Gly Leu Thr Ser Gln Leu Leu Pro Pro Leu Phe Phe Leu Leu Ala 1 5 10 15 Cys Ala Gly Asn Phe Val His Gly His Lys Cys Asp Ile Thr Leu Gln 20 25 30 Glu Ile Ile Lys Thr Leu Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys 35 40 45 Thr Glu Leu Thr Val Thr Asp Ile Phe Ala Ala Ser Lys Asn Thr Thr 50 55 60 Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu Arg Gln Phe Tyr 65 70 75 80 Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala Thr Ala Gln Gln 85 90 95 Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg 100 105 110 Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro Val Lys Glu Ala 115 120 125 Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu Lys Thr Ile Met 130 135 140 Arg Glu Lys Tyr Ser Lys Cys Ser Ser 145 150 7 1604 DNA Homo sapiens 7 gaattcctct ggtcctcatc caggtgcgcg ggaagcaggt gcccaggaga gaggggataa 60 tgaagattcc atgctgatga tcccaaagat tgaacctgca gaccaagcgc aaagtagaaa 120 ctgaaagtac actgctggcg gatcctacgg aagttatgga aaaggcaaag cgcagagcca 180 cgccgtagtg tgtgccgccc cccttgggat ggatgaaact gcagtcgcgg cgtgggtaag 240 aggaaccagc tgcagagatc accctgccca acacagactc ggcaactccg cggaagacca 300 gggtcctggg agtgactatg ggcggtgaga gcttgctcct gctccagttg cggtcatcat 360 gactacgccc gcctcccgca gaccatgttc catgtttctt ttaggtatat ctttggactt 420 cctcccctga tccttgttct gttgccagta gcatcatctg attgtgatat tgaaggtaaa 480 gatggcaaac aatatgagag tgttctaatg gtcagcatcg atcaattatt ggacagcatg 540 aaagaaattg gtagcaattg cctgaataat gaatttaact tttttaaaag acatatctgt 600 gatgctaata aggaaggtat gtttttattc cgtgctgctc gcaagttgag gcaatttctt 660 aaaatgaata gcactggtga ttttgatctc cacttattaa aagtttcaga aggcacaaca 720 atactgttga actgcactgg ccaggttaaa ggaagaaaac cagctgccct gggtgaagcc 780 caaccaacaa agagtttgga agaaaataaa tctttaaagg aacagaaaaa actgaatgac 840 ttgtgtttcc taaagagact attacaagag ataaaaactt gttggaataa aattttgatg 900 ggcactaaag aacactgaaa aatatggagt ggcaatatag aaacacgaac tttagctgca 960 tcctccaaga atctatctgc ttatgcagtt tttcagagtg gaatgcttcc tagaagttac 1020 tgaatgcacc atggtcaaaa cggattaggg catttgagaa atgcatattg tattactaga 1080 agatgaatac aaacaatgga aactgaatgc tccagtcaac aaactatttc ttatatatgt 1140 gaacatttat caatcagtat aattctgtac tgatttttgt aagacaatcc atgtaaggta 1200 tcagttgcaa taatacttct caaacctgtt taaatatttc aagacattaa atctatgaag 1260 tatataatgg tttcaaagat tcaaaattga cattgcttta ctgtcaaaat aattttatgg 1320 ctcactatga atctattata ctgtattaag agtgaaaatt gtcttcttct gtgctggaga 1380 tgttttagag ttaacaatga tatatggata atgccggtga gaataagaga gtcataaacc 1440 ttaagtaagc aacagcataa caaggtccaa gatacctaaa agagatttca agagatttaa 1500 ttaatcatga atgtgtaaca cagtgccttc aataaatggt atagcaaatg ttttgacatg 1560 aaaaaaggac aatttcaaaa aaataaaatg caaatttttt taaa 1604 8 177 PRT Homo sapiens 8 Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile 1 5 10 15 Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys 20 25 30 Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu 35 40 45 Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe 50 55 60 Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe 65 70 75 80 Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser 85 90 95 Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr 100 105 110 Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala 115 120 125 Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Glu Glu Asn Lys Ser Leu 130 135 140 Lys Glu Gln Lys Lys Leu Asn Asp Leu Cys Phe Leu Lys Arg Leu Leu 145 150 155 160 Gln Glu Ile Lys Thr Cys Trp Asn Lys Ile Leu Met Gly Thr Lys Glu 165 170 175 His 9 515 DNA Artificial sequence Viral IL-10 9 ccatggagcg aaggttagtg gtcactctgc agtgcctggt gctgctttac ctggcacctg 60 agtgtggagg tacagaccaa tgtgacaatt ttccccaaat gttgagggac ctaagagatg 120 ccttcagtcg tgttaaaacc tttttccaga caaaggacga ggtagataac cttttgctca 180 aggagtctct gctagaggac tttaagggct accttggatg ccaggccctg tcagaaatga 240 tccaattcta cctggaggaa gtcatgccac aggctgaaaa ccaggacccg gaggctaagg 300 accatgtcaa ttctttgggt gaaaatctaa agaccctacg gctccgcctg cgcaggtgcc 360 acaggttcct gccgtgtgag aacaagagta aagctgtgga acagataaaa aatgccttta 420 acaagctgca ggaaaaagga atttacaaag ccatgagtga atttgacatt tttattaact 480 acatagaagc atacatgaca attaaagcca ggtga 515 10 172 PRT Artificial Sequence Viral IL-10 10 Met Glu Arg Arg Leu Val Val Thr Leu Gln Cys Leu Val Leu Leu Tyr 1 5 10 15 Leu Ala Pro Glu Cys Gly Gly Asp Asn Gln Cys Asp Asn Phe Pro Gln 20 25 30 Met Leu Arg Asp Leu Arg Asp Ala Phe Ser Arg Val Leu Thr Phe Phe 35 40 45 Gln Tyr Leu Cys Glu Val Asp Asn Leu Leu Leu Lys Glu Ser Leu Leu 50 55 60 Gly Cys Phe Leu Gly Tyr Leu Gly Cys Gln Ala Leu Ser Glu Met Ile 65 70 75 80 Gln Phe Gln Leu Glu Glu Val Met Pro Gln Ala Glu Asn Gln Asn Pro 85 90 95 Glu Ala Leu Asn His Val Asn Ser Leu Gly Glu Ala Leu Leu Gln Leu 100 105 110 Arg Leu Arg Leu Arg Arg Cys His Arg Phe Leu Pro Cys Glu Asn Leu 115 120 125 Ser Leu Ala Val Glu Gln Ile Leu Asp Ala Phe Asp Lys Leu Gln Glu 130 135 140 Leu Gly Ile Gln Leu Ala Met Ser Glu Phe Cys Ile Phe Ile Asn Gln 145 150 155 160 Ile Glu Ala Gln Met Tyr Met Tyr Ile Leu Ala Arg 165 170 11 2527 DNA Homo Sapiens 11 acctccctcc gcggagcagc cagacagcga gggccccggc cgggggcagg ggggacgccc 60 cgtccggggc accccccccg gctctgagcc gcccgcgggg ccggcctcgg cccggagcgg 120 aggaaggagt cgccgaggag cagcctgagg ccccagagtc tgagacgagc cgccgccgcc 180 cccgccactg cggggaggag ggggaggagg agcgggagga gggacgagct ggtcgggaga 240 agaggaaaaa aacttttgag acttttccgt tgccgctggg agccggaggc gcggggacct 300 cttggcgcga cgctgccccg cgaggaggca ggacttgggg accccagacc gcctcccttt 360 gccgccgggg acgcttgctc cctccctgcc ccctacacgg cgtccctcag gcgcccccat 420 tccggaccag ccctcgggag tcgccgaccc ggcctcccgc aaagactttt ccccagacct 480 cgggcgcacc ccctgcacgc cgccttcatc cccggcctgt ctcctgagcc cccgcgcatc 540 ctagaccctt tctcctccag gagacggatc tctctccgac ctgccacaga tcccctattc 600 aagaccaccc accttctggt accagatcgc gcccatctag gttatttccg tgggatactg 660 agacaccccc ggtccaagcc tcccctccac cactgcgccc ttctccctga ggagcctcag 720 ctttccctcg aggccctcct accttttgcc gggagacccc cagcccctgc aggggcgggg 780 cctccccacc acaccagccc tgttcgcgct ctcggcagtg ccggggggcg ccgcctcccc 840 catgccgccc tccgggctgc ggctgctgcc gctgctgcta ccgctgctgt ggctactggt 900 gctgacgcct ggcccgccgg ccgcgggact atccacctgc aagactatcg acatggagct 960 ggtgaagcgg aagcgcatcg aggccatccg cggccagatc ctgtccaagc tgcggctcgc 1020 cagccccccg agccaggggg aggtgccgcc cggcccgctg cccgaggccg tgctcgccct 1080 ctacaacagc acccgcgacc gggtggccgg ggagagtgca gaaccggagc ccgagcctga 1140 ggccgactac tacgccaagg aggtcacccg cgtgctaatg gtggaaaccc acaacgaaat 1200 ctatgacaag ttcaagcaga gtacacacag catatatatg ttcttcaaca catcagagct 1260 ccgagaagcg gtacctgaac ccgtgttgct ctcccgggca gagctgcgtc tgctgaggct 1320 caagttaaaa gtggagcagc acgtggagct gtaccagaaa tacagcaaca attcctggcg 1380 atacctcagc aaccggctgc tggcacccag cgactcgcca gagtggttat cttttgatgt 1440 caccggagtt gtgcggcagt ggttgagccg tggaggggaa attgagggct ttcgccttag 1500 cgcccactgc tcctgtgaca gcagggataa cacactgcaa gtggacatca acgggttcac 1560 taccggccgc cgaggtgacc tggccaccat tcatggcatg aaccggcctt tcctgcttct 1620 catggccacc ccgctggaga gggcccagca tctgcaaagc tcccggcacc gccgagccct 1680 ggacaccaac tattgcttca gctccacgga gaagaactgc tgcgtgcggc agctgtacat 1740 tgacttccgc aaggacctcg gctggaagtg gatccacgag cccaagggct accatgccaa 1800 cttctgcctc gggccctgcc cctacatttg gagcctggac acgcagtaca gcaaggtcct 1860 ggccctgtac aaccagcata acccgggcgc ctcggcggcg ccgtgctgcg tgccgcaggc 1920 gctggagccg ctgcccatcg tgtactacgt gggccgcaag cccaaggtgg aggagctgtc 1980 caacatgatc gtgcgctcct gcaagtgcag ctgaggtccc gccccgcccc gccccgcccg 2040 gccccacccc gccccgcccc cgctgccttg cccatggggg ctgtatttaa ggacaccgtg 2100 ccccaagccc acctggggcc ccattaaaga tggagagagg actgcggatc tctgtgtcat 2160 tgggcgcctg cctggggtct ccatccctga cgttccccca ctcccactcc ctctctctcc 2220 ctctctgcct cctcctgcct gtctgcacta ttcctttgcc cggcatcaag gcacagggga 2280 ccagtgggga acactactgt agttagatct atttattgag caccttgggc actgttgaag 2340 tgccttacat taatgaactc attcagtcac catagcaaca ctctgagatg gcagggactc 2400 tgataacacc cattttaaag gttgaggaaa caagcccaga gaggttaagg gaggagttcc 2460 tgcccaccag gaacctgctt tagtggggga tagtgaagaa gacaataaaa gatagtagtt 2520 caggcca 2527 12 390 PRT Homo Sapiens 12 Met Pro Pro Ser Gly Leu Arg Leu Leu Leu Leu Leu Leu Pro Leu Leu 1 5 10 15 Trp Leu Leu Val Leu Thr Pro Gly Arg Pro Ala Ala Gly Leu Ser Thr 20 25 30 Cys Lys Thr Ile Asp Met Glu Leu Val Lys Arg Lys Arg Ile Glu Ala 35 40 45 Ile Arg Gly Gln Ile Leu Ser Lys Leu Arg Leu Ala Ser Pro Pro Ser 50 55 60 Gln Gly Glu Val Pro Pro Gly Pro Leu Pro Glu Ala Val Leu Ala Leu 65 70 75 80 Tyr Asn Ser Thr Arg Asp Arg Val Ala Gly Glu Ser Ala Glu Pro Glu 85 90 95 Pro Glu Pro Glu Ala Asp Tyr Tyr Ala Lys Glu Val Thr Arg Val Leu 100 105 110 Met Val Glu Thr His Asn Glu Ile Tyr Asp Lys Phe Lys Gln Ser Thr 115 120 125 His Ser Ile Tyr Met Phe Phe Asn Thr Ser Glu Leu Arg Glu Ala Val 130 135 140 Pro Glu Pro Val Leu Leu Ser Arg Ala Glu Leu Arg Leu Leu Arg Leu 145 150 155 160 Lys Leu Lys Val Glu Gln His Val Glu Leu Tyr Gln Lys Tyr Ser Asn 165 170 175 Asn Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala Pro Ser Asp Ser 180 185 190 Pro Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val Arg Gln Trp Leu 195 200 205 Ser Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser Ala His Cys Ser 210 215 220 Cys Asp Ser Arg Asp Asn Thr Leu Gln Val Asp Ile Asn Gly Phe Thr 225 230 235 240 Thr Gly Arg Arg Gly Asp Leu Ala Thr Ile His Gly Met Asn Arg Pro 245 250 255 Phe Leu Leu Leu Met Ala Thr Pro Leu Glu Arg Ala Gln His Leu Gln 260 265 270 Ser Ser Arg His Arg Arg Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser 275 280 285 Thr Glu Lys Asn Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys 290 295 300 Asp Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn 305 310 315 320 Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln Tyr 325 330 335 Ser Lys Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly Ala Ser Ala 340 345 350 Ala Pro Cys Cys Val Pro Gln Ala Leu Glu Pro Leu Pro Ile Val Tyr 355 360 365 Tyr Val Gly Arg Lys Pro Lys Val Glu Gln Leu Ser Asn Met Ile Val 370 375 380 Arg Ser Cys Lys Cys Ser 385 390 13 1695 DNA Homo Sapiens 13 caagcaggat acgtttttct gttgggcatt gactagattg tttgcaaaag tttcgcatca 60 aaaacaaaca acaacaacaa aaaaccaaac aactctcctt gatctatact ttgagaattg 120 ttgatttctt tttttttatt ctgactttta aaaacaactt ttttttccac ttttttaaaa 180 aatgcactac tgtgtgctga gcgcttttct gatcctgcat ctggtcacgg tcgcgctcag 240 cctgtctacc tgcagcacac tcgatatgga ccagttcatg cgcaagagga tcgaggcgat 300 ccgcgggcag atcctgagca agctgaagct caccagtccc ccagaagact atcctgagcc 360 cgaggaagtc cccccggagg tgatttccat ctacaacagc accagggact tgctccagga 420 gaaggcgagc cggagggcgg ccgcctgcga gcgcgagagg agcgacgaag agtactacgc 480 caaggaggtt tacaaaatag acatgccgcc cttcttcccc tccgaaaatg ccatcccgcc 540 cactttctac agaccctact tcagaattgt tcgatttgac gtctcagcaa tggagaagaa 600 tgcttccaat ttggtgaaag cagagttcag agtctttcgt ttgcagaacc caaaagccag 660 agtgcctgaa caacggattg agctatatca gattctcaag tccaaagatt taacatctcc 720 aacccagcgc tacatcgaca gcaaagttgt gaaaacaaga gcagaaggcg aatggctctc 780 cttcgatgta actgatgctg ttcatgaatg gcttcaccat aaagacagga acctgggatt 840 taaaataagc ttacactgtc cctgctgcac ttttgtacca tctaataatt acatcatccc 900 aaataaaagt gaagaactag aagcaagatt tgcaggtatt gatggcacct ccacatatac 960 cagtggtgat cagaaaacta taaagtccac taggaaaaaa aacagtggga agaccccaca 1020 tctcctgcta atgttattgc cctcctacag acttgagtca caacagacca accggcggaa 1080 gaagcgtgct ttggatgcgg cctattgctt tagaaatgtg caggataatt gctgcctacg 1140 tccactttac attgatttca agagggatct agggtggaaa tggatacacg aacccaaagg 1200 gtacaatgcc aacttctgtg ctggagcatg cccgtattta tggagttcag acactcagca 1260 cagcagggtc ctgagcttat ataataccat aaatccagaa gcatctgctt ctccttgctg 1320 cgtgtcccaa gatttagaac ctctaaccat tctctactac attggcaaaa cacccaagat 1380 tgaacagctt tctaatatga ttgtaaagtc ttgcaaatgc agctaaaatt cttggaaaag 1440 tggcaagacc aaaatgacaa tgatgatgat aatgatgatg acgacgacaa cgatgatgct 1500 tgtaacaaga aaacataaga gagccttggt tcatcagtgt taaaaaattt ttgaaaaggc 1560 ggtactagtt cagacacttt ggaagtttgt gttctgtttg ttaaaactgg catctgacac 1620 aaaaaaagtt gaaggcctta ttctacattt cacctacttt gtaagtgaga gagacaagaa 1680 gcaaattttt ttaaa 1695 14 414 PRT Homo Sapiens 14 Met His Tyr Cys Val Leu Ser Ala Phe Leu Ile Leu His Leu Val Thr 1 5 10 15 Val Ala Leu Ser Leu Ser Thr Cys Ser Thr Leu Asp Met Asp Gln Phe 20 25 30 Met Arg Lys Arg Ile Glu Ala Ile Arg Gly Gln Ile Leu Ser Lys Leu 35 40 45 Lys Leu Thr Ser Pro Pro Glu Asp Tyr Pro Glu Pro Glu Glu Val Pro 50 55 60 Pro Glu Val Ile Ser Ile Tyr Asn Ser Thr Arg Asp Leu Leu Gln Glu 65 70 75 80 Lys Ala Ser Arg Arg Ala Ala Ala Cys Glu Arg Glu Arg Ser Asp Glu 85 90 95 Glu Tyr Tyr Ala Lys Glu Val Tyr Lys Ile Asp Met Pro Pro Phe Phe 100 105 110 Pro Ser Glu Asn Ala Ile Pro Pro Thr Phe Tyr Arg Pro Tyr Phe Arg 115 120 125 Ile Val Arg Phe Asp Val Ser Ala Met Glu Lys Asn Ala Ser Asn Leu 130 135 140 Val Lys Ala Glu Phe Arg Val Phe Arg Leu Gln Asn Pro Lys Ala Arg 145 150 155 160 Val Pro Glu Gln Arg Ile Glu Leu Tyr Gln Ile Leu Lys Ser Lys Asp 165 170 175 Leu Thr Ser Pro Thr Gln Arg Tyr Ile Asp Ser Lys Val Val Lys Thr 180 185 190 Arg Ala Glu Gly Glu Trp Leu Ser Phe Asp Val Thr Asp Ala Val His 195 200 205 Glu Trp Leu His His Lys Asp Arg Asn Leu Gly Phe Lys Ile Ser Leu 210 215 220 His Cys Pro Cys Cys Thr Phe Val Pro Ser Asn Asn Tyr Ile Ile Pro 225 230 235 240 Asn Lys Ser Glu Glu Leu Glu Ala Arg Phe Ala Gly Ile Asp Gly Thr 245 250 255 Ser Thr Tyr Thr Ser Gly Asp Gln Lys Thr Ile Lys Ser Thr Arg Lys 260 265 270 Lys Asn Ser Gly Lys Thr Pro His Leu Leu Leu Met Leu Leu Pro Ser 275 280 285 Tyr Arg Leu Glu Ser Gln Gln Thr Asn Arg Arg Lys Lys Arg Ala Leu 290 295 300 Asp Ala Ala Tyr Cys Phe Arg Asn Val Gln Asp Asn Cys Cys Leu Arg 305 310 315 320 Pro Leu Tyr Ile Asp Phe Lys Arg Asp Leu Gly Trp Lys Trp Ile His 325 330 335 Glu Pro Lys Gly Tyr Asn Ala Asn Phe Cys Ala Gly Ala Cys Pro Tyr 340 345 350 Leu Trp Ser Ser Asp Thr Gln His Ser Arg Val Leu Ser Leu Tyr Asn 355 360 365 Thr Ile Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys Val Ser Gln Asp 370 375 380 Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Ile Gly Lys Thr Pro Lys Ile 385 390 395 400 Glu Gln Leu Ser Asn Met Ile Val Lys Ser Cys Lys Cys Ser 405 410 15 2574 DNA Homo Sapiens CDS (254)..(1492) 15 cctgtttaga cacatggaca acaatcccag cgctacaagg cacacagtcc gcttcttcgt 60 cctcagggtt gccagcgctt cctggaagtc ctgaagctct cgcagtgcag tgagttcatg 120 caccttcttg ccaagcctca gtctttggga tctggggagg ccgcctggtt ttcctccctc 180 cttctgcacg tctgctgggg tctcttcctc tccaggcctt gccgtccccc tggcctctct 240 tcccagctca cac atg aag atg cac ttg caa agg gct ctg gtg gtc ctg 289 Met Lys Met His Leu Gln Arg Ala Leu Val Val Leu 1 5 10 gcc ctg ctg aac ttt gcc acg gtc agc ctc tct ctg tcc act tgc acc 337 Ala Leu Leu Asn Phe Ala Thr Val Ser Leu Ser Leu Ser Thr Cys Thr 15 20 25 acc ttg gac ttc ggc cac atc aag aag aag agg gtg gaa gcc att agg 385 Thr Leu Asp Phe Gly His Ile Lys Lys Lys Arg Val Glu Ala Ile Arg 30 35 40 gga cag atc ttg agc aag ctc agg ctc acc agc ccc cct gag cca acg 433 Gly Gln Ile Leu Ser Lys Leu Arg Leu Thr Ser Pro Pro Glu Pro Thr 45 50 55 60 gtg atg acc cac gtc ccc tat cag gtc ctg gcc ctt tac aac agc acc 481 Val Met Thr His Val Pro Tyr Gln Val Leu Ala Leu Tyr Asn Ser Thr 65 70 75 cgg gag ctg ctg gag gag atg cat ggg gag agg gag gaa ggc tgc acc 529 Arg Glu Leu Leu Glu Glu Met His Gly Glu Arg Glu Glu Gly Cys Thr 80 85 90 cag gaa aac acc gag tcg gaa tac tat gcc aaa gaa atc cat aaa ttc 577 Gln Glu Asn Thr Glu Ser Glu Tyr Tyr Ala Lys Glu Ile His Lys Phe 95 100 105 gac atg atc cag ggg ctg gcg gag cac aac gaa ctg gct gtc tgc cct 625 Asp Met Ile Gln Gly Leu Ala Glu His Asn Glu Leu Ala Val Cys Pro 110 115 120 aaa gga att acc tcc aag gtt ttc cgc ttc aat gtg tcc tca gtg gag 673 Lys Gly Ile Thr Ser Lys Val Phe Arg Phe Asn Val Ser Ser Val Glu 125 130 135 140 aaa aat aga acc aac cta ttc cga gca gaa ttc cgg gtc ttg cgg gtg 721 Lys Asn Arg Thr Asn Leu Phe Arg Ala Glu Phe Arg Val Leu Arg Val 145 150 155 ccc aac ccc agc tct aag cgg aat gag cag agg atc gag ctc ttc cag 769 Pro Asn Pro Ser Ser Lys Arg Asn Glu Gln Arg Ile Glu Leu Phe Gln 160 165 170 atc ctt cgg cca gat gag cac att gcc aaa cag cgc tat atc ggt ggc 817 Ile Leu Arg Pro Asp Glu His Ile Ala Lys Gln Arg Tyr Ile Gly Gly 175 180 185 aag aat ctg ccc aca cgg ggc act gcc gag tgg ctg tcc ttt gat gtc 865 Lys Asn Leu Pro Thr Arg Gly Thr Ala Glu Trp Leu Ser Phe Asp Val 190 195 200 act gac act gtg cgt gag tgg ctg ttg aga aga gag tcc aac tta ggt 913 Thr Asp Thr Val Arg Glu Trp Leu Leu Arg Arg Glu Ser Asn Leu Gly 205 210 215 220 cta gaa atc agc att cac tgt cca tgt cac acc ttt cag ccc aat gga 961 Leu Glu Ile Ser Ile His Cys Pro Cys His Thr Phe Gln Pro Asn Gly 225 230 235 gat atc ctg gaa aac att cac gag gtg atg gaa atc aaa ttc aaa ggc 1009 Asp Ile Leu Glu Asn Ile His Glu Val Met Glu Ile Lys Phe Lys Gly 240 245 250 gtg gac aat gag gat gac cat ggc cgt gga gat ctg ggg cgc ctc aag 1057 Val Asp Asn Glu Asp Asp His Gly Arg Gly Asp Leu Gly Arg Leu Lys 255 260 265 aag cag aag gat cac cac aac cct cat cta atc ctc atg atg att ccc 1105 Lys Gln Lys Asp His His Asn Pro His Leu Ile Leu Met Met Ile Pro 270 275 280 cca cac cgg ctc gac aac ccg ggc cag ggg ggt cag agg aag aag cgg 1153 Pro His Arg Leu Asp Asn Pro Gly Gln Gly Gly Gln Arg Lys Lys Arg 285 290 295 300 gct ttg gac acc aat tac tgc ttc cgc aac ttg gag gag aac tgc tgt 1201 Ala Leu Asp Thr Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn Cys Cys 305 310 315 gtg cgc ccc ctc tac att gac ttc cga cag gat ctg ggc tgg aag tgg 1249 Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp Lys Trp 320 325 330 gtc cat gaa cct aag ggc tac tat gcc aac ttc tgc tca ggc cct tgc 1297 Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly Pro Cys 335 340 345 cca tac ctc cgc agt gca gac aca acc cac agc acg gtg ctg gga ctg 1345 Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr Val Leu Gly Leu 350 355 360 tac aac act ctg aac cct gaa gca tct gcc tcg cct tgc tgc gtg ccc 1393 Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys Val Pro 365 370 375 380 cag gac ctg gag ccc ctg acc atc ctg tac tat gtt ggg agg acc ccc 1441 Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg Thr Pro 385 390 395 aaa gtg gag cag ctc tcc aac atg gtg gtg aag tct tgt aaa tgt agc 1489 Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser Cys Lys Cys Ser 400 405 410 tga gaccccacgt gcgacagaga gaggggagag agaaccacca ctgcctgact 1542 gcccgctcct cgggaaacac acaagcaaca aacctcactg agaggcctgg agcccacaac 1602 cttcggctcc gggcaaatgg ctgagatgga ggtttccttt tggaacattt ctttcttgct 1662 ggctctgaga atcacggtgg taaagaaagt gtgggtttgg ttagaggaag gctgaactct 1722 tcagaacaca cagactttct gtgacgcaga cagaggggat ggggatagag gaaagggatg 1782 gtaagttgag atgttgtgtg gcaatgggat ttgggctacc ctaaagggag aaggaagggc 1842 agagaatggc tgggtcaggg ccagactgga agacacttca gatctgaggt tggatttgct 1902 cattgctgta ccacatctgc tctagggaat ctggattatg ttatacaagg caagcatttt 1962 tttttttaaa gacaggttac gaagacaaag tcccagaatt gtatctcata ctgtctggga 2022 ttaagggcaa atctattact tttgcaaact gtcctctaca tcaattaaca tcgtgggtca 2082 ctacagggag aaaatccagg tcatgcagtt cctggcccat caactgtatt gggccttttg 2142 gatatgctga acgcagaaga aagggtggaa atcaaccctc tcctgtctgc cctctgggtc 2202 cctcctctca cctctccctc gatcatattt ccccttggac acttggttag acgccttcca 2262 ggtcaggatg cacatttctg gattgtggtt ccatgcagcc ttggggcatt atgggtcttc 2322 ccccacttcc cctccaagac cctgtgttca tttggtgttc ctggaagcag gtgctacaac 2382 atgtgaggca ttcggggaag ctgcacatgt gccacacagt gacttggccc cagacgcata 2442 gactgaggta taaagacaag tatgaatatt actctcaaaa tctttgtata aataaatatt 2502 tttggggcat cctggatgat ttcatcttct ggaatattgt ttctagaaca gtaaaagcct 2562 tattctaagg tg 2574 16 412 PRT Homo Sapiens 16 Met Lys Met His Leu Gln Arg Ala Leu Val Val Leu Ala Leu Leu Asn 1 5 10 15 Phe Ala Thr Val Ser Leu Ser Leu Ser Thr Cys Thr Thr Leu Asp Phe 20 25 30 Gly His Ile Lys Lys Lys Arg Val Glu Ala Ile Arg Gly Gln Ile Leu 35 40 45 Ser Lys Leu Arg Leu Thr Ser Pro Pro Glu Pro Thr Val Met Thr His 50 55 60 Val Pro Tyr Gln Val Leu Ala Leu Tyr Asn Ser Thr Arg Glu Leu Leu 65 70 75 80 Glu Glu Met His Gly Glu Arg Glu Glu Gly Cys Thr Gln Glu Asn Thr 85 90 95 Glu Ser Glu Tyr Tyr Ala Lys Glu Ile His Lys Phe Asp Met Ile Gln 100 105 110 Gly Leu Ala Glu His Asn Glu Leu Ala Val Cys Pro Lys Gly Ile Thr 115 120 125 Ser Lys Val Phe Arg Phe Asn Val Ser Ser Val Glu Lys Asn Arg Thr 130 135 140 Asn Leu Phe Arg Ala Glu Phe Arg Val Leu Arg Val Pro Asn Pro Ser 145 150 155 160 Ser Lys Arg Asn Glu Gln Arg Ile Glu Leu Phe Gln Ile Leu Arg Pro 165 170 175 Asp Glu His Ile Ala Lys Gln Arg Tyr Ile Gly Gly Lys Asn Leu Pro 180 185 190 Thr Arg Gly Thr Ala Glu Trp Leu Ser Phe Asp Val Thr Asp Thr Val 195 200 205 Arg Glu Trp Leu Leu Arg Arg Glu Ser Asn Leu Gly Leu Glu Ile Ser 210 215 220 Ile His Cys Pro Cys His Thr Phe Gln Pro Asn Gly Asp Ile Leu Glu 225 230 235 240 Asn Ile His Glu Val Met Glu Ile Lys Phe Lys Gly Val Asp Asn Glu 245 250 255 Asp Asp His Gly Arg Gly Asp Leu Gly Arg Leu Lys Lys Gln Lys Asp 260 265 270 His His Asn Pro His Leu Ile Leu Met Met Ile Pro Pro His Arg Leu 275 280 285 Asp Asn Pro Gly Gln Gly Gly Gln Arg Lys Lys Arg Ala Leu Asp Thr 290 295 300 Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn Cys Cys Val Arg Pro Leu 305 310 315 320 Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp Lys Trp Val His Glu Pro 325 330 335 Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly Pro Cys Pro Tyr Leu Arg 340 345 350 Ser Ala Asp Thr Thr His Ser Thr Val Leu Gly Leu Tyr Asn Thr Leu 355 360 365 Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys Val Pro Gln Asp Leu Glu 370 375 380 Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg Thr Pro Lys Val Glu Gln 385 390 395 400 Leu Ser Asn Met Val Val Lys Ser Cys Lys Cys Ser 405 410 17 2064 DNA Homo sapiens 17 gaattccgca ggcgctcggg gttggagcca gcgaccgtcg gtagcagcat ggctctcctc 60 tttctcctac cccttgtcat gcagggtgtg agcagggctg agatgggcac cgcggatctg 120 gggccgtcct cagtgcctac accaactaat gttacaattg aatcctataa catgaaccct 180 atcgtatatt gggagtacca gatcatgcca caggtccctg tttttaccgt agaggtaaag 240 aactatggtg ttaagaattc agaatggatt gatgcctgca tcaatatttc tcatcattat 300 tgtaatattt ctgatcatgt tggtgatcca tcaaattctc tttgggtcag agttaaagcc 360 agggttggac aaaaagaatc tgcctatgca aagtcagaag aatttgctgt atgccgagat 420 ggaaaaattg gaccacctaa actggatatc agaaaggagg agaagcaaat catgattgac 480 atatttcacc cttcagtttt tgtaaatgga gacgagcagg aagtcgatta tgatcccgaa 540 actacctgtt acattagggt gtacaatgtg tatgtgagaa tgaacggaag tgagatccag 600 tataaaatac tcacgcagaa ggaagatgat tgtgacgaga ttcagtgcca gttagcgatt 660 ccagtatcct cactgaattc tcagtactgt gtttcagcag aaggagtctt acatgtgtgg 720 ggtgttacaa ctgaaaagtc aaaagaagtt tgtattacca ttttcaatag cagtataaaa 780 ggttctcttt ggattccagt tgttgctgct ttactactct ttctagtgct tagcctggta 840 ttcatctgtt tttatattaa gaaaattaat ccattgaagg aaaaaagcat aatattaccc 900 aagtccttga tctctgtggt aagaagtgct actttagaga caaaacctga atcaaaatat 960 gtatcactca tcacgtcata ccagccattt tccttagaaa aggaggtggt ctgtgaagag 1020 ccgttgtctc cagcaacagt tccaggcatg cataccgaag acaatccagg aaaagtggaa 1080 catacagaag aactttctag tataacagaa gtggtgacta ctgaagaaaa tattcctgac 1140 gtggtcccgg gcagccatct gactccaata gagagagaga gttcttcacc tttaagtagt 1200 aaccagtctg aacctggcag catcgcttta aactcgtatc actccagaaa ttgttctgag 1260 agtgatcact ccagaaatgg ttttgatact gattccagct gtctggaatc acatagctcc 1320 ttatctgact cagaatttcc cccaaataat aaaggtgaaa taaaaacaga aggacaagag 1380 ctcataaccg taataaaagc ccccacctcc tttggttatg ataaaccaca tgtgctagtg 1440 gatctacttg tggatgatag cggtaaagag tccttgattg gttatagacc aacagaagat 1500 tccaaagaat tttcatgaga tcagctaagt tgcaccaact ttgaagtctg attttcctgg 1560 acagttttct gctttaattt catgaaaaga ttatgatctc agaaattgta tcttagttgg 1620 tatcaaccaa atggagtgac ttagtgtaca tgaaagcgta aagaggatgt gtggcatttt 1680 cacttttggc ttgtaaagta cagacttttt ttttttttta aacaaaaaaa gcattgtaac 1740 ttatgaacct ttacatccag ataggttacc agtaacggaa catatccagt actcctggtt 1800 cctaggtgag caggtgatgc cccagggacc tttgtagcca cttcactttt tttcttttct 1860 ctgccttggt atagcatatg tgttttgtaa gtttatgcat acagtaattt taagtaattt 1920 cagaagaaat tctcgaagct tttcaaaatt ggacttaaaa tctaattcaa actaatagaa 1980 ttaatggaat atgtaaatag aaacgtgtat attttttatg aaacattaca gttagagatt 2040 tttaaataaa gaattttaaa actc 2064 18 489 PRT Homo sapiens 18 Met Ala Leu Leu Phe Leu Leu Pro Leu Val Met Gln Gly Val Ser Arg 1 5 10 15 Ala Glu Met Gly Thr Ala Asp Leu Gly Pro Ser Ser Val Pro Thr Pro 20 25 30 Thr Asn Val Thr Ile Glu Ser Tyr Asn Met Asn Pro Ile Val Tyr Trp 35 40 45 Glu Tyr Gln Ile Met Pro Gln Val Pro Val Phe Thr Val Glu Val Lys 50 55 60 Asn Tyr Gly Val Lys Asn Ser Glu Trp Ile Asp Ala Cys Ile Asn Ile 65 70 75 80 Ser His His Tyr Cys Asn Ile Ser Asp His Val Gly Asp Pro Ser Asn 85 90 95 Ser Leu Trp Val Arg Val Lys Ala Arg Val Gly Gln Lys Glu Ser Ala 100 105 110 Tyr Ala Lys Ser Glu Glu Phe Ala Val Cys Arg Asp Gly Lys Ile Gly 115 120 125 Pro Pro Lys Leu Asp Ile Arg Lys Glu Glu Lys Gln Ile Met Ile Asp 130 135 140 Ile Phe His Pro Ser Val Phe Val Asn Gly Asp Glu Gln Glu Val Asp 145 150 155 160 Tyr Asp Pro Glu Thr Thr Cys Tyr Ile Arg Val Tyr Asn Val Tyr Val 165 170 175 Arg Met Asn Gly Ser Glu Ile Gln Tyr Lys Ile Leu Thr Gln Lys Glu 180 185 190 Asp Asp Cys Asp Glu Ile Gln Cys Gln Leu Ala Ile Pro Val Ser Ser 195 200 205 Leu Asn Ser Gln Tyr Cys Val Ser Ala Glu Gly Val Leu His Val Trp 210 215 220 Gly Val Thr Thr Glu Lys Ser Lys Glu Val Cys Ile Thr Ile Phe Asn 225 230 235 240 Ser Ser Ile Lys Gly Ser Leu Trp Ile Pro Val Val Ala Ala Leu Leu 245 250 255 Leu Phe Leu Val Leu Ser Leu Val Phe Ile Cys Phe Tyr Ile Lys Lys 260 265 270 Ile Asn Pro Leu Lys Glu Lys Ser Ile Ile Leu Pro Lys Ser Leu Ile 275 280 285 Ser Val Val Arg Ser Ala Thr Leu Glu Thr Lys Pro Glu Ser Lys Tyr 290 295 300 Val Ser Leu Ile Thr Ser Tyr Gln Pro Phe Ser Leu Glu Lys Glu Val 305 310 315 320 Val Cys Glu Glu Pro Leu Ser Pro Ala Thr Val Pro Gly Met His Thr 325 330 335 Glu Asp Asn Pro Gly Lys Val Glu His Thr Glu Glu Leu Ser Ser Ile 340 345 350 Thr Glu Val Val Thr Thr Glu Glu Asn Ile Pro Asp Val Val Pro Gly 355 360 365 Ser His Leu Thr Pro Ile Glu Arg Glu Ser Ser Ser Pro Leu Ser Ser 370 375 380 Asn Gln Ser Glu Pro Gly Ser Ile Ala Leu Asn Ser Tyr His Ser Arg 385 390 395 400 Asn Cys Ser Glu Ser Asp His Ser Arg Asn Gly Phe Asp Thr Asp Ser 405 410 415 Ser Cys Leu Glu Ser His Ser Ser Leu Ser Asp Ser Glu Phe Pro Pro 420 425 430 Asn Asn Lys Gly Glu Ile Lys Thr Glu Gly Gln Glu Leu Ile Thr Val 435 440 445 Ile Lys Ala Pro Thr Ser Phe Gly Tyr Asp Lys Pro His Val Leu Val 450 455 460 Asp Leu Leu Val Asp Asp Ser Gly Lys Glu Ser Leu Ile Gly Tyr Arg 465 470 475 480 Pro Thr Glu Asp Ser Lys Glu Phe Ser 485 19 861 DNA Homo Sapiens CDS (49)..(861) 19 gaattccgca ggcgctcggg gttggagcca gcgaccgtcg gtagcagc atg gct ctc 57 Met Ala Leu 1 ctc ttt ctc cta ccc ctt gtc atg cag ggt gtg agc agg gct gag atg 105 Leu Phe Leu Leu Pro Leu Val Met Gln Gly Val Ser Arg Ala Glu Met 5 10 15 ggc acc gcg gat ctg ggg ccg tcc tca gtg cct aca cca act aat gtt 153 Gly Thr Ala Asp Leu Gly Pro Ser Ser Val Pro Thr Pro Thr Asn Val 20 25 30 35 aca att gaa tcc tat aac atg aac cct atc gta tat tgg gag tac cag 201 Thr Ile Glu Ser Tyr Asn Met Asn Pro Ile Val Tyr Trp Glu Tyr Gln 40 45 50 atc atg cca cag gtc cct gtt ttt acc gta gag gta aag aac tat ggt 249 Ile Met Pro Gln Val Pro Val Phe Thr Val Glu Val Lys Asn Tyr Gly 55 60 65 gtt aag aat tca gaa tgg att gat gcc tgc atc aat att tct cat cat 297 Val Lys Asn Ser Glu Trp Ile Asp Ala Cys Ile Asn Ile Ser His His 70 75 80 tat tgt aat att tct gat cat gtt ggt gat cca tca aat tct ctt tgg 345 Tyr Cys Asn Ile Ser Asp His Val Gly Asp Pro Ser Asn Ser Leu Trp 85 90 95 gtc aga gtt aaa gcc agg gtt gga caa aaa gaa tct gcc tat gca aag 393 Val Arg Val Lys Ala Arg Val Gly Gln Lys Glu Ser Ala Tyr Ala Lys 100 105 110 115 tca gaa gaa ttt gct gta tgc cga gat gga aaa att gga cca cct aaa 441 Ser Glu Glu Phe Ala Val Cys Arg Asp Gly Lys Ile Gly Pro Pro Lys 120 125 130 ctg gat atc aga aag gag gag aag caa atc atg att gac ata ttt cac 489 Leu Asp Ile Arg Lys Glu Glu Lys Gln Ile Met Ile Asp Ile Phe His 135 140 145 cct tca gtt ttt gta aat gga gac gag cag gaa gtc gat tat gat ccc 537 Pro Ser Val Phe Val Asn Gly Asp Glu Gln Glu Val Asp Tyr Asp Pro 150 155 160 gaa act acc tgt tac att agg gtg tac aat gtg tat gtg aga atg aac 585 Glu Thr Thr Cys Tyr Ile Arg Val Tyr Asn Val Tyr Val Arg Met Asn 165 170 175 gga agt gag atc cag tat aaa ata ctc acg cag aag gaa gat gat tgt 633 Gly Ser Glu Ile Gln Tyr Lys Ile Leu Thr Gln Lys Glu Asp Asp Cys 180 185 190 195 gac gag att cag tgc cag tta gcg att cca gta tcc tca ctg aat tct 681 Asp Glu Ile Gln Cys Gln Leu Ala Ile Pro Val Ser Ser Leu Asn Ser 200 205 210 cag tac tgt gtt tca gca gaa gga gtc tta cat gtg tgg ggt gtt aca 729 Gln Tyr Cys Val Ser Ala Glu Gly Val Leu His Val Trp Gly Val Thr 215 220 225 act gaa aag tca aaa gaa gtt tgt att acc att ttc aat agc agt ata 777 Thr Glu Lys Ser Lys Glu Val Cys Ile Thr Ile Phe Asn Ser Ser Ile 230 235 240 aaa ggt tct ctt tgg att cca gtt gtt gct gct tta cta ctc ttt cta 825 Lys Gly Ser Leu Trp Ile Pro Val Val Ala Ala Leu Leu Leu Phe Leu 245 250 255 gtg ctt agc ctg gta ttc atc tgt ttt tat att tga 861 Val Leu Ser Leu Val Phe Ile Cys Phe Tyr Ile 260 265 270 20 270 PRT Homo Sapiens 20 Met Ala Leu Leu Phe Leu Leu Pro Leu Val Met Gln Gly Val Ser Arg 1 5 10 15 Ala Glu Met Gly Thr Ala Asp Leu Gly Pro Ser Ser Val Pro Thr Pro 20 25 30 Thr Asn Val Thr Ile Glu Ser Tyr Asn Met Asn Pro Ile Val Tyr Trp 35 40 45 Glu Tyr Gln Ile Met Pro Gln Val Pro Val Phe Thr Val Glu Val Lys 50 55 60 Asn Tyr Gly Val Lys Asn Ser Glu Trp Ile Asp Ala Cys Ile Asn Ile 65 70 75 80 Ser His His Tyr Cys Asn Ile Ser Asp His Val Gly Asp Pro Ser Asn 85 90 95 Ser Leu Trp Val Arg Val Lys Ala Arg Val Gly Gln Lys Glu Ser Ala 100 105 110 Tyr Ala Lys Ser Glu Glu Phe Ala Val Cys Arg Asp Gly Lys Ile Gly 115 120 125 Pro Pro Lys Leu Asp Ile Arg Lys Glu Glu Lys Gln Ile Met Ile Asp 130 135 140 Ile Phe His Pro Ser Val Phe Val Asn Gly Asp Glu Gln Glu Val Asp 145 150 155 160 Tyr Asp Pro Glu Thr Thr Cys Tyr Ile Arg Val Tyr Asn Val Tyr Val 165 170 175 Arg Met Asn Gly Ser Glu Ile Gln Tyr Lys Ile Leu Thr Gln Lys Glu 180 185 190 Asp Asp Cys Asp Glu Ile Gln Cys Gln Leu Ala Ile Pro Val Ser Ser 195 200 205 Leu Asn Ser Gln Tyr Cys Val Ser Ala Glu Gly Val Leu His Val Trp 210 215 220 Gly Val Thr Thr Glu Lys Ser Lys Glu Val Cys Ile Thr Ile Phe Asn 225 230 235 240 Ser Ser Ile Lys Gly Ser Leu Trp Ile Pro Val Val Ala Ala Leu Leu 245 250 255 Leu Phe Leu Val Leu Ser Leu Val Phe Ile Cys Phe Tyr Ile 260 265 270 21 1890 DNA Mus musculus misc_feature (1390)..(1390) n = a, t, c or g 21 gatcctgttg ggttttactc tactccctga ggacctcagc acatttgccc cccagccatg 60 gcttgtcttg gactccggag gtacaaagct caactgcagc tgccttctag gacttggcct 120 tttgtagccc tgctcactct tcttttcatc ccagtcttct ctgaagccat acaggtgacc 180 caaccttcag tggtgttggc tagcagccat ggtgtcgcca gctttccatg tgaatattca 240 ccatcacaca acactgatga ggtccgggtg actgtgctgc ggcagacaaa tgaccaaatg 300 actgaggtct gtgccacgac attcacagag aagaatacag tgggcttcct agattacccc 360 ttctgcagtg gtacctttaa tgaaagcaga gtgaacctca ccatccaagg actgagagct 420 gttgacacgg gactgtacct ctgcaaggtg gaactcatgt acccaccgcc atactttgtg 480 ggcatgggca acgggacgca gatttatgtc attgatccag aaccatgccc ggattctgac 540 ttcctccttt ggatccttgt cgcagttagc ttggggttgt ttttttacag tttcctggtc 600 tctgctgttt ctttgagcaa gatgctaaag aaaagaagtc ctcttacaac aggggtctat 660 gtgaaaatgc ccccaacaga gccagaatgt gaaaagcaat ttcagcctta ttttattccc 720 atcaactgaa aggccgttta tgaagaagaa ggagcatact tcagtctcta aaagctgagg 780 caatttcaac tttccttttc tctccagcta tttttacctg tttgtatatt ttaaggagag 840 tatgcctctc tttaatagaa agctggagca aaattccaat taagcatact acaatttaaa 900 gctaaggagc agaacagaga gctgggatat ttctgttgtg tcagaaccat tttactaaaa 960 gcatcacttg gaagcagcat aaggatatag cattatggtg tggggtcaag ggaacattag 1020 ggaatggcac agcccaaaga aaggaagggg gtgaaggaag agattatatt gtacacatct 1080 tgtatttacc tgagaggggg tgaaggaaga gattatattg tacacatctt gtatttacct 1140 gagagatgtt tatgacttaa ataattttta aatttttcat gctgttattt tctttaacaa 1200 tgtataatta cacgaaggtt taaacattta ttcacagaga ctatgtgaca tagccagtgg 1260 ttccaaaggt tgtagtgttc caagatgtat ttttaagtaa tattgtacat gggtgtttca 1320 tgtgctgttg tgtatttgct ggtggtttga atataaacac tatgtatcag tgtcgtccca 1380 cagtgggtcn tggggaggtt tggctgggga gcttaggaca ctaatccatc aggttggact 1440 cgaggtcctg caccaactgg cttggaaact agatgaggct gtcacagggc tcagttgcat 1500 aaaccgatgg tgatggagtg tgggctgggt ctttacactc attttatttt ttgtttctgc 1560 ttttgttttc ttcaatgatt tgcaaggaaa ccaaaagctg gcagtgtttg tatgaacctg 1620 acagaacact gtcttcaagg aaatgcctca ttcctgagac cagtaggttt gtttttttag 1680 gaagttccaa tactaggacc ccctacaagt actatggctc ctcgaaaaca caaagttaat 1740 gccacaggaa gcagcagatg gtaggatggg atgcacaaga gttcctgaaa actaacactg 1800 ttagtgtttt ttttttaact caatattttc catgaaaatg caaccacatg tataatattt 1860 ttaattaaat aaaagtttct tgtgattgtt 1890 22 223 PRT Mus musculus 22 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro 1 5 10 15 Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro 20 25 30 Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala 35 40 45 Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His 50 55 60 Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln 65 70 75 80 Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly 85 90 95 Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Phe Leu Leu Trp Ile Leu Val Ala Val Ser Leu Gly Leu Phe Phe 165 170 175 Tyr Ser Phe Leu Val Ser Ala Val Ser Leu Ser Lys Met Leu Lys Lys 180 185 190 Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 195 200 205 Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 210 215 220 23 672 DNA Homo sapiens 23 atggcttgcc ttggatttca gcggcacaag gctcagctga acctggctgc caggacctgg 60 ccctgcactc tcctgttttt tcttctcttc atccctgtct tctgcaaagc aatgcacgtg 120 gcccagcctg ctgtggtact ggccagcagc cgaggcatcg ccagctttgt gtgtgagtat 180 gcatctccag gcaaagccac tgaggtccgg gtgacagtgc ttcggcaggc tgacagccag 240 gtgactgaag tctgtgcggc aacctacatg acggggaatg agttgacctt cctagatgat 300 tccatctgca cgggcacctc cagtggaaat caagtgaacc tcactatcca aggactgagg 360 gccatggaca cgggactcta catctgcaag gtggagctca tgtacccacc gccatactac 420 ctgggcatag gcaacggaac ccagatttat gtaattgatc cagaaccgtg cccagattct 480 gacttcctcc tctggatcct tgcagcagtt agttcggggt tgttttttta tagctttctc 540 ctcacagctg tttctttgag caaaatgcta aagaaaagaa gccctcttac aacaggggtc 600 tatgtgaaaa tgcccccaac agagccagaa tgtgaaaagc aatttcagcc ttattttatt 660 cccatcaatt ga 672 24 223 PRT Homo sapiens 24 Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala 1 5 10 15 Ala Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro 20 25 30 Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala 35 40 45 Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly 50 55 60 Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln 65 70 75 80 Val Thr Glu Val Cys Ala Ala Thr Tyr Met Thr Gly Asn Glu Leu Thr 85 90 95 Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe 165 170 175 Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys 180 185 190 Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu 195 200 205 Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn 210 215 220 25 960 DNA Artificial Sequence Mus musculus CTLA4-Mus musculus IgG3 25 atg gct tgt ctt gga ctc cgg agg tac aaa gct caa ctg cag ctg cct 48 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro 1 5 10 15 tct agg act tgg cct ttt gta gcc ctg ctc act ctt ctt ttc atc cca 96 Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro 20 25 30 gtc ttc tct gaa gcc ata cag gtg acc caa cct tca gtg gtg ttg gct 144 Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala 35 40 45 agc agc cat ggt gtc gcc agc ttt cca tgt gaa tat tca cca tca cac 192 Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His 50 55 60 aac act gat gag gtc cgg gtg act gtg ctg cgg cag aca aat gac caa 240 Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln 65 70 75 80 atg act gag gtc tgt gcc acg aca ttc aca gag aag aat aca gtg ggc 288 Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly 85 90 95 ttc cta gat tac ccc ttc tgc agt ggt acc ttt aat gaa agc aga gtg 336 Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val 100 105 110 aac ctc acc atc caa gga ctg aga gct gtt gac acg gga ctg tac ctc 384 Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu 115 120 125 tgc aag gtg gaa ctc atg tac cca ccg cca tac ttt gtg ggc atg ggc 432 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly 130 135 140 aac ggg acg cag att tat gtc att gat cca gaa cca tgc ccg gat tct 480 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 gat cag gag cct aga ata ccc aag ccc agt acc ccc cca ggt tct tca 528 Asp Gln Glu Pro Arg Ile Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser 165 170 175 tgc cca cct ggt aac atc ttg ggt gga cca tcc gtc ttc atc ttc ccc 576 Cys Pro Pro Gly Asn Ile Leu Gly Gly Pro Ser Val Phe Ile Phe Pro 180 185 190 cca aag ccc aag gat gca ctc atg atc tcc cta acc ccc aag gtt acg 624 Pro Lys Pro Lys Asp Ala Leu Met Ile Ser Leu Thr Pro Lys Val Thr 195 200 205 tgt gtg gtg gtg gat gtg agc gag gat gac cca gat gtc cat gtc agc 672 Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val His Val Ser 210 215 220 tgg ttt gtg gac aac aaa gaa gta cac aca gcc tgg acg cag ccc cgt 720 Trp Phe Val Asp Asn Lys Glu Val His Thr Ala Trp Thr Gln Pro Arg 225 230 235 240 gaa gct cag tac aac agt acc ttc cga gtg gtc agt gcc ctc ccc atc 768 Glu Ala Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu Pro Ile 245 250 255 cag cac cag gac tgg atg agg ggc aag gag ttc aaa tgc aag gtc aac 816 Gln His Gln Asp Trp Met Arg Gly Lys Glu Phe Lys Cys Lys Val Asn 260 265 270 aac aaa gcc ctc cca gcc ccc atc gag aga acc atc tca aaa ccc aaa 864 Asn Lys Ala Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys 275 280 285 gga aga gcc cag aca cct caa gta tac acc ata ccc cca cct cgt gaa 912 Gly Arg Ala Gln Thr Pro Gln Val Tyr Thr Ile Pro Pro Pro Arg Glu 290 295 300 caa atg tcc aag aag aag gtt agt ctg acc tgc ctg gtc acc aac ttc 960 Gln Met Ser Lys Lys Lys Val Ser Leu Thr Cys Leu Val Thr Asn Phe 305 310 315 320 26 320 PRT Artificial Sequence Mus musculus CTLA4-Mus musculus IgG3 26 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro 1 5 10 15 Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro 20 25 30 Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala 35 40 45 Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His 50 55 60 Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln 65 70 75 80 Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly 85 90 95 Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val 100 105 110 Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu 115 120 125 Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly 130 135 140 Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 145 150 155 160 Asp Gln Glu Pro Arg Ile Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser 165 170 175 Cys Pro Pro Gly Asn Ile Leu Gly Gly Pro Ser Val Phe Ile Phe Pro 180 185 190 Pro Lys Pro Lys Asp Ala Leu Met Ile Ser Leu Thr Pro Lys Val Thr 195 200 205 Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val His Val Ser 210 215 220 Trp Phe Val Asp Asn Lys Glu Val His Thr Ala Trp Thr Gln Pro Arg 225 230 235 240 Glu Ala Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu Pro Ile 245 250 255 Gln His Gln Asp Trp Met Arg Gly Lys Glu Phe Lys Cys Lys Val Asn 260 265 270 Asn Lys Ala Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys 275 280 285 Gly Arg Ala Gln Thr Pro Gln Val Tyr Thr Ile Pro Pro Pro Arg Glu 290 295 300 Gln Met Ser Lys Lys Lys Val Ser Leu Thr Cys Leu Val Thr Asn Phe 305 310 315 320 27 1004 DNA Homo sapiens 27 gcctcgctcg ggcgcccagt ggtcctgccg cctggtctca cctcgccatg gttcgtctgc 60 ctctgcagtg cgtcctctgg ggctgcttgc tgaccgctgt ccatccagaa ccacccactg 120 catgcagaga aaaacagtac ctaataaaca gtcagtgctg ttctttgtgc cagccaggac 180 agaaactggt gagtgactgc acagagttca ctgaaacgga atgccttcct tgcggtgaaa 240 gcgaattcct agacacctgg aacagagaga cacactgcca ccagcacaaa tactgcgacc 300 ccaacctagg gcttcgggtc cagcagaagg gcacctcaga aacagacacc atctgcacct 360 gtgaagaagg ctggcactgt acgagtgagg cctgtgagag ctgtgtcctg caccgctcat 420 gctcgcccgg ctttggggtc aagcagattg ctacaggggt ttctgatacc atctgcgagc 480 cctgcccagt cggcttcttc tccaatgtgt catctgcttt cgaaaaatgt cacccttgga 540 caagctgtga gaccaaagac ctggttgtgc aacaggcagg cacaaacaag actgatgttg 600 tctgtggtcc ccaggatcgg ctgagagccc tggtggtgat ccccatcatc ttcgggatcc 660 tgtttgccat cctcttggtg ctggtcttta tcaaaaaggt ggccaagaag ccaaccaata 720 aggcccccca ccccaagcag gaaccccagg agatcaattt tcccgacgat cttcctggct 780 ccaacactgc tgctccagtg caggagactt tacatggatg ccaaccggtc acccaggagg 840 atggcaaaga gagtcgcatc tcagtgcagg agagacagtg aggctgcacc cacccaggag 900 tgtggccacg tgggcaaaca ggcagttggc cagagagcct ggtgctgctg ctgcaggggt 960 gcaggcagaa gcggggagct atgcccagtc agtgccagcc cctc 1004 28 277 PRT Homo sapiens 28 Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr 1 5 10 15 Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu 20 25 30 Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val 35 40 45 Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu 50 55 60 Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Cys His Gln His 65 70 75 80 Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr 85 90 95 Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr 100 105 110 Ser Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly 115 120 125 Phe Gly Val Lys Gln Ile Ala Thr Gly Val Ser Asp Thr Ile Cys Glu 130 135 140 Pro Cys Pro Val Gly Phe Phe Ser Asn Val Ser Ser Ala Phe Glu Lys 145 150 155 160 Cys His Pro Trp Thr Ser Cys Glu Thr Lys Asp Leu Val Val Gln Gln 165 170 175 Ala Gly Thr Asn Lys Thr Asp Val Val Cys Gly Pro Gln Asp Arg Leu 180 185 190 Arg Ala Leu Val Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile 195 200 205 Leu Leu Val Leu Val Phe Ile Lys Lys Val Ala Lys Lys Pro Thr Asn 210 215 220 Lys Ala Pro His Pro Lys Gln Glu Pro Gln Glu Ile Asn Phe Pro Asp 225 230 235 240 Asp Leu Pro Gly Ser Asn Thr Ala Ala Pro Val Gln Glu Thr Leu His 245 250 255 Gly Cys Gln Pro Val Thr Gln Glu Asp Gly Lys Glu Ser Arg Ile Ser 260 265 270 Val Gln Glu Arg Gln 275 29 1890 DNA Homo sapiens 29 aaacagagag agatagagaa agagaaagac agaggtgttt cccttagcta tggaaactct 60 ataagagaga tccagcttgc ctcctcttga gcagtcagca acagggtccc gtccttgaca 120 cctcagcctc tacaggactg agaagaagta aaaccgtttg ctggggctgg cctgactcac 180 cagctgccat gcagcagccc ttcaattacc catatcccca gatctactgg gtggacagca 240 gtgccagctc tccctgggcc cctccaggca cagttcttcc ctgtccaacc tctgtgccca 300 gaaggcctgg tcaaaggagg ccaccaccac caccgccacc gccaccacta ccacctccgc 360 cgccgccgcc accactgcct ccactaccgc tgccacccct gaagaagaga gggaaccaca 420 gcacaggcct gtgtctcctt gtgatgtttt tcatggttct ggttgccttg gtaggattgg 480 gcctggggat gtttcagctc ttccacctac agaaggagct ggcagaactc cgagagtcta 540 ccagccagat gcacacagca tcatctttgg agaagcaaat aggccacccc agtccacccc 600 ctgaaaaaaa ggagctgagg aaagtggccc atttaacagg caagtccaac tcaaggtcca 660 tgcctctgga atgggaagac acctatggaa ttgtcctgct ttctggagtg aagtataaga 720 agggtggcct tgtgatcaat gaaactgggc tgtactttgt atattccaaa gtatacttcc 780 ggggtcaatc ttgcaacaac ctgcccctga gccacaaggt ctacatgagg aactctaagt 840 atccccagga tctggtgatg atggagggga agatgatgag ctactgcact actgggcaga 900 tgtgggcccg cagcagctac ctgggggcag tgttcaatct taccagtgct gatcatttat 960 atgtcaacgt atctgagctc tctctggtca attttgagga atctcagacg tttttcggct 1020 tatataagct ctaagagaag cactttggga ttctttccat tatgattctt tgttacaggc 1080 accgagaatg ttgtattcag tgagggtctt cttacatgca tttgaggtca agtaagaaga 1140 catgaaccaa gtggaccttg agaccacagg gttcaaaatg tctgtagctc ctcaactcac 1200 ctaatgttta tgagccagac aaatggagga atatgacgga agaacataga actctgggct 1260 gccatgtgaa gagggagaag catgaaaaag cagctaccca ggtgttctac actcatctta 1320 gtgcctgaga gtatttaggc agattgaaaa ggacaccttt taactcacct ctcaaggtgg 1380 gccttgctac ctcaaggggg actgtctttc agatacatgg ttgtgacctg aggatttaag 1440 ggatggaaaa ggaagactag aggcttgcat aataagctaa agaggctgaa agaggccaat 1500 gccccactgg cagcatcttc acttctaaat gcatatcctg agccatcggt gaaactaaca 1560 gataagcaag agagatgttt tggggactca tttcattcct aacacagcat gtgtatttcc 1620 agtgccaatt gtaggggtgt gtgtgtgtgt gtgtgtgtgt gtgtatgact aaagagagaa 1680 tgtagatatt gtgaagtaca tattaggaaa atatgggttg catttggtca agattttgaa 1740 tgcttcctga caatcaactc taatagtgct taaaaatcat tgattgtcag ctactaatga 1800 tgttttccta taatataata aatatttatg tagatgtgca tttttgtgaa atgaaaacat 1860 gtaataaaaa gtatatgtta ggatacaaat 1890 30 281 PRT Homo sapiens 30 Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp 1 5 10 15 Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys 20 25 30 Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro Pro 35 40 45 Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro 50 55 60 Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly 65 70 75 80 Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly 85 90 95 Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala 100 105 110 Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu 115 120 125 Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg 130 135 140 Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu 145 150 155 160 Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr 165 170 175 Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr 180 185 190 Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser 195 200 205 His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met 210 215 220 Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala 225 230 235 240 Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His 245 250 255 Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser 260 265 270 Gln Thr Phe Phe Gly Leu Tyr Lys Leu 275 280 31 1803 DNA Homo sapiens 31 tgccaccttc tctgccagaa gataccattt caactttaac acagcatgat cgaaacatac 60 aaccaaactt ctccccgatc tgcggccact ggactgccca tcagcatgaa aatttttatg 120 tatttactta ctgtttttct tatcacccag atgattgggt cagcactttt tgctgtgtat 180 cttcatagaa ggttggacaa gatagaagat gaaaggaatc ttcatgaaga ttttgtattc 240 atgaaaacga tacagagatg caacacagga gaaagatcct tatccttact gaactgtgag 300 gagattaaaa gccagtttga aggctttgtg aaggatataa tgttaaacaa agaggagacg 360 aagaaagaaa acagctttga aatgcaaaaa ggtgatcaga atcctcaaat tgcggcacat 420 gtcataagtg aggccagcag taaaacaaca tctgtgttac agtgggctga aaaaggatac 480 tacaccatga gcaacaactt ggtaaccctg gaaaatggga aacagctgac cgttaaaaga 540 caaggactct attatatcta tgcccaagtc accttctgtt ccaatcggga agcttcgagt 600 caagctccat ttatagccag cctctgccta aagtcccccg gtagattcga gagaatctta 660 ctcagagctg caaataccca cagttccgcc aaaccttgcg ggcaacaatc cattcacttg 720 ggaggagtat ttgaattgca accaggtgct tcggtgtttg tcaatgtgac tgatccaagc 780 caagtgagcc atggcactgg cttcacgtcc tttggcttac tcaaactctg aacagtgtca 840 ccttgcaggc tgtggtggag ctgacgctgg gagtcttcat aatacagcac agcggttaag 900 cccaccccct gttaactgcc tatttataac cctaggatcc tccttatgga gaactattta 960 ttatacactc caaggcatgt agaactgtaa taagtgaatt acaggtcaca tgaaaccaaa 1020 acgggccctg ctccataaga gcttatatat ctgaagcagc aaccccactg atgcagacat 1080 ccagagagtc ctatgaaaag acaaggccat tatgcacagg ttgaattctg agtaaacagc 1140 agataacttg ccaagttcag ttttgtttct ttgcgtgcag tgtctttcca tggataatgc 1200 atttgattta tcagtgaaga tgcagaaggg aaatggggag cctcagctca cattcagtta 1260 tggttgactc tgggttccta tggccttgtt ggagggggcc aggctctaga acgtctaaca 1320 cagtggagaa ccgaaacccc cccccccccc ccgccaccct ctcggacagt tattcattct 1380 ctttcaatct ctctctctcc atctctctct ttcagtctct ctctctcaac ctctttcttc 1440 caatctctct ttctcaatct ctctgtttcc ctttgtcagt ctcttccctc ccccagtctc 1500 tcttctcaat ccccctttct aacacacaca cacacacaca cacacacaca cacacacaca 1560 cacacacaca cagagtcagg ccgttgctag tcagttctct tctttccacc ctgtccctat 1620 ctctaccact atagatgagg gtgaggagta gggagtgcag ccctgagcct gcccactcct 1680 cattacgaaa tgactgtatt taaaggaaat ctattgtatc tacctgcagt ctccattgtt 1740 tccagagtga acttgtaatt atcttgttat ttattttttg aataataaag acctcttaac 1800 att 1803 32 261 PRT Homo sapiens 32 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly 1 5 10 15 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 20 25 30 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg 35 40 45 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val 50 55 60 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser 65 70 75 80 Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys 85 90 95 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu 100 105 110 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser 115 120 125 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly 130 135 140 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln 145 150 155 160 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr 165 170 175 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser 180 185 190 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala 195 200 205 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His 210 215 220 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn 225 230 235 240 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe 245 250 255 Gly Leu Leu Lys Leu 260 33 1212 DNA Mus musculus 33 gcgcactgga gctcatcgca gagcccagcg acaggcaggc gaccacaggg ggccacccga 60 ggtggctggg gccatggccg gggtcgcgtg cttggggaaa actgcggatg ccgatgaatg 120 gtgcgacagc ggcctgggct ctctaggtcc cgacgcagcg gctcccggag gaccaggtct 180 gggcgcagag cttggcccag agctgtcgtg ggcgccctta gtctttggct acgtcactga 240 ggatggggac acagccctgc acttggctgt gattcatcag catgagccct tcctggattt 300 cctcctgggc ttttccgccg gccacgagta ccttgacctg cagaatgacc taggccaaac 360 agccctgcat ctagcagcca tccttgggga ggcatctaca gtagagaagt tgtatgcagc 420 cggtgcagga gtgttggtgg ctgagagagg gggccacacg gcattgcact tggcctgccg 480 ggtcagggca cacacgtgcg cgtgcgtact gctccagccc cgtcccagcc acccaagaga 540 tgcctcagat acctacctca ctcagagcca ggactgtacc ccagacacca gccatgcccc 600 tgctgccgtg gattcccaac ccaacccaga gaacgaagag gagccgcgtg atgaagactg 660 gaggctacaa ctagaagctg aaaactatga tggccatacc ccactccatg tagctgtcat 720 ccacaaagat gcagagatgg tccggctgct cagggatgcc ggagccgacc tcaataaacc 780 ggagcctacg tgtggccgga cccctctgca cctggcagta gaagcccagg cagccagcgt 840 gctggaactt ctcctgaaag ccggtgctga ccccaccgcc cgcatgtatg ggggccgcac 900 cccgcttggc agtgccctgc tccggcccaa ccccatcctt gcccgcctcc tccgtgcaca 960 tggggcccct gaacctgagg acgaggacga taagcttagc ccttgcagca gcagcggcag 1020 cgacagtgac agtgacaaca gagatgaggg cgatgaatat gatgacatcg tggttcacag 1080 tggcaggagc caaaaccgac aaccgccttc cccggcatcc aaacctcttc ctgatgaccc 1140 caaccctgcc tgacttaagt gctaatatta atataatttc caacttaata aaattgcaga 1200 cctgacaacc ag 1212 34 359 PRT Mus musculus 34 Met Ala Gly Val Ala Cys Leu Gly Lys Thr Ala Asp Ala Asp Glu Trp 1 5 10 15 Cys Asp Ser Gly Leu Gly Ser Leu Gly Pro Asp Ala Ala Ala Pro Gly 20 25 30 Gly Pro Gly Leu Gly Ala Glu Leu Gly Pro Glu Leu Ser Trp Ala Pro 35 40 45 Leu Val Phe Gly Tyr Val Thr Glu Asp Gly Asp Thr Ala Leu His Leu 50 55 60 Ala Val Ile His Gln His Glu Pro Phe Leu Asp Phe Leu Leu Gly Phe 65 70 75 80 Ser Ala Gly His Glu Tyr Leu Asp Leu Gln Asn Asp Leu Gly Gln Thr 85 90 95 Ala Leu His Leu Ala Ala Ile Leu Gly Glu Ala Ser Thr Val Glu Lys 100 105 110 Leu Tyr Ala Ala Gly Ala Gly Val Leu Val Ala Glu Arg Gly Gly His 115 120 125 Thr Ala Leu His Leu Ala Cys Arg Val Arg Ala His Thr Cys Ala Cys 130 135 140 Val Leu Leu Gln Pro Arg Pro Ser His Pro Arg Asp Ala Ser Asp Thr 145 150 155 160 Tyr Leu Thr Gln Ser Gln Asp Cys Thr Pro Asp Thr Ser His Ala Pro 165 170 175 Ala Ala Val Asp Ser Gln Pro Asn Pro Glu Asn Glu Glu Glu Pro Arg 180 185 190 Asp Glu Asp Trp Arg Leu Gln Leu Glu Ala Glu Asn Tyr Asp Gly His 195 200 205 Thr Pro Leu His Val Ala Val Ile His Lys Asp Ala Glu Met Val Arg 210 215 220 Leu Leu Arg Asp Ala Gly Ala Asp Leu Asn Lys Pro Glu Pro Thr Cys 225 230 235 240 Gly Arg Thr Pro Leu His Leu Ala Val Glu Ala Gln Ala Ala Ser Val 245 250 255 Leu Glu Leu Leu Leu Lys Ala Gly Ala Asp Pro Thr Ala Arg Met Tyr 260 265 270 Gly Gly Arg Thr Pro Leu Gly Ser Ala Leu Leu Arg Pro Asn Pro Ile 275 280 285 Leu Ala Arg Leu Leu Arg Ala His Gly Ala Pro Glu Pro Glu Asp Glu 290 295 300 Asp Asp Lys Leu Ser Pro Cys Ser Ser Ser Gly Ser Asp Ser Asp Ser 305 310 315 320 Asp Asn Arg Asp Glu Gly Asp Glu Tyr Asp Asp Ile Val Val His Ser 325 330 335 Gly Arg Ser Gln Asn Arg Gln Pro Pro Ser Pro Ala Ser Lys Pro Leu 340 345 350 Pro Asp Asp Pro Asn Pro Ala 355 35 1769 DNA Homo sapiens 35 cctcactgac tataaaagaa tagagaagga agggcttcag tgaccggctg cctggctgac 60 ttacagcagt cagactctga caggatcatg gctatgatgg aggtccaggg gggacccagc 120 ctgggacaga cctgcgtgct gatcgtgatc ttcacagtgc tcctgcagtc tctctgtgtg 180 gctgtaactt acgtgtactt taccaacgag ctgaagcaga tgcaggacaa gtactccaaa 240 agtggcattg cttgtttctt aaaagaagat gacagttatt gggaccccaa tgacgaagag 300 agtatgaaca gcccctgctg gcaagtcaag tggcaactcc gtcagctcgt tagaaagatg 360 attttgagaa cctctgagga aaccatttct acagttcaag aaaagcaaca aaatatttct 420 cccctagtga gagaaagagg tcctcagaga gtagcagctc acataactgg gaccagagga 480 agaagcaaca cattgtcttc tccaaactcc aagaatgaaa aggctctggg ccgcaaaata 540 aactcctggg aatcatcaag gagtgggcat tcattcctga gcaacttgca cttgaggaat 600 ggtgaactgg tcatccatga aaaagggttt tactacatct attcccaaac atactttcga 660 tttcaggagg aaataaaaga aaacacaaag aacgacaaac aaatggtcca atatatttac 720 aaatacacaa gttatcctga ccctatattg ttgatgaaaa gtgctagaaa tagttgttgg 780 tctaaagatg cagaatatgg actctattcc atctatcaag ggggaatatt tgagcttaag 840 gaaaatgaca gaatttttgt ttctgtaaca aatgagcact tgatagacat ggaccatgaa 900 gccagttttt tcggggcctt tttagttggc taactgacct ggaaagaaaa agcaataacc 960 tcaaagtgac tattcagttt tcaggatgat acactatgaa gatgtttcaa aaaatctgac 1020 caaaacaaac aaacagaaaa cagaaaacaa aaaaacctct atgcaatctg agtagagcag 1080 ccacaaccaa aaaattctac aacacacact gttctgaaag tgactcactt atcccaagaa 1140 aatgaaattg ctgaaagatc tttcaggact ctacctcata tcagtttgct agcagaaatc 1200 tagaagactg tcagcttcca aacattaatg caatggttaa catcttctgt ctttataatc 1260 tactccttgt aaagactgta gaagaaagcg caacaatcca tctctcaagt agtgtatcac 1320 agtagtagcc tccaggtttc cttaagggac aacatcctta agtcaaaaga gagaagaggc 1380 accactaaaa gatcgcagtt tgcctggtgc agtggctcac acctgtaatc ccaacatttt 1440 gggaacccaa ggtgggtaga tcacgagatc aagagatcaa gaccatagtg accaacatag 1500 tgaaacccca tctctactga aagtgcaaaa attagctggg tgtgttggca catgcctgta 1560 gtcccagcta cttgagaggc tgaggcagga gaatcgtttg aacccgggag gcagaggttg 1620 cagtgtggtg agatcatgcc actacactcc agcctggcga cagagcgaga cttggtttca 1680 aaaaaaaaaa aaaaaaaaaa cttcagtaag tacgtgttat ttttttcaat aaaattctat 1740 tacagtatgt caaaaaaaaa aaaaaaaaa 1769 36 281 PRT Homo sapiens 36 Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys 1 5 10 15 Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala 20 25 30 Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys 35 40 45 Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr 50 55 60 Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val 65 70 75 80 Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser 85 90 95 Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro 100 105 110 Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly 115 120 125 Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu 130 135 140 Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly 145 150 155 160 His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile 165 170 175 His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe 180 185 190 Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln 195 200 205 Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys 210 215 220 Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr 225 230 235 240 Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile 245 250 255 Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala 260 265 270 Ser Phe Phe Gly Ala Phe Leu Val Gly 275 280 37 4150 DNA Homo sapiens 37 tccggcccca gagaactcag cctcattcct gctttaaaat ctctcggcca cctttgatga 60 ggggactggg cagttctaga cagtcccgaa gttctcaagg cacaggtctc ttcctggttt 120 gactgtcctt accccgggga ggcagtgcag ccagctgcaa gccccacagt gaagaacatc 180 tgagctcaaa tccagataag tgacataagt gacctgcttt gtaaagccat agagatggcc 240 tgtccttgga aatttctgtt caagaccaaa ttccaccagt atgcaatgaa tggggaaaaa 300 gacatcaaca acaatgtgga gaaagccccc tgtgccacct ccagtccagt gacacaggat 360 gaccttcagt atcacaacct cagcaagcag cagaatgagt ccccgcagcc cctcgtggag 420 acgggaaaga agtctccaga atctctggtc aagctggatg caaccccatt gtcctcccca 480 cggcatgtga ggatcaaaaa ctggggcagc gggatgactt tccaagacac acttcaccat 540 aaggccaaag ggattttaac ttgcaggtcc aaatcttgcc tggggtccat tatgactccc 600 aaaagtttga ccagaggacc cagggacaag cctacccctc cagatgagct tctacctcaa 660 gctatcgaat ttgtcaacca atattacggc tccttcaaag aggcaaaaat agaggaacat 720 ctggccaggg tggaagcggt aacaaaggag atagaaacaa caggaaccta ccaactgacg 780 ggagatgagc tcatcttcgc caccaagcag gcctggcgca atgccccacg ctgcattggg 840 aggatccagt ggtccaacct gcaggtcttc gatgcccgca gctgttccac tgcccgggaa 900 atgtttgaac acatctgcag acacgtgcgt tactccacca acaatggcaa catcaggtcg 960 gccatcaccg tgttccccca gcggagtgat ggcaagcacg acttccgggt gtggaatgct 1020 cagctcatcc actatgctgg ctaccagatg ccagatggca gcatcagagg ggaccctgcc 1080 aacgtggaat tcactcagct gtgcatcgac ctgggctgga agcccaagta cggccgcttc 1140 gatgtggtcc ccctggtcct gcaggccaat ggccgtgacc ctgagctctt cgaaatccca 1200 cctgaccttg tgcttgaggt ggccatggaa catcccaaat acgagtggtt tcgggaactg 1260 gagctaaagt ggtacgccct gcctgcagtg gccaacatgc tgcttgaggt gggcggcctg 1320 gagttcccag ggtgcccctt caatggctgg tacatgggca cagagatcgg agtccgggac 1380 ttctgtgacg tccagcgcta caacatcctg gaggaagtgg gcaggagaat gggcctggaa 1440 acgcacaagc tggcctcgct ctggaaagac caggctgtcg ttgagatcaa cattgctgtg 1500 ctccatagtt ttcagaagca gaatgtgacc atcatggacc accactcgac tgcagaatcc 1560 ttcatgaagt acatgcagaa tgaataccgg tcccgtgggg gctgcccggc agactggatt 1620 tggctggtcc ctcccatgtc tgggagcatc acccccgtgt ttcaccagga gatgctgaac 1680 tacgtcctgt cccctttcta ctactatcag gtagaggcct ggaaaaccca tgtctggcag 1740 gacgagaagc ggagacccaa gagaagagag attccattga aagtcttggt caaagctgtg 1800 ctctttgcct gtatgctgat gcgcaagaca atggcgtccc gagtcagagt caccatcctc 1860 tttgctacag agacaggaaa atcagaggcg ctggcctggg acctgggggc cttattcagc 1920 tgtgccttca accccaaggt tgtctgcatg gataagtaca ggctgagctg cctggaggag 1980 gaacggctgc tgttggtggt gaccagtacg tttggcaatg gagactgccc tggcaatgga 2040 gagaaactga agaaatcgct cttcatgctg aaagagctca acaacaaatt caggtacgct 2100 gtgtttggcc tcggctccag catgtaccct cggttctgcg cctttgctca tgacattgat 2160 cagaagctgt cccacctggg ggcctctcag ctcaccccga tgggagaagg ggatgagctc 2220 agtgggcagg aggacgcctt ccgcagctgg gccgtgcaaa ccttcaaggc agcctgtgag 2280 acgtttgatg tccgaggcaa acagcacatt cagatcccca agctctacac ctccaatgtg 2340 acctgggacc cgcaccacta caggctcgtg caggactcac agcctttgga cctcagcaaa 2400 gccctcagca gcatgcatgc caagaacgtg ttcaccatga ggctcaaatc tcggcagaat 2460 ctacaaagtc cgacatccag ccgtgccacc atcctggtgg aactctcctg tgaggatggc 2520 caaggcctga actacctgcc gggggagcac cttggggttt gtccaggcaa ccagccggcc 2580 ctggtccaag gtatcctgga gcgagtggtg gatggcccca caccccacca gacagtgcgc 2640 ctggaggccc tggatgagag tggcagctac tgggtcagtg acaagaggct gcccccctgc 2700 tcactcagcc aggccctcac ctacttcctg gacatcacca cacccccaac ccagctgctg 2760 ctccaaaagc tggcccaggt ggccacagaa gagcctgaga gacagaggct ggaggccctg 2820 tgccagccct cagagtacag caagtggaag ttcaccaaca gccccacatt cctggaggtg 2880 ctagaggagt tcccgtccct gcgggtgtct gctggcttcc tgctttccca gctccccatt 2940 ctgaagccca ggttctactc catcagctcc tcccgggatc acacgcccac agagatccac 3000 ctgactgtgg ccgtggtcac ctaccacacc cgagatggcc agggtcccct gcaccacggc 3060 gtctgcagca catggctcaa cagcctgaag ccccaagacc cagtgccctg ctttgtgcgg 3120 aatgccagcg gcttccacct ccccgaggat ccctcccatc cttgcatcct catcgggcct 3180 ggcacaggca tcgcgccctt ccgcagtttc tggcagcaac ggctccatga ctcccagcac 3240 aagggagtgc ggggaggccg catgaccttg gtgtttgggt gccgccgccc agatgaggac 3300 cacatctacc aggaggagat gctggagatg gcccagaagg gggtgctgca tgcggtgcac 3360 acagcctatt cccgcctgcc tggcaagccc aaggtctatg ttcaggacat cctgcggcag 3420 cagctggcca gcgaggtgct ccgtgtgctc cacaaggagc caggccacct ctatgtttgc 3480 ggggatgtgc gcatggcccg ggacgtggcc cacaccctga agcagctggt ggctgccaag 3540 ctgaaattga atgaggagca ggtcgaggac tatttctttc agctcaagag ccagaagcgc 3600 tatcacgaag atatctttgg tgctgtattt ccttacgagg cgaagaagga cagggtggcg 3660 gtgcagccca gcagcctgga gatgtcagcg ctctgagggc ctacaggagg ggttaaagct 3720 gccggcacag aacttaagga tggagccagc tctgcattat ctgaggtcac agggcctggg 3780 gagatggagg aaagtgatat cccccagcct caagtcttat ttcctcaacg ttgctcccca 3840 tcaagccctt tacttgacct cctaacaagt agcaccctgg attgatcgga gcctcctctc 3900 tcaaactggg gcctccctgg tcccttggag acaaaatctt aaatgccagg cctggcgagt 3960 gggtgaaaga tggaacttgc tgctgagtgc accacttcaa gtgaccacca ggaggtgcta 4020 tcgcaccact gtgtatttaa ctgccttgtg tacagttatt tatgcctctg tatttaaaaa 4080 actaacaccc agtctgttcc ccatggccac ttgggtcttc cctgtatgat tccttgatgg 4140 agatatttac 4150 38 1153 PRT Homo sapiens 38 Met Ala Cys Pro Trp Lys Phe Leu Phe Lys Thr Lys Phe His Gln Tyr 1 5 10 15 Ala Met Asn Gly Glu Lys Asp Ile Asn Asn Asn Val Glu Lys Ala Pro 20 25 30 Cys Ala Thr Ser Ser Pro Val Thr Gln Asp Asp Leu Gln Tyr His Asn 35 40 45 Leu Ser Lys Gln Gln Asn Glu Ser Pro Gln Pro Leu Val Glu Thr Gly 50 55 60 Lys Lys Ser Pro Glu Ser Leu Val Lys Leu Asp Ala Thr Pro Leu Ser 65 70 75 80 Ser Pro Arg His Val Arg Ile Lys Asn Trp Gly Ser Gly Met Thr Phe 85 90 95 Gln Asp Thr Leu His His Lys Ala Lys Gly Ile Leu Thr Cys Arg Ser 100 105 110 Lys Ser Cys Leu Gly Ser Ile Met Thr Pro Lys Ser Leu Thr Arg Gly 115 120 125 Pro Arg Asp Lys Pro Thr Pro Pro Asp Glu Leu Leu Pro Gln Ala Ile 130 135 140 Glu Phe Val Asn Gln Tyr Tyr Gly Ser Phe Lys Glu Ala Lys Ile Glu 145 150 155 160 Glu His Leu Ala Arg Val Glu Ala Val Thr Lys Glu Ile Glu Thr Thr 165 170 175 Gly Thr Tyr Gln Leu Thr Gly Asp Glu Leu Ile Phe Ala Thr Lys Gln 180 185 190 Ala Trp Arg Asn Ala Pro Arg Cys Ile Gly Arg Ile Gln Trp Ser Asn 195 200 205 Leu Gln Val Phe Asp Ala Arg Ser Cys Ser Thr Ala Arg Glu Met Phe 210 215 220 Glu His Ile Cys Arg His Val Arg Tyr Ser Thr Asn Asn Gly Asn Ile 225 230 235 240 Arg Ser Ala Ile Thr Val Phe Pro Gln Arg Ser Asp Gly Lys His Asp 245 250 255 Phe Arg Val Trp Asn Ala Gln Leu Ile His Tyr Ala Gly Tyr Gln Met 260 265 270 Pro Asp Gly Ser Ile Arg Gly Asp Pro Ala Asn Val Glu Phe Thr Gln 275 280 285 Leu Cys Ile Asp Leu Gly Trp Lys Pro Lys Tyr Gly Arg Phe Asp Val 290 295 300 Val Pro Leu Val Leu Gln Ala Asn Gly Arg Asp Pro Glu Leu Phe Glu 305 310 315 320 Ile Pro Pro Asp Leu Val Leu Glu Val Ala Met Glu His Pro Lys Tyr 325 330 335 Glu Trp Phe Arg Glu Leu Glu Leu Lys Trp Tyr Ala Leu Pro Ala Val 340 345 350 Ala Asn Met Leu Leu Glu Val Gly Gly Leu Glu Phe Pro Gly Cys Pro 355 360 365 Phe Asn Gly Trp Tyr Met Gly Thr Glu Ile Gly Val Arg Asp Phe Cys 370 375 380 Asp Val Gln Arg Tyr Asn Ile Leu Glu Glu Val Gly Arg Arg Met Gly 385 390 395 400 Leu Glu Thr His Lys Leu Ala Ser Leu Trp Lys Asp Gln Ala Val Val 405 410 415 Glu Ile Asn Ile Ala Val Leu His Ser Phe Gln Lys Gln Asn Val Thr 420 425 430 Ile Met Asp His His Ser Thr Ala Glu Ser Phe Met Lys Tyr Met Gln 435 440 445 Asn Glu Tyr Arg Ser Arg Gly Gly Cys Pro Ala Asp Trp Ile Trp Leu 450 455 460 Val Pro Pro Met Ser Gly Ser Ile Thr Pro Val Phe His Gln Glu Met 465 470 475 480 Leu Asn Tyr Val Leu Ser Pro Phe Tyr Tyr Tyr Gln Val Glu Ala Trp 485 490 495 Lys Thr His Val Trp Gln Asp Glu Lys Arg Arg Pro Lys Arg Arg Glu 500 505 510 Ile Pro Leu Lys Val Leu Val Lys Ala Val Leu Phe Ala Cys Met Leu 515 520 525 Met Arg Lys Thr Met Ala Ser Arg Val Arg Val Thr Ile Leu Phe Ala 530 535 540 Thr Glu Thr Gly Lys Ser Glu Ala Leu Ala Trp Asp Leu Gly Ala Leu 545 550 555 560 Phe Ser Cys Ala Phe Asn Pro Lys Val Val Cys Met Asp Lys Tyr Arg 565 570 575 Leu Ser Cys Leu Glu Glu Glu Arg Leu Leu Leu Val Val Thr Ser Thr 580 585 590 Phe Gly Asn Gly Asp Cys Pro Gly Asn Gly Glu Lys Leu Lys Lys Ser 595 600 605 Leu Phe Met Leu Lys Glu Leu Asn Asn Lys Phe Arg Tyr Ala Val Phe 610 615 620 Gly Leu Gly Ser Ser Met Tyr Pro Arg Phe Cys Ala Phe Ala His Asp 625 630 635 640 Ile Asp Gln Lys Leu Ser His Leu Gly Ala Ser Gln Leu Thr Pro Met 645 650 655 Gly Glu Gly Asp Glu Leu Ser Gly Gln Glu Asp Ala Phe Arg Ser Trp 660 665 670 Ala Val Gln Thr Phe Lys Ala Ala Cys Glu Thr Phe Asp Val Arg Gly 675 680 685 Lys Gln His Ile Gln Ile Pro Lys Leu Tyr Thr Ser Asn Val Thr Trp 690 695 700 Asp Pro His His Tyr Arg Leu Val Gln Asp Ser Gln Pro Leu Asp Leu 705 710 715 720 Ser Lys Ala Leu Ser Ser Met His Ala Lys Asn Val Phe Thr Met Arg 725 730 735 Leu Lys Ser Arg Gln Asn Leu Gln Ser Pro Thr Ser Ser Arg Ala Thr 740 745 750 Ile Leu Val Glu Leu Ser Cys Glu Asp Gly Gln Gly Leu Asn Tyr Leu 755 760 765 Pro Gly Glu His Leu Gly Val Cys Pro Gly Asn Gln Pro Ala Leu Val 770 775 780 Gln Gly Ile Leu Glu Arg Val Val Asp Gly Pro Thr Pro His Gln Thr 785 790 795 800 Val Arg Leu Glu Ala Leu Asp Glu Ser Gly Ser Tyr Trp Val Ser Asp 805 810 815 Lys Arg Leu Pro Pro Cys Ser Leu Ser Gln Ala Leu Thr Tyr Phe Leu 820 825 830 Asp Ile Thr Thr Pro Pro Thr Gln Leu Leu Leu Gln Lys Leu Ala Gln 835 840 845 Val Ala Thr Glu Glu Pro Glu Arg Gln Arg Leu Glu Ala Leu Cys Gln 850 855 860 Pro Ser Glu Tyr Ser Lys Trp Lys Phe Thr Asn Ser Pro Thr Phe Leu 865 870 875 880 Glu Val Leu Glu Glu Phe Pro Ser Leu Arg Val Ser Ala Gly Phe Leu 885 890 895 Leu Ser Gln Leu Pro Ile Leu Lys Pro Arg Phe Tyr Ser Ile Ser Ser 900 905 910 Ser Arg Asp His Thr Pro Thr Glu Ile His Leu Thr Val Ala Val Val 915 920 925 Thr Tyr His Thr Arg Asp Gly Gln Gly Pro Leu His His Gly Val Cys 930 935 940 Ser Thr Trp Leu Asn Ser Leu Lys Pro Gln Asp Pro Val Pro Cys Phe 945 950 955 960 Val Arg Asn Ala Ser Gly Phe His Leu Pro Glu Asp Pro Ser His Pro 965 970 975 Cys Ile Leu Ile Gly Pro Gly Thr Gly Ile Ala Pro Phe Arg Ser Phe 980 985 990 Trp Gln Gln Arg Leu His Asp Ser Gln His Lys Gly Val Arg Gly Gly 995 1000 1005 Arg Met Thr Leu Val Phe Gly Cys Arg Arg Pro Asp Glu Asp His 1010 1015 1020 Ile Tyr Gln Glu Glu Met Leu Glu Met Ala Gln Lys Gly Val Leu 1025 1030 1035 His Ala Val His Thr Ala Tyr Ser Arg Leu Pro Gly Lys Pro Lys 1040 1045 1050 Val Tyr Val Gln Asp Ile Leu Arg Gln Gln Leu Ala Ser Glu Val 1055 1060 1065 Leu Arg Val Leu His Lys Glu Pro Gly His Leu Tyr Val Cys Gly 1070 1075 1080 Asp Val Arg Met Ala Arg Asp Val Ala His Thr Leu Lys Gln Leu 1085 1090 1095 Val Ala Ala Lys Leu Lys Leu Asn Glu Glu Gln Val Glu Asp Tyr 1100 1105 1110 Phe Phe Gln Leu Lys Ser Gln Lys Arg Tyr His Glu Asp Ile Phe 1115 1120 1125 Gly Ala Val Phe Pro Tyr Glu Ala Lys Lys Asp Arg Val Ala Val 1130 1135 1140 Gln Pro Ser Ser Leu Glu Met Ser Ala Leu 1145 1150 39 2943 DNA Homo sapiens 39 accaggcaac accattgaag gctcatatgt aaaaatccat gccttccttt ctcccaatct 60 ccattcccaa acttagccac tggcttctgg ctgaggcctt acgcatacct cccggggctt 120 gcacacacct tcttctacag aagacacacc ttgggcatat cctacagaag accaggcttc 180 tctctggtcc ttggtagagg gctactttac tgtaacaggg ccagggtgga gagttctctc 240 ctgaagctcc atcccctcta taggaaatgt gttgacaata ttcagaagag taagaggatc 300 aagacttctt tgtgctcaaa taccactgtt ctcttctcta ccctgcccta accaggagct 360 tgtcacccca aactctgagg tgatttatgc cttaatcaag caaacttccc tcttcagaaa 420 agatggctca ttttccctca aaagttgcca ggagctgcca agtattctgc caattcaccc 480 tggagcacaa tcaacaaatt cagccagaac acaactacag ctactattag aactattatt 540 attaataaat tcctctccaa atctagcccc ttgacttcgg atttcacgat ttctcccttc 600 ctcctagaaa cttgataagt ttcccgcgct tccctttttc taagactaca tgtttgtcat 660 cttataaagc aaaggggtga ataaatgaac caaatcaata acttctggaa tatctgcaaa 720 caacaataat atcagctatg ccatctttca ctattttagc cagtatcgag ttgaatgaac 780 atagaaaaat acaaaactga attcttccct gtaaattccc cgttttgacg acgcacttgt 840 agccacgtag ccacgcctac ttaagacaat tacaaaaggc gaagaagact gactcaggct 900 taagctgcca gccagagagg gagtcatttc attggcgttt gagtcagcaa agaagtcaag 960 atggccaaag ttccagacat gtttgaagac ctgaagaact gttacagtga aaatgaagaa 1020 gacagttcct ccattgatca tctgtctctg aatcagaaat ccttctatca tgtaagctat 1080 ggcccactcc atgaaggctg catggatcaa tctgtgtctc tgagtatctc tgaaacctct 1140 aaaacatcca agcttacctt caaggagagc atggtggtag tagcaaccaa cgggaaggtt 1200 ctgaagaaga gacggttgag tttaagccaa tccatcactg atgatgacct ggaggccatc 1260 gccaatgact cagaggaaga aatcatcaag cctaggtcag caccttttag cttcctgagc 1320 aatgtgaaat acaactttat gaggatcatc aaatacgaat tcatcctgaa tgacgccctc 1380 aatcaaagta taattcgagc caatgatcag tacctcacgg ctgctgcatt acataatctg 1440 gatgaagcag tgaaatttga catgggtgct tataagtcat caaaggatga tgctaaaatt 1500 accgtgattc taagaatctc aaaaactcaa ttgtatgtga ctgcccaaga tgaagaccaa 1560 ccagtgctgc tgaaggagat gcctgagata cccaaaacca tcacaggtag tgagaccaac 1620 ctcctcttct tctgggaaac tcacggcact aagaactatt tcacatcagt tgcccatcca 1680 aacttgttta ttgccacaaa gcaagactac tgggtgtgct tggcaggggg gccaccctct 1740 atcactgact ttcagatact ggaaaaccag gcgtaggtct ggagtctcac ttgtctcact 1800 tgtgcagtgt tgacagttca tatgtaccat gtacatgaag aagctaaatc ctttactgtt 1860 agtcatttgc tgagcatgta ctgagccttg taattctaaa tgaatgttta cactctttgt 1920 aagagtggaa ccaacactaa catataatgt tgttatttaa agaacaccct atattttgca 1980 tagtaccaat cattttaatt attattcttc ataacaattt taggaggacc agagctactg 2040 actatggcta ccaaaaagac tctacccata ttacagatgg gcaaattaag gcataagaaa 2100 actaagaaat atgcacaata gcagttgaaa caagaagcca cagacctagg atttcatgat 2160 ttcatttcaa ctgtttgcct tctactttta agttgctgat gaactcttaa tcaaatagca 2220 taagtttctg ggacctcagt tttatcattt tcaaaatgga gggaataata cctaagcctt 2280 cctgccgcaa cagtttttta tgctaatcag ggaggtcatt ttggtaaaat acttcttgaa 2340 gccgagcctc aagatgaagg caaagcacga aatgttattt tttaattatt atttatatat 2400 gtatttataa atatatttaa gataattata atatactata tttatgggaa ccccttcatc 2460 ctctgagtgt gaccaggcat cctccacaat agcagacagt gttttctggg ataagtaagt 2520 ttgatttcat taatacaggg cattttggtc caagttgtgc ttatcccata gccaggaaac 2580 tctgcattct agtacttggg agacctgtaa tcatataata aatgtacatt aattaccttg 2640 agccagtaat tggtccgatc tttgactctt ttgccattaa acttacctgg gcattcttgt 2700 ttcaattcca cctgcaatca agtcctacaa gctaaaatta gatgaactca actttgacaa 2760 ccatgagacc actgttatca aaactttctt ttctggaatg taatcaatgt ttcttctagg 2820 ttctaaaaat tgtgatcaga ccataatgtt acattattat caacaatagt gattgataga 2880 gtgttatcag tcataactaa ataaagcttg caacaaaatt ctctgacaaa aaaaaaaaaa 2940 aaa 2943 40 271 PRT Homo sapiens 40 Met Ala Lys Val Pro Asp Met Phe Glu Asp Leu Lys Asn Cys Tyr Ser 1 5 10 15 Glu Asn Glu Glu Asp Ser Ser Ser Ile Asp His Leu Ser Leu Asn Gln 20 25 30 Lys Ser Phe Tyr His Val Ser Tyr Gly Pro Leu His Glu Gly Cys Met 35 40 45 Asp Gln Ser Val Ser Leu Ser Ile Ser Glu Thr Ser Lys Thr Ser Lys 50 55 60 Leu Thr Phe Lys Glu Ser Met Val Val Val Ala Thr Asn Gly Lys Val 65 70 75 80 Leu Lys Lys Arg Arg Leu Ser Leu Ser Gln Ser Ile Thr Asp Asp Asp 85 90 95 Leu Glu Ala Ile Ala Asn Asp Ser Glu Glu Glu Ile Ile Lys Pro Arg 100 105 110 Ser Ala Pro Phe Ser Phe Leu Ser Asn Val Lys Tyr Asn Phe Met Arg 115 120 125 Ile Ile Lys Tyr Glu Phe Ile Leu Asn Asp Ala Leu Asn Gln Ser Ile 130 135 140 Ile Arg Ala Asn Asp Gln Tyr Leu Thr Ala Ala Ala Leu His Asn Leu 145 150 155 160 Asp Glu Ala Val Lys Phe Asp Met Gly Ala Tyr Lys Ser Ser Lys Asp 165 170 175 Asp Ala Lys Ile Thr Val Ile Leu Arg Ile Ser Lys Thr Gln Leu Tyr 180 185 190 Val Thr Ala Gln Asp Glu Asp Gln Pro Val Leu Leu Lys Glu Met Pro 195 200 205 Glu Ile Pro Lys Thr Ile Thr Gly Ser Glu Thr Asn Leu Leu Phe Phe 210 215 220 Trp Glu Thr His Gly Thr Lys Asn Tyr Phe Thr Ser Val Ala His Pro 225 230 235 240 Asn Leu Phe Ile Ala Thr Lys Gln Asp Tyr Trp Val Cys Leu Ala Gly 245 250 255 Gly Pro Pro Ser Ile Thr Asp Phe Gln Ile Leu Glu Asn Gln Ala 260 265 270 41 1358 DNA Homo sapiens 41 aaaagccatg gccgacaagg tcctgaagga gaagagaaag ctgtttatcc gttccatggg 60 tgaaggtaca ataaatggct tactggatga attattacag acaagggtgc tgaacaagga 120 agagatggag aaagtaaaac gtgaaaatgc tacagttatg gataagaccc gagctttgat 180 tgactccgtt attccgaaag gggcacaggc atgccaaatt tgcatcacat acatttgtga 240 agaagacagt tacctggcag ggacgctggg actctcagca gatcaaacat ctggaaatta 300 ccttaatatg caagactctc aaggagtact ttcttccttt ccagctcctc aggcagtgca 360 ggacaaccca gctatgccca catcctcagg ctcagaaggg aatgtcaagc tttgctccct 420 agaagaagct caaaggatat ggaaacaaaa gtcggcagag atttatccaa taatggacaa 480 gtcaagccgc acacgtcttg ctctcattat ctgcaatgaa gaatttgaca gtattcctag 540 aagaactgga gctgaggttg acatcacagg catgacaatg ctgctacaaa atctggggta 600 cagcgtagat gtgaaaaaaa atctcactgc ttcggacatg actacagagc tggaggcatt 660 tgcacaccgc ccagagcaca agacctctga cagcacgttc ctggtgttca tgtctcatgg 720 tattcgggaa ggcatttgtg ggaagaaaca ctctgagcaa gtcccagata tactacaact 780 caatgcaatc tttaacatgt tgaataccaa gaactgccca agtttgaagg acaaaccgaa 840 ggtgatcatc atccaggcct gccgtggtga cagccctggt gtggtgtggt ttaaagattc 900 agtaggagtt tctggaaacc tatctttacc aactacagaa gagtttgagg atgatgctat 960 taagaaagcc cacatagaga aggattttat cgctttctgc tcttccacac cagataatgt 1020 ttcttggaga catcccacaa tgggctctgt ttttattgga agactcattg aacatatgca 1080 agaatatgcc tgttcctgtg atgtggagga aattttccgc aaggttcgat tttcatttga 1140 gcagccagat ggtagagcgc agatgcccac cactgaaaga gtgactttga caagatgttt 1200 ctacctcttc ccaggacatt aaaataagga aactgtatga atgtctgtgg gcagggtgaa 1260 gagatccttc tgtaaaggtt tttgaattat gtctgctgaa taataaactt ttttgaaata 1320 ataaatctgg tagaaaaatg aaaaaaaaaa aaaaaaaa 1358 42 404 PRT Homo sapiens 42 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe Ile Arg Ser 1 5 10 15 Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Gln Thr 20 25 30 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 35 40 45 Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser Val Ile Pro Lys 50 55 60 Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp 65 70 75 80 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gln Thr Ser Gly 85 90 95 Asn Tyr Leu Asn Met Gln Asp Ser Gln Gly Val Leu Ser Ser Phe Pro 100 105 110 Ala Pro Gln Ala Val Gln Asp Asn Pro Ala Met Pro Thr Ser Ser Gly 115 120 125 Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala Gln Arg Ile 130 135 140 Trp Lys Gln Lys Ser Ala Glu Ile Tyr Pro Ile Met Asp Lys Ser Ser 145 150 155 160 Arg Thr Arg Leu Ala Leu Ile Ile Cys Asn Glu Glu Phe Asp Ser Ile 165 170 175 Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Thr Gly Met Thr Met Leu 180 185 190 Leu Gln Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala 195 200 205 Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His 210 215 220 Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly Ile Arg 225 230 235 240 Glu Gly Ile Cys Gly Lys Lys His Ser Glu Gln Val Pro Asp Ile Leu 245 250 255 Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser 260 265 270 Leu Lys Asp Lys Pro Lys Val Ile Ile Ile Gln Ala Cys Arg Gly Asp 275 280 285 Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn 290 295 300 Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala Ile Lys Lys 305 310 315 320 Ala His Ile Glu Lys Asp Phe Ile Ala Phe Cys Ser Ser Thr Pro Asp 325 330 335 Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe Ile Gly Arg 340 345 350 Leu Ile Glu His Met Gln Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu 355 360 365 Ile Phe Arg Lys Val Arg Phe Ser Phe Glu Gln Pro Asp Gly Arg Ala 370 375 380 Gln Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu 385 390 395 400 Phe Pro Gly His 43 6752 DNA Homo sapiens 43 ctgaatagtg tccaggtgat ttagaggata aataaaaatc cattaaagag gtaaagacat 60 aaaaacgaga aacatggact ggtttacaca taacacatac aaagtctatt ataaaactag 120 catcagtatc cttgaatgca aacctttttc tgagtattta acaatcgcac cctttaaaaa 180 atgtacaata gacattaaga gacttaaaca gatatataat cattttaaat taaaatagcg 240 ttaaacagta cctcaagctc aataagcatt ttaagtattc taatcttagt atttctctag 300 ctgacatgta agaagcaatc tatcttattg tatgcaatta gctcattgtg tggataaaaa 360 ggtaaaacca ttctgaaaca ggaaaccaat acacttcctg tttaatcaac aaatctaaac 420 atttattctt ttcatctgtt tactcttgct cttgtccacc acaatatgct attcacatgt 480 tcagtgtagt tttatgacaa agaaaatttt ctgagttact tttgtatccc caccccctta 540 aagaaaggag gaaaaactgt ttcatacaga aggcgttaat tgcatgaatt agagctatca 600 cctaagtgtg ggctaatgta acaaagaggg atttcaccta catccattca gtcagtcttt 660 gggggtttaa agaaattcca aagagtcatc agaagaggaa aaatgaaggt aatgtttttt 720 cagacaggta aagtctttga aaatatgtgt aatatgtaaa acattttgac acccccataa 780 tatttttcca gaattaacag tataaattgc atctcttgtt caagagttcc ctatcactct 840 ctttaatcac tactcacagt aacctcaact cctgccacaa tgtacaggat gcaactcctg 900 tcttgcattg cactaagtct tgcacttgtc acaaacagtg cacctacttc aagttctaca 960 aagaaaacac agctacaact ggagcattta ctgctggatt tacagatgat tttgaatgga 1020 attaatgtaa gtatatttcc tttcttacta aaattattac atttagtaat ctagctggag 1080 atcatttctt aataacaatg cattatactt tcttagaatt acaagaatcc caaactcacc 1140 aggatgctca catttaagtt ttacatgccc aagaaggtaa gtacaatatt ttatgttcaa 1200 tttctgtttt aataaaattc aaagtaatat gaaaatttgc acagatggga ctaatagcag 1260 ctcatctgag gtaaagagta actttaattt gtttttttga aaacccaagt ttgataatga 1320 agcctctatt aaaacagttt tacctatatt tttaatatat atttgtgtgt tggtgggggt 1380 gggaagaaaa cataaaaata atattctcac tttatcgata agacaattct aaacaaaaat 1440 gttcatttat ggtttcattt aaaaatgtaa aactctaaaa tatttgatta tgtcatttta 1500 gtatgtaaaa taccaaaatc tatttccaag gagcccactt ttaaaaatct tttcttgttt 1560 taggaaaggt ttctaagtga gaggcagcat aacactaata gcacagagtc tggggccaga 1620 tatctgaagt gaaatctcag ctctgccatg tcctagcttt catgatcttt ggcaaattac 1680 ctactctgtt tgtgattcag tttcatgtct acttaaatga ataactgtat atacttaata 1740 tggctttgtg agaattagta agtaaatgta aagcactcag aaccgtgtct ggcataaggt 1800 aaataccata caagcattag ctattattag tagtattaaa gataaaattt tcactgagaa 1860 atacaaagta aaattttgga ctttatcttt ttaccaatag aacttgagat ttataatgct 1920 atatgactta ttttccaaga ttaaaagctt cattaggttg tttttggatt cagatagagc 1980 ataagcataa tcatccaagc tcctaggcta cattaggtgt gtaaagctac ctagtagctg 2040 tgccagttaa gagagaatga acaaaatctg gtgccagaaa gagcttgtgc cagggtgaat 2100 ccaagcccag aaaataatag gatttaaggg gacacagatg caatcccatt gactcaaatt 2160 ctattaattc aagagaaatc tgcttctaac tacccttctg aaagatgtaa aggagacagc 2220 ttacagatgt tactctagtt taatcagagc cacataatgc aactccagca acataaagat 2280 actagatgct gttttctgaa gaaaatttct ccacattgtt catgccaaaa acttaaaccc 2340 gaatttgtag aatttgtagt ggtgaattga aagcgcaata gatggacata tcaggggatt 2400 ggtattgtct tgacctacct ttcccactaa agagtgttag aaagatgaga ttatgtgcat 2460 aatttagggg gtggtagaat tcatggaaat ctaagtttga aaccaaaagt aatgataaac 2520 tctattcatt tgttcattta accctcattg cacatttaca aaagatttta gaaactaata 2580 aaaatatttg attccaagga tgctatgtta atgctataat gagaaagaaa tgaaatctaa 2640 ttctggctct acctacttat gtggtcaaat tctgagattt agtgtgctta tttataaagt 2700 ggagatgata cttcactgcc tacttcaaaa gatgactgtg agaagtaaat gggcctattt 2760 tggagaaaat tcttttaaat tgtaatatac catagaaata tgaaatatta tatataatat 2820 agaatcaaga ggcctgtcca aaagtcctcc caaagtatta taatctttta tttcactggg 2880 acaaacattt ttaaaatgca tcttaatgta gtgattgtag aaaagtaaaa atttaagaca 2940 tatttaaaaa tgtgtcttgc tcaaggctat attgagagcc actactacat gattattgtt 3000 acctagtgta aaatgttggg attgtgatag atggcatcca agagttcctt ctctctcaac 3060 attctgtgat tcttaactct tagactatca aatattataa tcatagaatg tgatttttat 3120 gcttccacat tctaactcat ctggttctaa tgattttcta tgcagattgg aaaagtaatc 3180 agcctacatc tgtaataggc atttagatgc agaaagtcta acattttgca aagccaaatt 3240 aagctaaaac cagtgagtca actatcactt aacgctagtc ataggtactt gagccctagt 3300 ttttccagtt ttataatgta aactctactg gtccatcttt acagtgacat tgagaacaga 3360 gagaatggta aaaactacat actgctactc caaataaaat aaattggaaa ttaatttctg 3420 attctgacct ctatgtaaac tgagctgatg ataattatta ttctaggcca cagaactgaa 3480 acatcttcag tgtctagaag aagaactcaa acctctggag gaagtgctaa atttagctca 3540 aagcaaaaac tttcacttaa gacccaggga cttaatcagc aatatcaacg taatagttct 3600 ggaactaaag gtaaggcatt actttatttg ctctcctgga aataaaaaaa aaaaagtagg 3660 gggaaaagta ccccatttta aagtgacata acatttttgg tatttgtaaa gtacccatgc 3720 atgtaattag cctacatttt aagtacactg tgaacatgaa tcatttctaa tgttaaatga 3780 ttaactgggg agtataagct actgagtttg cacctaccat ctactaatgg acaagcctca 3840 tcccaaactc catcaccttt catattaaca caaaactggg agtgagagaa ggtactgagt 3900 tgagtttcac agaaagcagg cagattttat tatatatttt tcaattcctt cagatcattt 3960 actggaatag ccaatactga ttacctgaaa ggcttttcaa atggtgtttc cttatcattt 4020 gatggaagga ctacccataa gagatttgtc ttaaaaaaaa aaactggagc cattaaaatg 4080 gccagtggac taaacaaaca acaatctttt tagaggcaat ccccactttc agaatcttaa 4140 gtatttttaa atgcacagga agcataaaat atgcaaggga ctcaggtgat gtaaaagaga 4200 ttcacttttg tctttttata tcccgtctcc taaggtataa aattcatgag ttaataggta 4260 tcctaaataa gcagcataag tatagtagta aaagacattc ctaaaagtaa ctccagttgt 4320 gtccaaatga atcacttatt agtggactgt ttcagttgaa ttaaaaaaat acattgagat 4380 caatgtcatc tagacattga cagattcagt tccttatcta tggcaagagt tttactctaa 4440 aataattaac atcagaaaac tcattcttaa ctcttgatac aaatttaaga caaaaccatg 4500 caaaaatctg aaaactgtgt ttcaaaagcc aaacactttt taaaataaaa aaatcccaag 4560 atatgacaat atttaaacaa ttatgcttaa gaggatacag aacactgcaa cagtttttta 4620 aaagagaata cttatttaaa gggaacactc tatctcacct gcttttgttc ccagggtagg 4680 aatcacttca aatttgaaaa gctctctttt aaatctcact atatatcaaa aatatttcct 4740 ccttagctta tcaactagag gaagcgttta aatagctcct ttcagcagag aagcctaatt 4800 tctaaaaagc cagtccacag aacaaaattt ctaatgttta aacttttaaa agttggcaaa 4860 ttcacctgca ttgatactat gatggggtag ggataggtgt aagtatttat gaagatgttc 4920 ttcacacaaa tttatcccaa acagaagcat gtcctagctt actctagtgt agttctgttc 4980 tgctttgggg aaaatataag gagattcact taagtagaaa aataggagac tctaatcaag 5040 atttagaaaa gaagaaagta taatgtgcat atcaattcat acatttaact tacacaaata 5100 taggtgtaca ttcagaggaa aagcgatcaa gtttatttca catccagcat ttaatatttg 5160 tctagatcta tttttattta aatctttatt tgcacccaat ttagggaaaa aatttttgtg 5220 ttcattgact gaattaacaa atgaggaaaa tctcagcttc tgtgttacta tcatttggta 5280 tcataacaaa atatgtaatt ttggcattca ttttgatcat ttcaagaaaa tgtgaataat 5340 taatatgttt ggtaagcttg aaaataaagg caacaggcct ataagacttc aattgggaat 5400 aactgtatat aaggtaaact actctgtact ttaaaaaatt aacatttttc ttttataggg 5460 atctgaaaca acattcatgt gtgaatatgc tgatgagaca gcaaccattg tagaatttct 5520 gaacagatgg attacctttt gtcaaagcat catctcaaca ctgacttgat aattaagtgc 5580 ttcccactta aaacatatca ggccttctat ttatttaaat atttaaattt tatatttatt 5640 gttgaatgta tggtttgcta cctattgtaa ctattattct taatcttaaa actataaata 5700 tggatctttt atgattcttt ttgtaagccc taggggctct aaaatggttt cacttattta 5760 tcccaaaata tttattatta tgttgaatgt taaatatagt atctatgtag attggttagt 5820 aaaactattt aataaatttg ataaatataa acaagcctgg atatttgtta ttttggaaac 5880 agcacagagt aagcatttaa atatttctta gttacttgtg tgaactgtag gatggttaaa 5940 atgcttacaa aagtcactct ttctctgaag aaatatgtag aacagagatg tagacttctc 6000 aaaagccctt gctttgtcct ttcaagggct gatcagaccc ttagttctgg catctcttag 6060 cagattatat tttccttctt cttaaaatgc caaacacaaa cactcttgaa actcttcata 6120 gatttggtgt ggctatgaat tctccaatat cttacaccct gcccagtgct gtgaggaggc 6180 tcacctgtat ggcctatatc aaaggtcttc cctgcccttt ggctttccat tgggtcctgc 6240 cactggggag tgctggtagg aactatgagg aacataagag attcccttga ctccctcctt 6300 gtggagtaga cccaggatgg ctgtgtctct caagcaagga acccagatta cctcaaggtg 6360 gcactctggg tactttttcc ttctgagtga ttctggtaat cttcccttgt ccctttaagc 6420 ctagggaggg tggtactttt gctgttagca actccagggt acttgtacca tcccttgcag 6480 tttccctgaa ctctgaccat agctttttaa atagtccttt tattaaatcc tccttttgat 6540 tgagtatgcc atctatttcc tgctgggact cagatacagt aattgtatca gaaatagccc 6600 cagaaaatag accctcaaaa taggattctg ggactgggtt gttcatatat tcaaggaatg 6660 caaggataat aggacatggg aaatctacgg gatgtagtag catcgcaatt actgaactta 6720 tcatcaatgg tagaatggga tgaaatgcag ac 6752 44 153 PRT Homo sapiens 44 Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 1 5 10 15 Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu 20 25 30 Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile 35 40 45 Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe 50 55 60 Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu 65 70 75 80 Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys 85 90 95 Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile 100 105 110 Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala 115 120 125 Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe 130 135 140 Cys Gln Ser Ile Ile Ser Thr Leu Thr 145 150 45 924 DNA Homo sapiens 45 cagagcccca cgaaggacca gaacaagaca gagtgcctcc tgccgatcca aacatgagcc 60 gcctgcccgt cctgctcctg ctccaactcc tggtccgccc cggactccaa gctcccatga 120 cccagacaac gcccttgaag acaagctggg ttaactgctc taacatgatc gatgaaatta 180 taacacactt aaagcagcca cctttgcctt tgctggactt caacaacctc aatggggaag 240 accaagacat tctgatggaa aataaccttc gaaggccaaa cctggaggca ttcaacaggg 300 ctgtcaagag tttacagaac gcatcagcaa ttgagagcat tcttaaaaat ctcctgccat 360 gtctgcccct ggccacggcc gcacccacgc gacatccaat ccatatcaag gacggtgact 420 ggaatgaatt ccggaggaaa ctgacgttct atctgaaaac ccttgagaat gcgcaggctc 480 aacagacgac tttgagcctc gcgatctttt gagtccaacg tccagctcgt tctctgggcc 540 ttctcaccac agagcctcgg gacatcaaaa acagcagaac ttctgaaacc tctgggtcat 600 ctctcacaca ttccaggacc agaagcattt caccttttcc tgcggcatca gatgaattgt 660 taattatcta atttctgaaa tgtgcagctc ccatttggcc ttgtgcggtt gtgttctcat 720 ttttatccca ttgagactat ttatttatgt atgtatgtat ttatttattt attgcctgga 780 gtgtgaactg tatttatttt agcagaggag ccatgtcctg ctgcttctgc aaaaaactca 840 gagtggggtg gggagcatgt tcatttgtac ctcgagtttt aaactggttc ctagggatgt 900 gtgagaataa actagactct gaac 924 46 152 PRT Homo sapiens 46 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro 1 5 10 15 Gly Leu Gln Ala Pro Met Thr Gln Thr Thr Pro Leu Lys Thr Ser Trp 20 25 30 Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln 35 40 45 Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln 50 55 60 Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe 65 70 75 80 Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile 85 90 95 Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr 100 105 110 Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg 115 120 125 Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln 130 135 140 Thr Thr Leu Ser Leu Ala Ile Phe 145 150 47 921 DNA Homo sapiens 47 ttctatgcaa agcaaaaagc cagcagcagc cccaagctga taagattaat ctaaagagca 60 aattatggtg taatttccta tgctgaaact ttgtagttaa ttttttaaaa aggtttcatt 120 ttcctattgg tctgatttca caggaacatt ttacctgttt gtgaggcatt ttttctcctg 180 gaagagaggt gctgattggc cccaagtgac tgacaatctg gtgtaacgaa aatttccaat 240 gtaaactcat tttccctcgg tttcagcaat tttaaatcta tatatagaga tatctttgtc 300 agcattgcat cgttagcttc tcctgataaa ctaattgcct cacattgtca ctgcaaatcg 360 acacctatta atgggtctca cctcccaact gcttccccct ctgttcttcc tgctagcatg 420 tgccggcaac tttgtccacg gacacaagtg cgatatcacc ttacaggaga tcatcaaaac 480 tttgaacagc ctcacagagc agaagactct gtgcaccgag ttgaccgtaa cagacatctt 540 tgctgcctcc aagaacacaa ctgagaagga aaccttctgc agggctgcga ctgtgctccg 600 gcagttctac agccaccatg agaaggacac tcgctgcctg ggtgcgactg cacagcagtt 660 ccacaggcac aagcagctga tccgattcct gaaacggctc gacaggaacc tctggggcct 720 ggcgggcttg aattcctgtc ctgtgaagga agccaaccag agtacgttgg aaaacttctt 780 ggaaaggcta aagacgatca tgagagagaa atattcaaag tgttcgagct gaatatttta 840 atttatgagt ttttgatagc tttatttttt aagtatttat atatttataa ctcatcataa 900 aataaagtat atatagaatc t 921 48 153 PRT Homo sapiens 48 Met Gly Leu Thr Ser Gln Leu Leu Pro Pro Leu Phe Phe Leu Leu Ala 1 5 10 15 Cys Ala Gly Asn Phe Val His Gly His Lys Cys Asp Ile Thr Leu Gln 20 25 30 Glu Ile Ile Lys Thr Leu Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys 35 40 45 Thr Glu Leu Thr Val Thr Asp Ile Phe Ala Ala Ser Lys Asn Thr Thr 50 55 60 Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu Arg Gln Phe Tyr 65 70 75 80 Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala Thr Ala Gln Gln 85 90 95 Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg 100 105 110 Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro Val Lys Glu Ala 115 120 125 Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu Lys Thr Ile Met 130 135 140 Arg Glu Lys Tyr Ser Lys Cys Ser Ser 145 150 49 1125 DNA Homo sapiens 49 ttctgccctc gagcccaccg ggaacgaaag agaagctcta tctcgcctcc aggagcccag 60 ctatgaactc cttctccaca agcgccttcg gtccagttgc cttctccctg gggctgctcc 120 tggtgttgcc tgctgccttc cctgccccag tacccccagg agaagattcc aaagatgtag 180 ccgccccaca cagacagcca ctcacctctt cagaacgaat tgacaaacaa attcggtaca 240 tcctcgacgg catctcagcc ctgagaaagg agacatgtaa caagagtaac atgtgtgaaa 300 gcagcaaaga ggcactggca gaaaacaacc tgaaccttcc aaagatggct gaaaaagatg 360 gatgcttcca atctggattc aatgaggaga cttgcctggt gaaaatcatc actggtcttt 420 tggagtttga ggtataccta gagtacctcc agaacagatt tgagagtagt gaggaacaag 480 ccagagctgt gcagatgagt acaaaagtcc tgatccagtt cctgcagaaa aaggcaaaga 540 atctagatgc aataaccacc cctgacccaa ccacaaatgc cagcctgctg acgaagctgc 600 aggcacagaa ccagtggctg caggacatga caactcatct cattctgcgc agctttaagg 660 agttcctgca gtccagcctg agggctcttc ggcaaatgta gcatgggcac ctcagattgt 720 tgttgttaat gggcattcct tcttctggtc agaaacctgt ccactgggca cagaacttat 780 gttgttctct atggagaact aaaagtatga gcgttaggac actattttaa ttatttttaa 840 tttattaata tttaaatatg tgaagctgag ttaatttatg taagtcatat ttatattttt 900 aagaagtacc acttgaaaca ttttatgtat tagttttgaa ataataatgg aaagtggcta 960 tgcagtttga atatcctttg tttcagagcc agatcatttc ttggaaagtg taggcttacc 1020 tcaaataaat ggctaactta tacatatttt taaagaaata tttatattgt atttatataa 1080 tgtataaatg gtttttatac caataaatgg cattttaaaa aattc 1125 50 212 PRT Homo sapiens 50 Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu 1 5 10 15 Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro 20 25 30 Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr 35 40 45 Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile 50 55 60 Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn Met Cys Glu Ser 65 70 75 80 Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met Ala 85 90 95 Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu 100 105 110 Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr 115 120 125 Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln 130 135 140 Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn 145 150 155 160 Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu 165 170 175 Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His 180 185 190 Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala 195 200 205 Leu Arg Gln Met 210 51 5191 DNA Homo sapiens 51 gaattcagta acccaggcat tattttatcc tcaagtctta ggttggttgg agaaagataa 60 caaaaagaaa catgattgtg cagaaacaga caaacctttt tggaaagcat ttgaaaatgg 120 cattccccct ccacagtgtg ttcacagtgt gggcaaattc actgctctgt cgtactttct 180 gaaaatgaag aactgttaca ccaaggtgaa ttatttataa attatgtact tgcccagaag 240 cgaacagact tttactatca taagaaccct tccttggtgt gctctttatc tacagaatcc 300 aagacctttc aagaaaggtc ttggattctt ttcttcagga cactaggaca taaagccacc 360 tttttatgat ttgttgaaat ttctcactcc atcccttttg ctgatgatca tgggtcctca 420 gaggtcagac ttggtgtcct tggataaaga gcatgaagca acagtggctg aaccagagtt 480 ggaacccaga tgctctttcc actaagcata caactttcca ttagataaca cctccctccc 540 accccaacca agcagctcca gtgcaccact ttctggagca taaacatacc ttaactttac 600 aacttgagtg gccttgaata ctgttcctat ctggaatgtg ctgttctctt tcatcttcct 660 ctattgaagc cctcctattc ctcaatgcct tgctccaact gcctttggaa gattctgctc 720 ttatgcctcc actggaatta atgtcttagt accacttgtc tattctgcta tatagtcagt 780 ccttacattg ctttcttctt ctgatagacc aaactcttta aggacaagta cctagtctta 840 tctatttcta gatcccccac attactcaga aagttactcc ataaatgttt gtggaactga 900 tttctatgtg aagacatgtg ccccttcact ctgttaacta gcattagaaa aacaaatctt 960 ttgaaaagtt gtagtatgcc cctaagagca gtaacagttc ctagaaactc tctaaaatgc 1020 ttagaaaaag atttatttta aattacctcc ccaataaaat gattggctgg cttatcttca 1080 ccatcatgat agcatctgta attaactgaa aaaaaataat tatgccatta aaagaaaatc 1140 atccatgatc ttgttctaac acctgccact ctagtactat atctgtcaca tggtctatga 1200 taaagttatc tagaaataaa aaagcataca attgataatt caccaaattg tggagcttca 1260 gtattttaaa tgtatattaa aattaaatta ttttaaagat caaagaaaac tttcgtcata 1320 ctccgtattt gataaggaac aaataggaag tgtgatgact caggtttgcc ctgaggggat 1380 gggccatcag ttgcaaatcg tggaatttcc tctgacataa tgaaaagatg agggtgcata 1440 agttctctag tagggtgatg atataaaaag ccaccggagc actccataag gcacaaactt 1500 tcagagacag cagagcacac aagcttctag gacaagagcc aggaagaaac caccggaagg 1560 aaccattctc actgtgtgta aacatgactt ccaagctggc cgtggctctc ttggcagcct 1620 tcctgatttc tgcagctctg tgtgaaggta agcacatctt tctgacctac agcgttttcc 1680 tatgtctaaa tgtgatcctt agatagcaaa gctattcttg atgctttggt aacaaacatc 1740 ctttttattc agaaacagaa tataatctta gcagtcaatt aatgttaaat tgaagattta 1800 gaaaaaacta tatataacac ttaggaaata taaaggtttg atcaatatag atattctgct 1860 tttataattt ataccaggta gcatgcatat atttaacgta aataagtaat ttatagtatg 1920 tcctattgag aaccacggtt acctatatta tgtattaata ttgagttgag caaggtaact 1980 cagacaattc cactccttgt agtatttcat tgacaagcct cagatttgtc attaattcct 2040 gtctggttta aagataccct gattatagac caggcatgta taacttattt atatatttct 2100 gttaattctt tctgaaggca atttctatgc tggagagtct tagcttgcct actataaata 2160 acactgtggt atcacagagg attatgcaat attgaccaga taaaaatacc atgaagatgt 2220 tgatattgta caaaaagaac tctaactctt atataggaag ttgttcaatg ttgtcagtta 2280 tgactgtttt ttaaaacaaa gaactaactg aggtcaaggg ctaggagata ttcaggaatg 2340 agttcactag aaacatgatg ccttccatag tctccaaata atcatattgg aattagaagg 2400 aagtagctgg cagagctgtg cctgttgata aaatcaatcc ttaatcactt tttcccccaa 2460 caggtgcagt tttgccaagg agtgctaaag aacttagatg tcagtgcata aagacatact 2520 ccaaaccttt ccaccccaaa tttatcaaag aactgagagt gattgagagt ggaccacact 2580 gcgccaacac agaaattatg taagtacttt aaaaaagatt agatattttg ttttagcaaa 2640 cttaaaatta aggaaggtgg aaatatttag gaaagttcca ggtgttagga ttacagtagt 2700 aaatgaaaca aaacaaaata aaaatatttg tctacatgac atttaaatat ggtagcttcc 2760 acaactacta taaatgttat tttggactta gactttatgc ctgacttaag gaatcatgat 2820 ttgaatgcaa aaactaaata ttaatctgaa ccatttcttt cttatttcag tgtaaagctt 2880 tctgatggaa gagagctctg tctggacccc aaggaaaact gggtgcagag ggttgtggag 2940 aagtttttga agaggtaagt tatatatttt ttaatttaaa tttttcattt atcctgagac 3000 atataatcca aagtcagcct ataaatttct ttctgttgct aaaaatcgtc attaggtatc 3060 tgcctttttg gttaaaaaaa aaggaatagc atcaatagtg agtttgttgt acttatgacc 3120 agaaagacca tacatagttt gcccaggaaa ttctgggttt aagcttgtgt cctatactct 3180 tagtaaagtt ctttgtcact cccagtagtg tcctatttta gatgataatt tctttgatct 3240 ccctatttat agttgagaat atagagcatt tctaacacat gaatgtcaaa gactatattg 3300 acttttcaag aaccctactt tccttcttat taaacatagc tcatctttat atttttaatt 3360 ttattttagg gctgagaatt cataaaaaaa ttcattctct gtggtatcca agaatcagtg 3420 aagatgccag tgaaacttca agcaaatcta cttcaacact tcatgtattg tgtgggtctg 3480 ttgtagggtt gccagatgca atacaagatt cctggttaaa tttgaatttc agtaaacaat 3540 gaatagtttt tcattgtacc atgaaatatc cagaacatac ttatatgtaa agtattattt 3600 atttgaatct acaaaaaaca acaaataatt tttaaatata aggattttcc tagatattgc 3660 acgggagaat atacaaatag caaaattggg ccaagggcca agagaatatc cgaactttaa 3720 tttcaggaat tgaatgggtt tgctagaatg tgatatttga agcatcacat aaaaatgatg 3780 ggacaataaa ttttgccata aagtcaaatt tagctggaaa tcctggattt ttttctgtta 3840 aatctggcaa ccctagtctg ctagccagga tccacaagtc cttgttccac tgtgccttgg 3900 tttctccttt atttctaagt ggaaaaagta ttagccacca tcttacctca cagtgatgtt 3960 gtgaggacat gtggaagcac tttaagtttt ttcatcataa cataaattat tttcaagtgt 4020 aacttattaa cctatttatt atttatgtat ttatttaagc atcaaatatt tgtgcaagaa 4080 tttggaaaaa tagaagatga atcattgatt gaatagttat aaagatgtta tagtaaattt 4140 attttatttt agatattaaa tgatgtttta ttagataaat ttcaatcagg gtttttagat 4200 taaacaaaca aacaattggg tacccagtta aattttcatt tcagatatac aacaaataat 4260 tttttagtat aagtacatta ttgtttatct gaaattttaa ttgaactaac aatcctagtt 4320 tgatactccc agtcttgtca ttgccagctg tgttggtagt gctgtgttga attacggaat 4380 aatgagttag aactattaaa acagccaaaa ctccacagtc aatattagta atttcttgct 4440 ggttgaaact tgtttattat gtacaaatag attcttataa tattatttaa atgactgcat 4500 ttttaaatac aaggctttat atttttaact ttagtgtttt tatgtgctct ccaaattttt 4560 tttactgttt ctgattgtat ggaaatataa aagtaaatat gaaacattta aaatataatt 4620 tgttgtcaaa gtaatcaagt gtttgtcttt tttttagttt tagcttattg ggattctctt 4680 tgtttatatt taaaattata ctttgattta gaaaacataa atgcttcccc ttagcatttt 4740 gttatggaaa attacaaact tttattttta gaaaacagaa ctcctttcca gaaataggtt 4800 acaaacagta gtgtcctcca cagaatgttg gaaatgtttt caactcccca ctgtatacta 4860 tcttgctaat aagtctgtct tcagatttcg attaaccggt ttgtatgtct gtgcacttta 4920 gcatagctgg acattaaaga ggaaagagag tacatattat aagttgctta tcagtaactg 4980 aggagtaaaa ctgataaatg tgaggcaaag aagtttaaaa tatggttaaa gcctaagcat 5040 atttgcaaac aaatcaaaca atactctgag aagtaaaaac ataattattt aattaacaaa 5100 tttcagtgga taaattttat aacaaattag acacagttga aaataaaatt agaaaactag 5160 aaaatagaac aaaagaaact tctggaattc a 5191 52 99 PRT Homo sapiens 52 Met Thr Ser Lys Leu Ala Val Ala Leu Leu Ala Ala Phe Leu Ile Ser 1 5 10 15 Ala Ala Leu Cys Glu Gly Ala Val Leu Pro Arg Ser Ala Lys Glu Leu 20 25 30 Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro Phe His Pro Lys Phe 35 40 45 Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro His Cys Ala Asn Thr 50 55 60 Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu Leu Cys Leu Asp Pro 65 70 75 80 Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys Phe Leu Lys Arg Ala 85 90 95 Glu Asn Ser 53 4663 DNA Homo sapiens 53 cccgggaggc agaggttgca gcgaacctgg attgtgccac cgcactccag cctggtgaca 60 gagggagact ctgtctcaaa aaaaaaaaaa aaaaaaaaag aaatgttact agtatgtagt 120 aagttctcag taaatgttag ctactatact ctttcaagtg ctgggttttt acttgatgtc 180 atacagtgtt atataagatc tccaaagata ctgaggagtc ctcaaggcca attttaacaa 240 gcatggttgc cgcattcttg tgcttatagt tgaacatttc ttctttcaga cacttgcaca 300 aagtgatact tctaagatgc atttgcatta ggtggcaaac ttcatcctgg gtatgaaaaa 360 cattgagatt tgggaataaa gcatagtaag actgaggttg caattactaa aggaaaaccc 420 caacagagat aagtgaagtt ctgcaatatc atgcaccctc ccccaacccg ctctgtctcc 480 ccaggccccc cttcgttaga acacccatga ctggctatat tatatcagca tttcccataa 540 tgtaaaaagg gaaaatacag acctgggcgt tcatggaaag tattctaact ctcacaacca 600 gaatccctgt ctttgaattt tttttcttgg tttttagatc tttaactttt ccttcagcat 660 ttcagtactc aactttttga aaatcatctt ttctgaggaa tgatatttcc tggcacagca 720 tcatctctgt caagtgactc agtttgattt ttttgtttgt tagtataaag tggccccaac 780 ttacagagaa aaagtgggct cttggtatca gtttgatgtc agggtttttc cgtgtttgag 840 agggagcttt aaataccact cgatttgaag gtgtctgcaa gcgagctcca gtccgctgtc 900 aagatgcttc tggccatggt ccttacctct gccctgctcc tgtgctccgt ggcaggccag 960 gggtgtccaa ccttggcggg gatcctggac atcaacttcc tcatcaacaa gatgcaggta 1020 ggctgcaggg ggagcccatg ggaaagacag ctactgacaa agtgaaatat gtatgaggat 1080 gaaaaaactc ggggctgact aaaggttctt atctctctat ctactttagg aagatccagc 1140 ttccaagtgc cactgcagtg ctaatgtgag tgaatgctct ttaagaactt tccaaattaa 1200 ttttaatttt cacatctgga atcttcactc tgaaatttcc cttgcaggtg accagttgtc 1260 tctgtttggg cattccctct gtaagtatag tgaaataaca taatgttgac cttggatttt 1320 tttggtttgt ttttaagtaa aaataagttg ctttatttaa tatttaatgt tatacattgt 1380 tgcttaattt aattgttaca gattagtatt ccctgttaaa accacattgt tacaaattat 1440 tcccttttaa aactacgatc ttgaaatcct atattatgaa catttctttg tatttaatta 1500 actttatgcc tcttgagaag tttgaacact tttcaacatt aaaaaaagaa tcctgaatat 1560 ctttttagat aggtggccat gtgcacaatt aaataaaact ggaactaagg atataataat 1620 tgctgtagct catatcatat tgctttctaa ctcatttact gataactcta gagttgtgaa 1680 acaatgtaaa taaaatgaca actccttatc tttcatctgt catgaatgat ctatgcgcta 1740 tacctccccc tccctgcctc ctcccttcct ccccaccacc ctgttgtctg tctagctgat 1800 tagagtgact gttggtttga atgctgccct ctgggcaggt agaggatctg aggttgtgag 1860 tggaaggagg gcttccagag ggccactgcc cactacggca ggaaggatgg gtggcaggaa 1920 agttctgatt cctaattcaa actcctggtt agggtgagga ggaggcactt ctccaaggtg 1980 cagtgcttta ttctttctca tgcaaggcct gggagaatct gaagaatctg agcttcttgc 2040 cctggctagg gtaagacatc gcacccatcg cggtccatcc attagatgag aagaggatag 2100 agtgccttct gggcaggaac caggcagaca gcacagcccc tgtcccttgg agtaccgtcc 2160 atgtttttag ctgctgctga aataccagct gcattcaatt gtcacatccc attagctggt 2220 gtgaaaaggc ttttcctcac tctgcacttt cagacttaca agccttgaag ccgggaagca 2280 cccgttgaaa agaacattca gagccgacta tttcagggcc cagagccctc atgtttcctg 2340 gatgtaacat acaggaagtc tcctccaggg gatgtcactg tggaaaaatg gcatcccctt 2400 taaatacggg agatcacttc ctacattggc aagggacctg tctaaaaata atgcaagttt 2460 gagtaatggt gattaaataa aaatcatctc tattatattg ctctttgtga tatatttcca 2520 aagctgtcct cagaatattt ctttgaataa atccttacta tttaccagga caactgcacc 2580 agaccatgct tcagtgagag actgtctcag atgaccaata ccaccatgca aacaagatac 2640 ccactgattt tcagtcgggt gaaaaaatca gttgaagtac taaagaacaa caagtgtcca 2700 gtaagtttgt tttcatatgt gatatgttcc tgttggtgat ttctatgtga atggtgatgc 2760 caaccctgtt tgaacacaaa aggatgataa agttggaatt ggtagttcaa ggttgataaa 2820 agacatctaa gaattttaat cagaagtaat ataattaaag tgagatccac tgaaacaata 2880 gaattaaagt gagatagatc attgttcctg acgaggccat ttacttctct ctactatgga 2940 ataatgaaag aatcctttct gagtgtaatt agaagctaca atctagagaa tcagggatgt 3000 agctcacata atactaaatt atcctagaga ttcaatgtac taactgaatg gatgttgtta 3060 acagggattt ttttttcctg ttggttaagg aggttttgtt ttgttttgga gacagagtct 3120 tgctctgttg cccaggctgg agtgcagtgg tgccatctga gctcactgca gcctctgcct 3180 cccgggttca agtgattatc ctgcctcagc ctcccgagta gctggcatta caggtgcgtg 3240 ccaccatgcc tggctaattt ttgtattttt aatagagatg gggtttcacc atgttggcca 3300 ggttgctctc caactcctga actcaagtga tttgcccgcc ttgacctccc aaagtgctgg 3360 gatgacaggt gtgagccacc atgcctggcc tgcattaagg aggtatttaa agggcaatgc 3420 acccaggtca aggtggaagc ttgctactca tcctgaatgc ccatccacac attcttttct 3480 tcagcatata ccctagtccc tgacagcaga ctgggatggc aagttgggta gaggtgacct 3540 ccctgtgttt tttgggtatt agcatctcca cacaagatcc tagaaggctg aaagccctga 3600 gctcagctgt ttagctgcat gcgtttctac catcaatggc atctagttct aagtgcttaa 3660 tatatgctgt ctcactgaat aaatacatac cttagggaca attattcaat ttattactct 3720 cagtgaggtt aactaatttg cctaaggctg catatttgat aagtggcaga gctgagattt 3780 gaactcaggc ctatatgacc tcagagcccc actcttagcc attgtactgt caaatgacct 3840 tggaaagaca acctaaaagg ataatgatac aattttaggc ctcaaagagt ccccagaaaa 3900 ggctttctct aatgcagaga tttagggcca cttaataggg gtgtgtgtgt gtgtgtgtgt 3960 gtgtgtgtgt gtgtgtgtgt gtgtgtaaag acccctgaaa tccaatttga ggtcaaccac 4020 ctatgctgtc tttacaccac atgagctagc ctggacctgc ccacctattt gctctgtgtc 4080 tcaagccact tcccttccca tccccacaat cctcaccacc gactctggct cttggcaggt 4140 aggcttctgg ggctgcttgg ctctacatca tttgagtcac tctgtcctta tcaactttca 4200 tccccacagt atttttcctg tgaacagcca tgcaaccaaa ccacggcagg caacgcgctg 4260 acatttctga agagtcttct ggaaattttc cagaaagaaa agatgagagg gatgagaggc 4320 aagatatgaa gatgaaatat tatttatcct atttattaaa tttaaaaagc tttctcttta 4380 agttgctaca atttaaaaat caagtaagct actctaaatc agtatcagtt gtgattattt 4440 gtttaacatt gtatgtcttt attttgaaat aaatacatat gtggaaaaaa caacatgagc 4500 tggtctcttg gcaattattc atttcttgct gctcagaaca aagaaagcta caagtgttgt 4560 taaggggaag aatagatcag agactcctgt aggagtctct gtgataagac tcctgatgct 4620 gaatacagac cctcaggctc ataggctgtg gctggagctg cag 4663 54 140 PRT Homo sapiens 54 Met Val Leu Thr Ser Ala Leu Leu Leu Cys Ser Val Ala Gly Gln Gly 1 5 10 15 Cys Pro Thr Leu Ala Gly Ile Leu Asp Ile Asn Phe Leu Ile Asn Lys 20 25 30 Met Gln Glu Asp Pro Ala Ser Lys Cys His Cys Ser Ala Asn Val Thr 35 40 45 Ser Cys Leu Cys Leu Gly Ile Pro Ser Asp Asn Cys Thr Arg Pro Cys 50 55 60 Phe Ser Glu Arg Leu Ser Gln Met Thr Asn Thr Thr Met Gln Thr Arg 65 70 75 80 Tyr Pro Leu Ile Phe Ser Arg Val Lys Lys Ser Val Glu Val Leu Lys 85 90 95 Asn Asn Lys Cys Pro Tyr Phe Ser Cys Glu Gln Pro Cys Asn Gln Thr 100 105 110 Thr Ala Gly Asn Ala Leu Thr Phe Leu Lys Ser Leu Leu Glu Ile Phe 115 120 125 Gln Lys Glu Lys Met Arg Gly Met Arg Gly Lys Ile 130 135 140 55 4089 DNA Homo sapiens 55 atgcaccctc caaaatctat ttgcataagc acacacacac acacacacac acacacccca 60 gcagttcttg cctgcccaga ttcctctgca gctaaagtga tgaaacttac tgggcggagc 120 ttcctaaaaa gattattagg gtctcctggg ttggtgtgcc tttaaacctt tggactttac 180 cacctcctat ctctcctatc tccttgcaac aaaggttagg agaacaagaa tgcagaaaaa 240 acgggtcctg gatgacatct gagtgcctgc tttgggcttc ttgatgagtg agacagaaaa 300 taaaatacaa ccccctcttt taaaagccat gcttactcag gttttccttc atttgcagct 360 aaatacagaa atgagagaat attttggagc agggatggaa gaagagaggt attccccttc 420 ccacaacctt ctgatttccc agtacatccc ccactggaaa aattcattta aaatcagtat 480 aataagcatt gattagatgc ctactatgca tctgggcttg agggcaaact ggactcaggc 540 cttttggcct caagaagctc acagtgtgag agtggcattt gtgtcctctt gaaattcaca 600 ggactaaatt gtgcccaggc tgacattcta tccatccata ggtgcctgcc ttctcacttc 660 cctctcttca tgggctcttg ccttgtacca aaatccaaac ccaaatctcc tcacatgtga 720 gtgttggcat tcatgtctca gacatgacct atgggcttgg gacttttccc cgtggacccc 780 agtgactttt cagatgaaca ggtatcttca aaaacttgag aaataggagt cctgtttgtt 840 gttcttgttg ctttgtcaat ataaggacac agggtcttta ttcaaatgtt catatctatc 900 tcttgacaga aatactatga gacatattga tggagaagcc gttatctcca tatgctaaat 960 gaggacttgc accagggaac ttgcccatgg ttctctccaa ccacttaaat tctgaaattt 1020 tgaaatgaga gtggacagta atttcaaatc aatggggaaa gaatcaaatc ttcagcaaat 1080 ggcttgagat aattagctac acatttcaga acaaataaag aagtcagatc cgggccgggc 1140 acagtggctc atgcctgtaa tctcagcact ctgggaggcc aaggcgggcg gatcataagg 1200 tcaggagatc gagaccatcc tggttaacac agtgaaaccc cgtctctaat aaaaatacaa 1260 aaaaaaataa aaaaacttag ccgggcgtgg tgccaggcgc ctgtagtccc agctactcgg 1320 gacgctgagg caggagaatg gcttgaactc gggaggcaga gcttgcagtg agctgagatc 1380 atgccactgc actccagcct gggcaacaga gcgagactct gtctcaaaaa aaaaaaagaa 1440 gtcagatcct aacctcaacc ctatttaaca gattatagat gaaagaaagg tacaaatggc 1500 ttttacatac ctcccttctc cctgacattt tgtatgtgtg tgtgtgtgta tttacacaca 1560 catctcatat aaggaaattg aagggaggct gcctgcatcc ctgagtcact ctccctctcc 1620 ttctgaatgc ttacctgtgc ccagaccacc tccttagcct cgcaccctcc aggcttacag 1680 ggcactcttc tatgcccatc ccaagtatag ctgatacctt ccaagggcca gacttggtgc 1740 taagtaccaa gtacgcaaag attaataaaa caatgtcctg tttcagggag ctcaaagctg 1800 attcggcagg gcatggtgtg tacatgaatg ataaccacgt agggttgcag gtttcctagt 1860 gaggtaagca caaggcaaga tgggaaacaa aggaaggagg ggttcacagc ctcacccaga 1920 gtccagaacc cctggcctgc ctggtgccca tgctgagtcc acttctggaa cacccagctc 1980 agagaggggg ttagacctgc aggctaacac agacacagcc cagaaaaccc aggagccgag 2040 ggggaaggag aaaggtgcaa gaaggggaaa cccaggtcct ggtccccttc tctctgcttc 2100 ctggcagcag aactcagaca gaacccttaa gccagtctaa gtctggcagg accagtaagt 2160 tctgagttag ctccatacta gtttctagca ggctctttct cacttcctga ttcttaggtt 2220 tctacattga cactccctga agagttggga agagacacca cagtcccctg accctgatcc 2280 ataggtcaca cagcagggac atccacaggg tgggcgtggg ccctctcatc cctccctccc 2340 actcacttca cgctggctgg gccccaaggt gtttgcaccc cttgcagtga gtgaccttct 2400 ctagtgcagc aagctcagaa cctgctgcca ctggagttgt cccattgctg atgcagaaag 2460 gtgaagaact agcagaacac tggaaatgcc ctccatctgg gtccatggct acttaagctc 2520 aatgctccct ggcaggcagg aggacaggtg ctattgccct gttgggacag atgaaaaaca 2580 gacacaggga ggatgagtga tttgccctga ctatagagtg gcagggccaa ggcagagccc 2640 aggcctcctg cacctaggtc agtgttcctc ccagttacag tctaaactgg aatggcaggc 2700 aaagcccctg tggaagggga aggtgaaggc tcaatcaaag gatccccaga gactttccag 2760 atatctgaag aagtcctgat gtcactgccc cggtccttcc ccaggtagag caacactcct 2820 cgccgcaacc caactggctc cccttacctt ctacacacac acacacacac acacacacac 2880 acacacacac acacaaatcc aagacaacac tactaaggct tctttgggaa ggggaagtag 2940 ggataggtaa gaggaaagta agggacctcc tatccagcct ccatggaatc ctgacttctt 3000 ttccttgtta tttcaacttc ttccacccca tcttttaaac tttagactcc agccacagaa 3060 gcttacaact aaaagaaact ctaaggccaa tttaatccaa ggtttcattc tatgtgctgg 3120 agatggtgta cagtagggtg aggaaaccaa attctcagtt ggcactggtg tacccttgta 3180 caggtgatgt aacatctctg tgcctcagtt tgctcactat aaaatagaga cggtaggggt 3240 catggtgagc actacctgac tagcatataa gaagctttca gcaagtgcag actactctta 3300 cccacttccc ccaagcacag ttggggtggg ggacagctga agaggtggaa acatgtgcct 3360 gagaatccta atgaaatcgg ggtaaaggag cctggaacac atcctgtgac cccgcctgtc 3420 ctgtaggaag ccagtctctg gaaagtaaaa tggaagggct gcttgggaac tttgaggata 3480 tttagcccac cccctcattt ttacttgggg aaactaaggc ccagagacct aaggtgactg 3540 cctaagttag caaggagaag tcttgggtat tcatcccagg ttggggggac ccaattattt 3600 ctcaatccca ttgtattctg gaatgggcaa tttgtccacg tcactgtgac ctaggaacac 3660 gcgaatgaga acccacagct gagggcctct gcgcacagaa cagctgttct ccccaggaaa 3720 tcaacttttt ttaattgaga agctaaaaaa ttattctaag agaggtagcc catcctaaaa 3780 atagctgtaa tgcagaagtt catgttcaac caatcatttt tgcttacgat gcaaaaattg 3840 aaaactaagt ttattagaga ggttagagaa ggaggagctc taagcagaaa aaatcctgtg 3900 ccgggaaacc ttgattgtgg ctttttaatg aatgaagagg cctccctgag cttacaatat 3960 aaaaggggga cagagaggtg aaggtctaca catcaggggc ttgctcttgc aaaaccaaac 4020 cacaagacag acttgcaaaa gaaggcatgc acagctcagc actgctctgt tgcctggtcc 4080 tcctgactg 4089 56 14 PRT Homo sapiens 56 Met His Ser Ser Ala Leu Leu Cys Cys Leu Val Leu Leu Thr 1 5 10 57 762 DNA Homo sapiens 57 atgtggcccc ctgggtcagc ctcccagcca ccgccctcac ctgccgcggc cacaggtctg 60 catccagcgg ctcgccctgt gtccctgcag tgccggctca gcatgtgtcc agcgcgcagc 120 ctcctccttg tggctaccct ggtcctcctg gaccacctca gtttggccag aaacctcccc 180 gtggccactc cagacccagg aatgttccca tgccttcacc actcccaaaa cctgctgagg 240 gccgtcagca acatgctcca gaaggccaga caaactctag aattttaccc ttgcacttct 300 gaagagattg atcatgaaga tatcacaaaa gataaaacca gcacagtgga ggcctgttta 360 ccattggaat taaccaagaa tgagagttgc ctaaattcca gagagacctc tttcataact 420 aatgggagtt gcctggcctc cagaaagacc tcttttatga tggccctgtg ccttagtagt 480 atttatgaag acttgaagat gtaccaggtg gagttcaaga ccatgaatgc aaagcttctg 540 atggatccta agaggcagat ctttctagat caaaacatgc tggcagttat tgatgagctg 600 atgcaggccc tgaatttcaa cagtgagact gtgccacaaa aatcctccct tgaagaaccg 660 gatttttata aaactaaaat caagctctgc atacttcttc atgctttcag aattcgggca 720 gtgactattg atagagtgat gagctatctg aatgcttcct aa 762 58 253 PRT Homo sapiens 58 Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Ala 1 5 10 15 Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg 20 25 30 Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val 35 40 45 Leu Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro 50 55 60 Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg 65 70 75 80 Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr 85 90 95 Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys 100 105 110 Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu 115 120 125 Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys 130 135 140 Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser 145 150 155 160 Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn 165 170 175 Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn 180 185 190 Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser 195 200 205 Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys 210 215 220 Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala 225 230 235 240 Val Thr Ile Asp Arg Val Met Ser Tyr Leu Asn Ala Ser 245 250 59 471 DNA Homo sapiens 59 tactttggca agcttgaatc taaattatca gtcataagaa atttgaatga ccaagttctc 60 ttcattgacc aaggaaatcg gcctctattt gaagatatga ctgattctga ctgtagagat 120 aatgcacccc ggaccatatt tattataagt atgtataaag atagccagcc tagaggtatg 180 gctgtaacta tctctgtgaa gtgtgagaaa atttcaactc tctcctgtga gaacaaaatt 240 atttccttta aggaaatgaa tcctcctgat aacatcaagg atacaaaaag tgacatcata 300 ttctttcaga gaagtgtccc aggacatgat aataagatgc aatttgaatc ttcatcatac 360 gaaggatact ttctagcttg tgaaaaagag agagaccttt ttaaactcat tttgaaaaaa 420 gaggatgaat tgggggatag atctataatg ttcactgttc aaaacgaaga c 471 60 1831 DNA Homo sapiens 60 gctggagtgc aatggtgaaa ttatagcaga ctgcagtctt caactcctga cctcaagcaa 60 ttgtcctgcc tcctcaactt cctgactaca ggtgtgcatg aggactacag gcaggcatgt 120 gccaacacat gcagcttttt tttttttttt ttttcagaga tgtggtctcg ctttgttgcc 180 tacactggtc tcaaactctt ggcctcaagg gatcctccca cctcggcttc ccaaagtgca 240 gagattacag tctcattttc tctctctctg cattaatcaa gaatgagaga accctccagg 300 ggacaagatg aaggggaaat agatgatgtg caaagaaatc cttgctttat gaggggaaaa 360 agtgttcctc atgaagttca acaaaatgat gcaggtaaag cagttagcta gcacctggca 420 catggcagac actcatagct gcctaaggca ttggagaact ggatcgtgct gcagccagag 480 gcacctgcag agcctcatgg gctggctgct gcagggtgtg gctgattgag agtgcttttg 540 tgagttggcc tgcagggtac acttggtaac gtgccacagc tctcaggaaa gtgacctaag 600 ttggattttt ctgcatggac atagaattgc aaaaaattct catttgcatg gagatgggga 660 gtttattttt cctagaagct gcatgtcaag acccagaaga aagaggcatt tcataataat 720 gattaatcag ctatatctta aagaagaaag aaaacaatta aggaaataca atactaagaa 780 aacaagggga aaaaacaatc tccccaaggt ggatccaccc agcaaacctt gacagcattt 840 cctcttatcc acctgaataa aaatgaccag ccctttccaa atggcagaga gcactgagag 900 gagacacaag gagcagcccg caagcaccaa gtgagaggca tgaagttaca gtgtgtttcc 960 ctttggctcc tgggtacaat actgatattg tgctcagtag acaaccacgg tctcaggaga 1020 tgtctgattt ccacagacat gcaccatata gaagagagtt tccaagaaat caaaagagcc 1080 atccaagcta aggacacctt cccaaatgtc actatcctgt ccacattgga gactctgcag 1140 atcattaagc ccttagatgt gtgctgcgtg accaagaacc tcctggcgtt ctacgtggac 1200 agggtgttca aggatcatca ggagccaaac cccaaaatct tgagaaaaat cagcagcatt 1260 gccaactctt tcctctacat gcagaaaact ctgcggcaat gtcaggaaca gaggcagtgt 1320 cactgcaggc aggaagccac caatgccacc agagtcatcc atgacaacta tgatcagctg 1380 gaggtccacg ctgctgccat taaatccctg ggagagctcg acgtctttct agcctggatt 1440 aataagaatc atgaagtaat gttctcagct tgatgacaag gaacctgtat agtgatccag 1500 ggatgaacac cccctgtgcg gtttactgtg ggagacagcc caccttgaag gggaaggaga 1560 tggggaaggc cccttgcagc tgaaagtccc actggctggc ctcaggctgt cttattccgc 1620 ttgaaaatag ccaaaaagtc tactgtggta tttgtaataa actctatctg ctgaaagggc 1680 ctgcaggcca tcctgggagt aaagggctgc cttcccatct aatttattgt aaagtcatat 1740 agtccatgtc tgtgatgtga gccaagtgat atcctgtagt acacattgta ctgagtggtt 1800 tttctgaata aattccatat tttacctatg a 1831 61 177 PRT Homo sapiens 61 Met Lys Leu Gln Cys Val Ser Leu Trp Leu Leu Gly Thr Ile Leu Ile 1 5 10 15 Leu Cys Ser Val Asp Asn His Gly Leu Arg Arg Cys Leu Ile Ser Thr 20 25 30 Asp Met His His Ile Glu Glu Ser Phe Gln Glu Ile Lys Arg Ala Ile 35 40 45 Gln Ala Lys Asp Thr Phe Pro Asn Val Thr Ile Leu Ser Thr Leu Glu 50 55 60 Thr Leu Gln Ile Ile Lys Pro Leu Asp Val Cys Cys Val Thr Lys Asn 65 70 75 80 Leu Leu Ala Phe Tyr Val Asp Arg Val Phe Lys Asp His Gln Glu Pro 85 90 95 Asn Pro Lys Ile Leu Arg Lys Ile Ser Ser Ile Ala Asn Ser Phe Leu 100 105 110 Tyr Met Gln Lys Thr Leu Arg Gln Cys Gln Glu Gln Arg Gln Cys His 115 120 125 Cys Arg Gln Glu Ala Thr Asn Ala Thr Arg Val Ile His Asp Asn Tyr 130 135 140 Asp Gln Leu Glu Val His Ala Ala Ala Ile Lys Ser Leu Gly Glu Leu 145 150 155 160 Asp Val Phe Leu Ala Trp Ile Asn Lys Asn His Glu Val Met Phe Ser 165 170 175 Ala 62 711 DNA Homo sapiens 62 tggggttcca ggcgggcagc agctgcaggc tgaccttgca gcttggcgga atggactggc 60 ctcacaacct gctgtttctt cttaccattt ccatcttcct ggggctgggc cagcccagga 120 gccccaaaag caagaggaag gggcaagggc ggcctgggcc cctggcccct ggccctcacc 180 aggtgccact ggacctggtg tcacggatga aaccgtatgc ccgcatggag gagtatgaga 240 ggaacatcga ggagatggtg gcccagctga ggaacagctc agagctggcc cagagaaagt 300 gtgaggtcaa cttgcagctg tggatgtcca acaagaggag cctgtctccc tggggctaca 360 gcatcaacca cgaccccagc cgtatccccg tggacctgcc ggaggcacgg tgcctgtgtc 420 tgggctgtgt gaaccccttc accatgcagg aggaccgcag catggtgagc gtgccggtgt 480 tcagccaggt tcctgtgcgc cgccgcctct gcccgccacc gccccgcaca gggccttgcc 540 gccagcgcgc agtcatggag accatcgctg tgggctgcac ctgcatcttc tgaattacct 600 ggcccagaag ccaggccagc agcccgagac catcctcctt gcacctttgt gccaagaaag 660 gcctatgaaa agtaaacact gacttttgaa agcaaaaaaa aaaaaaaaaa a 711 63 180 PRT Homo sapiens 63 Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe 1 5 10 15 Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln 20 25 30 Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp 35 40 45 Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg 50 55 60 Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala 65 70 75 80 Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg 85 90 95 Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile 100 105 110 Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn 115 120 125 Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe 130 135 140 Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr 145 150 155 160 Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys 165 170 175 Thr Cys Ile Phe 180 64 1049 DNA Mus musculus 64 aaaacaacag gaagcagctt acaaactcgg tgaacaactg agggaaccaa accagagacg 60 cgctgaacag agagaatcag gctcaaagca agtggaagtg ggcagagatt ccaccaggac 120 tggtgcaagg cgcagagcca gccagatttg agaagaaggc aaaaagatgc tggggagcag 180 agctgtaatg ctgctgttgc tgctgccctg gacagctcag ggcagagctg tgcctggggg 240 cagcagccct gcctggactc agtgccagca gctttcacag aagctctgca cactggcctg 300 gagtgcacat ccactagtgg gacacatgga tctaagagaa gagggagatg aagagactac 360 aaatgatgtt ccccatatcc agtgtggaga tggctgtgac ccccaaggac tcagggacaa 420 cagtcagttc tgcttgcaaa ggatccacca gggtctgatt ttttatgaga agctgctagg 480 atcggatatt ttcacagggg agccttctct gctccctgat agccctgtgg gccagcttca 540 tgcctcccta ctgggcctca gccaactcct gcagcctgag ggtcaccact gggagactca 600 gcagattcca agcctcagtc ccagccagcc atggcagcgt ctccttctcc gcttcaaaat 660 ccttcgcagc ctccaggcct ttgtggctgt agccgcccgg gtctttgccc atggagcagc 720 aaccctgagt ccctaaaggc agcagctcaa ggatggcact cagatctcca tggcccagca 780 aggccaagat aaatctacca ccccaggcac ctgtgagcca acaggttaat tagtccatta 840 attttagtgg gacctgcata tgttgaaaat taccaatact gactgacatg tgatgctgac 900 ctatgataag gttgagtatt tattagatgg gaagggaaat ttggggatta tttatcctcc 960 tggggacagt ttggggagga ttatttattg tatttatatt gaattatgta cttttttcaa 1020 taaagtctta tttttgtggc taaaaaaaa 1049 65 189 PRT Mus musculus 65 Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr 1 5 10 15 Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln 20 25 30 Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 35 40 45 Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr 50 55 60 Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln 65 70 75 80 Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 85 90 95 Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 100 105 110 Pro Ser Leu Leu Pro Asp Ser Pro Val Gly Gln Leu His Ala Ser Leu 115 120 125 Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr 130 135 140 Gln Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu 145 150 155 160 Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala 165 170 175 Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro 180 185 66 732 DNA Homo sapiens 66 atgggccaga cggcaggcga ccttggctgg cgtctcagcc tgttgctgct tcccttgctc 60 ctggttcaag ctggtgtctg gggattccca aggcccccag ggaggcccca gctgagcctg 120 caggagctgc ggagggagtt cacagtcagc ctgcatctcg ccaggaagct gctctccgag 180 gttcggggcc aggcccaccg ctttgcggaa tctcacctgc caggagtgaa cctgtacctc 240 ctgcccctgg gagagcagct ccctgatgtt tccctgacct tccaggcctg gcgccgcctc 300 tctgacccgg agcgtctctg cttcatctcc accacgcttc agcccttcca tgccccgctg 360 ggagggctgg ggacccaggg ccgctggacc aacatggaga ggatgcagct gtgggccatg 420 aggctggacc tccgcgatct gcagcggcac ctccgcttcc aggtgctggc tgcaggattc 480 aacctcccgg aggaggagga ggaggaagag gaggaggagg aggaggagag gaaggggctg 540 ctcccagggg cactgggcag cgccttacag ggcccggccc aggtgtcctg gccccagctc 600 ctctccacct accgcctgct gcactccttg gagctcgtct tatctcgggc cgtgcgggag 660 ttgctgctgc tgtccaaggc tgggcactca gtctggccct tggggttccc aacattgagc 720 ccccagccct ga 732 67 243 PRT Homo sapiens 67 Met Gly Gln Thr Ala Gly Asp Leu Gly Trp Arg Leu Ser Leu Leu Leu 1 5 10 15 Leu Pro Leu Leu Leu Val Gln Ala Gly Val Trp Gly Phe Pro Arg Pro 20 25 30 Pro Gly Arg Pro Gln Leu Ser Leu Gln Glu Leu Arg Arg Glu Phe Thr 35 40 45 Val Ser Leu His Leu Ala Arg Lys Leu Leu Ser Glu Val Arg Gly Gln 50 55 60 Ala His Arg Phe Ala Glu Ser His Leu Pro Gly Val Asn Leu Tyr Leu 65 70 75 80 Leu Pro Leu Gly Glu Gln Leu Pro Asp Val Ser Leu Thr Phe Gln Ala 85 90 95 Trp Arg Arg Leu Ser Asp Pro Glu Arg Leu Cys Phe Ile Ser Thr Thr 100 105 110 Leu Gln Pro Phe His Ala Pro Leu Gly Gly Leu Gly Thr Gln Gly Arg 115 120 125 Trp Thr Asn Met Glu Arg Met Gln Leu Trp Ala Met Arg Leu Asp Leu 130 135 140 Arg Asp Leu Gln Arg His Leu Arg Phe Gln Val Leu Ala Ala Gly Phe 145 150 155 160 Asn Leu Pro Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 165 170 175 Arg Lys Gly Leu Leu Pro Gly Ala Leu Gly Ser Ala Leu Gln Gly Pro 180 185 190 Ala Gln Val Ser Trp Pro Gln Leu Leu Ser Thr Tyr Arg Leu Leu His 195 200 205 Ser Leu Glu Leu Val Leu Ser Arg Ala Val Arg Glu Leu Leu Leu Leu 210 215 220 Ser Lys Ala Gly His Ser Val Trp Pro Leu Gly Phe Pro Thr Leu Ser 225 230 235 240 Pro Gln Pro 68 736 DNA Homo sapiens 68 ttcaaggtta cccatctcaa gtagcctagc aatattggca acatcccaat ggccctgtcc 60 ttttctttac tgatggccgt gctggtgctc agctacaaat ccatctgttc tctgggctgt 120 gatctgcctc agacccacag cctgggtaat aggagggcct tgatactcct ggcacaaatg 180 ggaagaatct ctcctttctc ctgcctgaag gacagacatg actttggatt cccccaggag 240 gagtttgatg gcaaccagtt ccagaaggct caagccatct ctgtcctcca tgagatgatc 300 cagcagacct tcaatctctt cagcacaaag gactcatctg ctacttggga acagagcctc 360 ctagaaaaat tttccactga acttaaccag cagctgaatg acctggaagc ctgcgtgata 420 caggaggttg gggtggaaga gactcccctg atgaatgtgg actccatcct ggctgtgaag 480 aaatacttcc aaagaatcac tctttatctg acagagaaga aatacagccc ttgtgcctgg 540 gaggttgtca gagcagaaat catgagatcc ttctctttat caaaaatttt tcaagaaaga 600 ttaaggagga aggaatgaaa cctgtttcaa catggaaatg atctgtattg actaatacac 660 cagtccacac ttctatgact tctgccattt caaagactca tttctcctat aaccaccgca 720 tgagttgact caaaac 736 69 181 PRT Homo sapiens 69 Met Ala Val Leu Val Leu Ser Tyr Lys Ser Ile Cys Ser Leu Gly Cys 1 5 10 15 Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu Ile Leu 20 25 30 Leu Ala Gln Met Gly Arg Ile Ser Pro Phe Ser Cys Leu Lys Asp Arg 35 40 45 His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe Gln 50 55 60 Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln Thr Phe 65 70 75 80 Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Thr Trp Glu Gln Ser Leu 85 90 95 Leu Glu Lys Phe Ser Thr Glu Leu Asn Gln Gln Leu Asn Asp Leu Glu 100 105 110 Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu Met Asn 115 120 125 Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile Thr Leu 130 135 140 Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg 145 150 155 160 Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Lys Ile Phe Gln Glu Arg 165 170 175 Leu Arg Arg Lys Glu 180 70 840 DNA Homo sapiens 70 acattctaac tgcaaccttt cgaagccttt gctctggcac aacaggtagt aggcgacact 60 gttcgtgttg tcaacatgac caacaagtgt ctcctccaaa ttgctctcct gttgtgcttc 120 tccactacag ctctttccat gagctacaac ttgcttggat tcctacaaag aagcagcaat 180 tttcagtgtc agaagctcct gtggcaattg aatgggaggc ttgaatactg cctcaaggac 240 aggatgaact ttgacatccc tgaggagatt aagcagctgc agcagttcca gaaggaggac 300 gccgcattga ccatctatga gatgctccag aacatctttg ctattttcag acaagattca 360 tctagcactg gctggaatga gactattgtt gagaacctcc tggctaatgt ctatcatcag 420 ataaaccatc tgaagacagt cctggaagaa aaactggaga aagaagattt caccagggga 480 aaactcatga gcagtctgca cctgaaaaga tattatggga ggattctgca ttacctgaag 540 gccaaggagt acagtcactg tgcctggacc atagtcagag tggaaatcct aaggaacttt 600 tacttcatta acagacttac aggttacctc cgaaactgaa gatctcctag cctgtgcctc 660 tgggactgga caattgcttc aagcattctt caaccagcag atgctgttta agtgactgat 720 ggctaatgta ctgcatatga aaggacacta gaagattttg aaatttttat taaattatga 780 gttattttta tttatttaaa ttttattttg gaaaataaat tatttttggt gcaaaagtca 840 71 187 PRT Homo sapiens 71 Met Thr Asn Lys Cys Leu Leu Gln Ile Ala Leu Leu Leu Cys Phe Ser 1 5 10 15 Thr Thr Ala Leu Ser Met Ser Tyr Asn Leu Leu Gly Phe Leu Gln Arg 20 25 30 Ser Ser Asn Phe Gln Cys Gln Lys Leu Leu Trp Gln Leu Asn Gly Arg 35 40 45 Leu Glu Tyr Cys Leu Lys Asp Arg Met Asn Phe Asp Ile Pro Glu Glu 50 55 60 Ile Lys Gln Leu Gln Gln Phe Gln Lys Glu Asp Ala Ala Leu Thr Ile 65 70 75 80 Tyr Glu Met Leu Gln Asn Ile Phe Ala Ile Phe Arg Gln Asp Ser Ser 85 90 95 Ser Thr Gly Trp Asn Glu Thr Ile Val Glu Asn Leu Leu Ala Asn Val 100 105 110 Tyr His Gln Ile Asn His Leu Lys Thr Val Leu Glu Glu Lys Leu Glu 115 120 125 Lys Glu Asp Phe Thr Arg Gly Lys Leu Met Ser Ser Leu His Leu Lys 130 135 140 Arg Tyr Tyr Gly Arg Ile Leu His Tyr Leu Lys Ala Lys Glu Tyr Ser 145 150 155 160 His Cys Ala Trp Thr Ile Val Arg Val Glu Ile Leu Arg Asn Phe Tyr 165 170 175 Phe Ile Asn Arg Leu Thr Gly Tyr Leu Arg Asn 180 185 72 750 DNA Homo sapiens 72 atggccatgc tcagggtcca gcccgaggcc caagccaagg tggatgtgtt tcgtgaagac 60 ctctgtacca agacagagaa cctgctcggg agctatttcc ccaagaagat ttctgagctg 120 gatgcatttt taaaggagcc agctctcaat gaagccaact tgagcaatct gaaggcccca 180 ttggacatcc cagtgcctga tccagtcaag gagaaagaga aagaggagcg gaagaaacag 240 caggagaagg aagacaagga tgaaaagaag aagggggagg atgaagacaa aggtcctccc 300 tgtggcccag tgaactgcaa tgaaaagatc gtggtccttc tgcagcgctt gaagcctgag 360 atcaaggatg tcattgagca gctcaacctg gtcaccacct ggttgcagct gcagatacct 420 cggattgagg atggtaacaa ttttggagtg gctgtccagg agaaggtgtt tgagctgatg 480 accagcctcc acaccaagct agaaggcttc cacactcaaa tctctaagta tttctctgag 540 cgtggtgatg cagtgactaa agcagccaag cagccccatg tgggtgatta tcggcagctg 600 gtgcacgagc tggatgaggc agagtaccgg gacatccggc tgatggtcat ggagatccgc 660 aatgcttatg ctgtgttata tgacatcatc ctgaagaact tcgagaagct caagaagccc 720 aggggagaaa caaagggaat gatctattga 750 73 249 PRT Homo sapiens 73 Met Ala Met Leu Arg Val Gln Pro Glu Ala Gln Ala Lys Val Asp Val 1 5 10 15 Phe Arg Glu Asp Leu Cys Thr Lys Thr Glu Asn Leu Leu Gly Ser Tyr 20 25 30 Phe Pro Lys Lys Ile Ser Glu Leu Asp Ala Phe Leu Lys Glu Pro Ala 35 40 45 Leu Asn Glu Ala Asn Leu Ser Asn Leu Lys Ala Pro Leu Asp Ile Pro 50 55 60 Val Pro Asp Pro Val Lys Glu Lys Glu Lys Glu Glu Arg Lys Lys Gln 65 70 75 80 Gln Glu Lys Glu Asp Lys Asp Glu Lys Lys Lys Gly Glu Asp Glu Asp 85 90 95 Lys Gly Pro Pro Cys Gly Pro Val Asn Cys Asn Glu Lys Ile Val Val 100 105 110 Leu Leu Gln Arg Leu Lys Pro Glu Ile Lys Asp Val Ile Glu Gln Leu 115 120 125 Asn Leu Val Thr Thr Trp Leu Gln Leu Gln Ile Pro Arg Ile Glu Asp 130 135 140 Gly Asn Asn Phe Gly Val Ala Val Gln Glu Lys Val Phe Glu Leu Met 145 150 155 160 Thr Ser Leu His Thr Lys Leu Glu Gly Phe His Thr Gln Ile Ser Lys 165 170 175 Tyr Phe Ser Glu Arg Gly Asp Ala Val Thr Lys Ala Ala Lys Gln Pro 180 185 190 His Val Gly Asp Tyr Arg Gln Leu Val His Glu Leu Asp Glu Ala Glu 195 200 205 Tyr Arg Asp Ile Arg Leu Met Val Met Glu Ile Arg Asn Ala Tyr Ala 210 215 220 Val Leu Tyr Asp Ile Ile Leu Lys Asn Phe Glu Lys Leu Lys Lys Pro 225 230 235 240 Arg Gly Glu Thr Lys Gly Met Ile Tyr 245 74 1669 DNA Homo sapiens 74 ctccctcagc aaggacagca gaggaccagc taagagggag agaagcaact acagaccccc 60 cctgaaaaca accctcagac gccacatccc ctgacaagct gccaggcagg ttctcttcct 120 ctcacatact gacccacggc tccaccctct ctcccctgga aaggacacca tgagcactga 180 aagcatgatc cgggacgtgg agctggccga ggaggcgctc cccaagaaga caggggggcc 240 ccagggctcc aggcggtgct tgttcctcag cctcttctcc ttcctgatcg tggcaggcgc 300 caccacgctc ttctgcctgc tgcactttgg agtgatcggc ccccagaggg aagagttccc 360 cagggacctc tctctaatca gccctctggc ccaggcagtc agatcatctt ctcgaacccc 420 gagtgacaag cctgtagccc atgttgtagc aaaccctcaa gctgaggggc agctccagtg 480 gctgaaccgc cgggccaatg ccctcctggc caatggcgtg gagctgagag ataaccagct 540 ggtggtgcca tcagagggcc tgtacctcat ctactcccag gtcctcttca agggccaagg 600 ctgcccctcc acccatgtgc tcctcaccca caccatcagc cgcatcgccg tctcctacca 660 gaccaaggtc aacctcctct ctgccatcaa gagcccctgc cagagggaga ccccagaggg 720 ggctgaggcc aagccctggt atgagcccat ctatctggga ggggtcttcc agctggagaa 780 gggtgaccga ctcagcgctg agatcaatcg gcccgactat ctcgactttg ccgagtctgg 840 gcaggtctac tttgggatca ttgccctgtg aggaggacga acatccaacc ttcccaaacg 900 cctcccctgc cccaatccct ttattacccc ctccttcaga caccctcaac ctcttctggc 960 tcaaaaagag aattgggggc ttagggtcgg aacccaagct tagaacttta agcaacaaga 1020 ccaccacttc gaaacctggg attcaggaat gtgtggcctg cacagtgaag tgctggcaac 1080 cactaagaat tcaaactggg gcctccagaa ctcactgggg cctacagctt tgatccctga 1140 catctggaat ctggagacca gggagccttt ggttctggcc agaatgctgc aggacttgag 1200 aagacctcac ctagaaattg acacaagtgg accttaggcc ttcctctctc cagatgtttc 1260 cagacttcct tgagacacgg agcccagccc tccccatgga gccagctccc tctatttatg 1320 tttgcacttg tgattattta ttatttattt attatttatt tatttacaga tgaatgtatt 1380 tatttgggag accggggtat cctgggggac ccaatgtagg agctgccttg gctcagacat 1440 gttttccgtg aaaacggagc tgaacaatag gctgttccca tgtagccccc tggcctctgt 1500 gccttctttt gattatgttt tttaaaatat ttatctgatt aagttgtcta aacaatgctg 1560 atttggtgac caactgtcac tcattgctga gcctctgctc cccaggggag ttgtgtctgt 1620 aatcgcccta ctattcagtg gcgagaaata aagtttgctt agaaaagaa 1669 75 233 PRT Homo sapiens 75 Met Ser Thr Glu Ser Met Ile Arg Asp Val Glu Leu Ala Glu Glu Ala 1 5 10 15 Leu Pro Lys Lys Thr Gly Gly Pro Gln Gly Ser Arg Arg Cys Leu Phe 20 25 30 Leu Ser Leu Phe Ser Phe Leu Ile Val Ala Gly Ala Thr Thr Leu Phe 35 40 45 Cys Leu Leu His Phe Gly Val Ile Gly Pro Gln Arg Glu Glu Phe Pro 50 55 60 Arg Asp Leu Ser Leu Ile Ser Pro Leu Ala Gln Ala Val Arg Ser Ser 65 70 75 80 Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro 85 90 95 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu 100 105 110 Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser 115 120 125 Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly 130 135 140 Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile Ser Arg Ile Ala 145 150 155 160 Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro 165 170 175 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu 180 185 190 Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu 195 200 205 Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly 210 215 220 Gln Val Tyr Phe Gly Ile Ile Ala Leu 225 230 76 37797 DNA Homo sapiens 76 cctccttaga caagcttcta catgctactc atctctccat caaaccacca tattcgggct 60 ttggccatct gctctccaca gccaagtccc cagtggcctc tctgcttctg acacagtgaa 120 agccattcag atctgtcttg ttggcagcat tcctcacttt gagcagcgcc ctcctactag 180 gatacccctc cttgactaca accccacatt ctctacttcc tgggctcttc tgtcactgga 240 ggatgactcc caggtgtgaa tcttcatccc gcgtccctca ctcaagcccc cgatcctcat 300 atccagcttt atcctcatgg gatgcttcac caggatgagt cataagcacc tcagactcag 360 ggtgtcccaa accactcatc tacctggcaa gcctgcactc tgcatgtgcc tcattctgaa 420 catggcacca tcacctgctg caatgtccag accacaaaca ccctacaata tccttgactc 480 tcctttctcc ccttctccct gtatacagac tccaaattct attgagacta ttacctccta 540 cacccctcac atttgcccag ccttccccat ctctgcctct accaccatag ttcaagctct 600 cccatggtcc cttcctggtt acctgttctt cttgcctcct taagcctctc atgacactgg 660 ccatgtcact tgcctccacc catcacccgc taggctctta gctggagtct gggccctgct 720 accttcctcc ccttcttccc tacccttgac tccacctccc tgtgcttcag ccaaccagat 780 aacttgagtt tcgtgaatgc atgcctcagt ttacctgatt aactcatttt catctttcag 840 gcctcagagc aggtatcacc ctgtcagggc caggtgcctc ttcttagctc ccaaagcccc 900 agctactctt catggaacat cattggcttg ggctacggat cttcccaaat tggagctttt 960 tcacaaaggg cttaggtctc actcattcta ttaatccatc tgtgtctccc cagggctagc 1020 agtgccaagt aactgacggg tgattaatag atgcttgggt aagtatcacc tctttaccat 1080 gtgacaattt gtttacctgc cttgagctcc tccagggcag gactcttgcc tttgcagaat 1140 ctatctggca ggtactgttg cagagatgtt tactgaagaa gggaatgaat tagtaccaag 1200 gtgaggaccc cacccttccc cacgggctcc aaaagcagct tagagcccaa caaaacctgc 1260 cccacatttt tggcgtttct gtggatcaca cgatttactc atctgtcttt caatgagcat 1320 gacaggtggg gtgggggtgg agggattaga gattgaggag ctggggaggg tggtcagctc 1380 ctggggtgca gaaacaagtc tgatgggcca tggtgttctg ggaatcagca ctgcctcccc 1440 tcacccctcc ctgcagtgtt ttgtagcctc aagatcagtg agggaatctt cgggccccca 1500 gcatgcagga ccgaagcccc cgagacagct gtccctcagt cccaaggtcc ccatttggaa 1560 gcagccacag gaggcctaag ggacctatac ccttggtttg aggaagactg tggcgaggga 1620 gagagggagg gagggctggc agtgagggca agggctggga aaactgagca cgggcacagt 1680 gcgggagcgg gtgggtgccc agggcagcca ggggcgcacg ggttgggagg cgccaggcgg 1740 cccgccctcc ttgcacgggc cggcccagct tccccgcccc tggcgtccgc tccctcccgc 1800 tcgcagctta cttaacctgg cccgggcggc ggaggcgctc tcacttccct ggagccgccc 1860 gcttgcccgt cggtcgctag ctcgctcggt gcgcgtcgtc ccgctccatg gcgctcttcg 1920 tgcggctgct ggctctcgcc ctggctctgg ccctgggccc cgccgcgacc ctggcgggtc 1980 ccgccaagtc gccctaccag ctggtgctgc agcacagcag gctccggggc cgccagcacg 2040 ggtaagccga gccgcctggc caggggctgc ggaaggtcag gtagtcgggg ctcggagcgc 2100 aagccgctgg gggcattgaa ctgggctggg ggcgcagggg acaaagcccg aactaaaaac 2160 cttgcagcgt ggagcgctcg gacaccagcc ctgcacgcgg tggaaggaga gagggaggga 2220 ggtggaggac catggaggga aagcgggagg ccgccgcttt gtagaaggga gtggggaagt 2280 ggaccagaga ccttcgactc aggccaagag cctgagacgg acagcgcttt cagcttctcc 2340 tcccagccac tgcagaaagg gggaaatggc aactctttgg ccataatcac cgggggaggg 2400 tgccaagggc aaagcccacc cagcagtaca cctattccaa cccagccagg cccccggcca 2460 gcgactccag acaagaacct gggccacaca cggtggcagc atctaaggtg ccccaggctc 2520 ctgtgctcct ggccaggccc tgcactcaga cactgctggc acccgacact gctctctggg 2580 tacagcaagg gcaatgtggc acttcttgtc ctgcccgatg aagagcagga gaatgcactg 2640 ggccctcaca cacactgttc aaatggggaa actgagtcct gagtggttcc actttcccac 2700 agtcctgaag tgtgcactgg agccaggatt ggagtctgtc ttaaagtaat agctgggttt 2760 gtaaatgtag gacactatca ttgcaggaat tcctttgaga ccctgaagat gtgttggctt 2820 taggagacaa actcaagcag aaggtctggt ctgatagtgg ccctaatact gacccaggca 2880 gaggcaggca acatttctac ctcaaaaacc aggccatacc tgcgtcacaa atacccaggc 2940 tttgctgcag cttccagcct acctggttgc accaacttct ttttcataac taggtaaaac 3000 tatatatgag tagaatcttg tagtgactcc tcagaggaag cctaaatacc atcggggtct 3060 ggcgttcaca cccacaagca atgcccaaac ctccaagaga ctgggcagat ctgtgctcaa 3120 atcaaaactc attgttgggg gtgatagagt tgacttcaca ggccctgaaa gtcttggctc 3180 cttgcactag gagtgctctg ggtacgggta caggctgccc cttgtagggc atagttgctc 3240 ttgtttcctc tacttgtggc tttatggtct aggcctttca ggagtttggg gctctggcgg 3300 agagggcctg ctgggagcac atctggccac cctgcagagt gaaatcaaac caggcctggc 3360 tgcaacctca acaccctcct ggaaagagga gaatactggg gatatcctgg ggtctttctg 3420 gaagtgggag aatcagcttt gacttgggca gtgtgcagaa tagagtgagg ggggatgtca 3480 gaaagatgag agggatatga ggcctcaaca tcaaaatgca agcacctggc atttttatta 3540 tctctgccca cctctccgtt ggtctctctg cctttcctgc caatgaattg tgttatgttt 3600 gggtgcctca atttgcctag gagggttcta tttcttctgt atcttcgcca ctaagtcagg 3660 agaagatcct tatagcatgc cctgcaacag tgtcacctgt aagggcatct ctctgcacag 3720 ccacagtgaa ggatcctcaa aggtattgag ggctttccat caagagccat ctttacagca 3780 aacctctttc ccttcagagc ccagaagagt gctgaccagc tggaaaacag ggtttttttc 3840 ttaaatgcag atgctcttga ttatgagttc cagatattag atcaacttcc ccaccatacc 3900 cctgcaggca aagcctctta attagcttcc tgcagcacag ctggaaaggc ctattgtaat 3960 ctgtgatggg cagagtaatc taagaagtca caggagcacc cctgtcccag tagaatctgg 4020 atgcgcaggc acatgaacca tggcaaaatg gttgcaggca cagttgtatt tactctgatc 4080 taactgtccc tgttaatgcc acagggctgc ctggcctggc acacagggct gtggcgcctt 4140 gtgcaaatgg ataacgttgt tctagctcca gcctttcatt caaagtgaaa actgttagaa 4200 agggaaggaa aactttgcta ttttaaggaa ttgtagcgtg ctgcctgata tgaaggaaga 4260 aataacagct gtgccttgct tgtgcgcagc actcgattgc cgcttttgct ttcgacctca 4320 ccacaacaca gtgagatcta ctgttcatgt tcccatttta caggaggtga aactgcagct 4380 tagtgaggta gagagtgact tagttcagac acagaatgct gttgggagag taataactat 4440 gatatggtct cttgactccc agctatatct gtgttgctat agggaagggg aaaaataata 4500 ctgaaagaga agtaaaaata caatcacact tccaaacatc aaccaccaaa aactgaactg 4560 aatttcctga agcacttggt tttcaaatct aagctgaaca tcaatgctgt tattcttgag 4620 gcccagaagc aacttgctca tttcaattaa gcttcagcat gaacttccta tgtacacagc 4680 ccacccacac tccccgatgt gagaaggaga gggtcacagc cgcccccagc ctctgctgct 4740 gccacaagga cagcagcagt ggaaacattc agcaaaggaa tgttggagcc acatccacaa 4800 gagactcact gaagattcgc caaacgccta cggaaagtgg cagggaattc attgacagta 4860 attgtttcct gcttgatcag attgaagagc ttctgggatt ctgtaacaat aaataggacc 4920 gggggctgga gtatggccag caaggactct tcaggggtta ttcagggact gtctaacctg 4980 tgaatcctag gcagcaaaca gaaaccaggt attcagaaat ctggaggatt tggtcaggcc 5040 cagctaggac tagggaggca tgggcctctg ctggctgtgg tcccttctcc agccttcact 5100 tctcttgtcc ctagatcctt acatggattc attaatgctc attgtccctc ctgggcccac 5160 tcactttcac ctgttgaaca aaaaactggc caagaggtga cagtcatatc accgcagaag 5220 agacagggca gagaaatgaa ggggcagaat ggactcccac ccaaaagcct gactctgaat 5280 atttgagaat tgttcaagtt cctgcagagg aatcatgatg gggacagtag gtgtagtttt 5340 tactgcaata ttggtgtctt cttaacaaat acgctgcaca tcaagtgatg tctgtggatg 5400 gcattcttaa agtaacaggg aaattgatgt taaagaaata cttcatcctt tgggtgatac 5460 ctgaagttct ctgagcttgg aggtcttgtg aaagccctca gtattgtttg ttttatttgc 5520 tttcctctga cttgtgattc agtcagatgc atgcctgcct ctggctcagg aagatcaacc 5580 ctctcctgac tgaccacgcc tctcctgact gaccacgtag cacagcagct tcctttccct 5640 aggggctcct aatgaagctt tcacaatcac ctggcctgag cacagtttgg gtcaggactt 5700 ggtatatact tgaaaaaaac atgcaaaacc aaaatcctgt ggttctggaa aaggcttctt 5760 agcagaaccc ccagacattt acactctgct ttttcacagg gtccctgagg attctttgga 5820 tctgggtagt ttggggagca gtattttcaa caagttcatt tcgtgctcct tctacaccct 5880 gcctggatgc taggccccat ctagaatgtg aacaacagaa caaggcagaa cacttgtcct 5940 caaggttctg ttgagtgtta gatgcagaga agagacaccc cccacctccc cgcatcactt 6000 acaggaattc tgtttggaac ccaacatcaa ataaggaccg tatccactgt cagaggatgg 6060 gaagcagcat gtcatctggg acattggaga aaggctcctg ggggaagtgg gacttgagct 6120 gtgatctaag taatgaacaa ctgagagtta aatgggagag catcccctat cagggtcctg 6180 agagcaacca gccatggttt aaaccagcta taaagcctcg ggtttatagg atagacagta 6240 acaatggctt gtctttggga gccaagcagc tggtccaggc atgcagagca tgtctgtatg 6300 gagagctgcc tgagagatgc ttttgtttac acttatcaat tgcccatgtc aaagaaggat 6360 atgtacatga agttacatca gtatgtaaga gagattttaa caatttttgc aggggaagct 6420 ttcatggggg ctgatgggaa tctaggtaaa cagaaccaaa gtctaaaccc aagatatccc 6480 cagtaccaag actgaaatga ctctctcctc tatctctaga aagttccagt gacccaagga 6540 ggcaaacacg atgggagtca ttaaagtggg gtggacgtgc tgatcatctt cctaattctg 6600 ctgcttttgt tttcagcccc aacgtgtgtg ctgtgcagaa ggttattggc actaatagga 6660 agtacttcac caactgcaag cagtggtacc aaaggaaaat ctgtggcaaa tcaacgtgag 6720 tatctgtaac cagccaggag accaagctgt atgcacgctg gctgcagttc cccagggcct 6780 gggccagcct tctagaaggt caggttgcct aaaaagccat gaagatgcat gtgcgaacat 6840 gtctgggacc tgcgtgctag ggagtggcat ttttaggaag ctggccaatt ttgttttgca 6900 tttttaaggc tgctgacaag acttggagac atttttcagg gctggtttgg gtttgcaaga 6960 aacatgaaac actgcgtgtg tgtgtgtgtg tgtgtgtttc tcaatcctca taaaataata 7020 cagatatgca gtggagaagc caccagcatg tgactctgga aaagaaagcc cattggtgaa 7080 tctgtactaa agaatgccat ccctatctta cagtcctaag gtaaacaccc caaaaagact 7140 tagagcacta aacatatgca gattatgaga cagcatagca tataatattt gcacagactt 7200 cctcattcaa accctagctc tacctgggcc agtcgattca tctttagaac cctccattgc 7260 tttacctgaa aagttcgtat aacaaaagga cccaccttat ggggttgtta caaggattga 7320 atgaaataat gtacataaga gactgaatat ggtgcccagc acatatcagt gctcaataaa 7380 tgctagctac tattattatt atcaccctag atttgcaaat ctagaccaca caagcagaag 7440 taagagtgcc aacggggtgt ggaccagtgt ggttacaata gggcttgttg atgtctgttt 7500 cagcaaggag ggaggcagct tttaccccac tgcccagctc cctggtggaa tcaggtgcat 7560 gttctaacaa ttctggggaa acctaatctg ttttggcact gtcaacagat ctcaaagctg 7620 gctgtctcct atagctagga agatgtgtat gacaaatctc ctgagccact tgtgaaggcc 7680 tgaccttcct cctgtctcca tacataatgg gatgattaag aaactctaag ccactctctt 7740 aagcactttt caatgttagg gatttttaag tttattgttg tgacattgct tttgagcaga 7800 catctcctcc aatttaatag ccaactgaaa gaagagaaaa tgctctttcc ttaaactgta 7860 tgtggaaata aatattccaa tgtgtgaccc tgattatgtt aggcaattag caatcctaat 7920 atgaattgag ggaagttggg attcatggca cagctgggga gataccagca gtccctggga 7980 gcctgtccag ggcaggtcca tggcagcttg ctccatgcct gattgacagc ccagcctgca 8040 agctaaaagt tgagtgagct aggaggacac actgccaaga ttcagctaac agacacccag 8100 cgatattctt gctgctatga acaaaaggag actatgcaaa ttatacacca cccattcttc 8160 caggatgcct gacttaaaaa ataagaaaaa agatgggccg ggcacagtgg ctcacgcctg 8220 taatcccaac actttgggag gccgaggtgg gcggatcaca aggtcaggag acagagacca 8280 tcctggctaa catggtgaaa ccccgtctct actaaaaaaa tacaaaaata ttagcgggcg 8340 tggtggcggg cacctgtagt cccagctact cgggaggctg aggcaggaga atggcgtgaa 8400 cctgggaggc ggagcttgca gtgagccaag atcgtgccac tgcagtccag cctgggtgac 8460 agagtgagac accgtctcaa aaaaaaaaaa aaaaaaagaa aagaaaacct ttagtactga 8520 ttgatttttt cccatgtgtg tatattatct actcaaatta acaattaatt acttaattaa 8580 acacaaagcc aggcctcacc taattgcttc ttggaaggtg accagagtgc tagtgccaag 8640 caaacaactc ttctatatct caagagccct gggcttcaga gggccatctt ttttgttaat 8700 tcaagtttct ctgaaaatgg agacccgttt atgatgacaa gctggctaca gggtagcatc 8760 tgccacactg tttcgggggt gccgctgggc tgaagcattt gcccagctag ttaacaatag 8820 ctcgataaca ttccctatca gtgtccaggc tgagaatact gtcagtgatg agtcgccttg 8880 gctcttgtac ctgtatcttt gtgtgccagg acaaggcaca agcaacagag ctgtgtgttg 8940 ccaaaatgtt cctgatgagc aggtcaaccc ctcgggggca ggtttggata tgataatgtg 9000 gtgatgtggt ggcgcagctc ccttacccag tgagcacaag gggagtcctc taggaaaagg 9060 aagaaatgtc tggatgaggt ggggagatgg ggttcagagt ggactcaggc aaagcccgat 9120 gcccagtccc agctgttggc ctagtctcac aaagccagaa ggatatgaca tttacattca 9180 actcttgaat ttgtggccac tgctttgggc aacttcaaag agagaaaatg aagatagaaa 9240 aatattattt gatataaaac ttctaggaca agagaggccc ttcctggaac attacatgta 9300 gtattaggaa ggtggagctg ccctggaaaa gatccagaga actcagagag aggaagaggt 9360 ggaacccatc tctgttcttg tagagagctc agtaagagtg gcttggcagg gctcctgtgt 9420 acctgagacc aagaccagtg aggaggctac tgtctgacca ccatacggtc agaattcagt 9480 gccatgggtg gtcaggtggg aaggggagag gactgtgctg gctggagttg atgttatcct 9540 ggggaaagta ggtccctaga tgcctttagt tgagtgagga gcagactggg aaatgggagc 9600 acagtagtgg ttggggcaaa aaggactgtc tctgcatgag gtccataggc agttggaatt 9660 ttctcagcaa gactccagag aaggaggctg gagcagaggt gtatgttggg atgaaaagga 9720 gtaaagtatc atgggggagg aggcagctca ggttgtcaag ggtcaagaaa ccagaaggag 9780 aatttcacct tggaagcaga caacgggtac caagcataca ggggaatact ttgtggtgag 9840 aggtcacaca gagatacagg agccgacctg gtgagacagg agcctggagc cacctgcctg 9900 cttttgtgag gccccagact ccactgctat catcaggtga agctctgttg cctgcacaca 9960 aaagcttttc tgcatttaca aagagagaag ggcctgagtt tctggtgcaa tgcgtcaagc 10020 tgacatatgg actttattac aggaagtggt taccagtggg tccctattta gtggctgtta 10080 ttgtgaattt tattgttcgg aaattcactt tagcatttat ttcagatcct aaatagcacc 10140 ggagtgatac aatggctaat caaacaaaga gggctgtggg gagcagacag tcagcatccc 10200 cctctgtgat ttcaggccct ggtttgatta gtagccataa aattttttac gtgtggcact 10260 ttgagcaaag gtgcaggaaa ttgtggtcag gaagcctggc tgcctctcga caggcttcct 10320 ttgtgctagc cccagggaga ggaggcctat ttaacagcca agtccaagtt gacatcatgg 10380 gactggaata gtcatagcag gagctcagac atcataaacg tggcataggg agggctggtg 10440 gaggagctag cgggtatggg tggcagctat tcattccaaa agtcttgaaa ttgtttcacg 10500 agcaacacat ttcacaagtg cgaagccctt ctctggagcc aagatgagct ggcagagcac 10560 tcctgtttct ctagtagcaa gtgttccttt gcccaggggc aaaaatatta atactccttc 10620 agcactgcat taatgcttaa agatttaact tttaaagaga tcagctggtg catggtcgag 10680 cttttccatc agctggcagg gctttttcag taggtgtcct tctgggcagg gcactgggga 10740 cagctgacgt gaaggtgaag aagagctgtc gttttcctcc cttatatccc acaaccttgg 10800 tcccaagagg aaaaaaaaga agatggtgag aagtcatcca agcagacccc agacccatac 10860 tagtgcctcc tttcctgttt catatccctg tgcagccagc tgggatctct tgaataatct 10920 gctctggggg cactgagatt ggacatacac caaacagcgg agatcgacca aacgcctctg 10980 ttgggcagtg tttcctgagg gttctgtccc attctgtaaa ctaggaggct gactagctga 11040 caaggaattt tattctgttg ggtatttaca tgaacctatg tgccacctgg ggtaagaccc 11100 tgtggtaggt agaaacatga cttcccaaaa atgtccacat cctaatctct aattctgtaa 11160 atatattccc ttactggaaa aagagacttt gcaggtgtga ttaaattaag gatcataaga 11220 gggagagatt atccaggatt atttgatgag tctaatataa tcatcagggt acttaaaaga 11280 gggaggcagg ctgtgcctgg tggttcacgc ctttaatccc agcactttgg gagactgagg 11340 cgagcgggtc acgaggacag gagttcgaga ccagcctgac caacatggtg aaactccccc 11400 tctagtaaaa aaaaaaatac aaaaattagc caggcatggt ggtacacacc tgtaatccca 11460 gctactcagg aggctgaggc gggagaattg cttgaaccca ggaggcagag gttgtggtga 11520 gctgagatcg caccactgcc ctccagcctg ggcaacagag caagactcca tctcaaaaaa 11580 aaaaaaagag ggaggcagtg ggatcagagt cagagaaggc aacgtgatga tgaaagctga 11640 catttgagtg atgcaaccac aagccaagga atgcaggcag cttctcaaag ctggaaagga 11700 cgagcaatgg attcttccct acagcctctg tgaggaatgc agcctttgat tttaacccca 11760 taaggccgat ttctgactct agcctctgga attgtaagat aatttgcatg atctcaagcc 11820 actaaatttg tggtaatttg tcacagaaag caatgggaag ccaacacagg ccttatttgt 11880 tgacttatag atgcattttt ctttatttca atgtactttt atcaatggtc tcatgtaggg 11940 tattgctttc aatgaagata ttaacatagt ttcaacttta aggtttatat ctggagtttc 12000 tttagaagct tcacaactga ccacttagta aacagtaagc atctgttaag tgcttctcat 12060 atgtaagttc attcaattct cacaatcaca ctataagata aatatgatta ttagcccatt 12120 tacagatgag gagacaggct caaaagactt ttatgcaacc tggtcaaagt cattcactgg 12180 taagctgagg aggtctgtcc acttcctttt gctgccccca gggggtatca agcctggcag 12240 ttagtgtcag cgacttagga ggtgaacaag tgagcaggcc tgtaggacct ggctaaactg 12300 ccccaggtct ctgtctacag cctcaaacct gtggctgtgg gtcccagaga caaggcctcc 12360 tcagcatcag agaaggatgc ctttgtctca gggtcatcaa ccttctccag gttgctcacc 12420 ccctgctgta aaggggatcc ccaagaccgc tcatcagaca aggagcttgg gaactgagga 12480 gacacagtca gcctccagga gtgcccaaaa tgccctcaca tgctgcatac agattgccac 12540 aaataaagta catccacatt ctgaagactc tgtcctcatc accaaccagg ctggcccctg 12600 gtgagggctg tagtggttga ggcctttgtt ggtagacggt aggttaaagc aagccatgat 12660 tttctattgg gaggcttcag aatcagctca gctgtgtttc caagaccagg agggcagaaa 12720 gcaaaccatc ccaggcaagc agtccatggg ccatgtcaga tgtctagacg ttatgggtct 12780 gtgtttgctc tgccattcct ctcggaaact atgatgccct gtatggttta ccttcagtca 12840 caggtgactg gcctacaggg ccattccttg ttccaacgac ttctcgagta taattaatcc 12900 ccaggcattt acggccagag cagccggcca aatccgtgaa gtgcagtggt tgttttaaat 12960 tatattaact tcttggaaac ttattttagg gagagaaaac tcagtacttc tctctatcca 13020 atcttgagta aaaatgttag aagggactgg tggagagcct cccagacatc cctacacata 13080 gactttgggt tgacattatc tctttgcacc ttccttgaaa ctttcttcta aattaggtgc 13140 cttccctaat ttaggcacct tcccagtact agtctgtgac ctgttaggaa ccaggccaca 13200 cagcaggagt tgagtggcag ggagtgagca ttattgcctg agctccgcct cctgtcagat 13260 cagcagtggc attagattct catagcagtc cgaatactat tgtgaactgt gcgtgtaagg 13320 gatctagctt gtgcattcct tatgagaatc taatgcccga tggtctgaga tggaagagtt 13380 tcataccaaa accacccctt ccccctgcca ccatctgggg aaatattgtc taccacgaaa 13440 ctgatccctg gtgccaaaaa ggttggggac cgctgtccta agggatctgc tttttctgac 13500 ctgaggtttt tctttattag actgtatctg gctgaggaga agcctgaagc ctttaatcgg 13560 aacagctttg gctgatgaga ttagattcag aaaccaacag attggtcttt tctatgcagg 13620 gaagcctagg aactgggggg ctatggctgg gaagccccct attgtttcca tcctttccta 13680 tgttcatcct ggaggaatgg catcagaccc atgcctctgt gattgctccc agcccatcca 13740 accacagcat ctatgttctg cctgggacca gggccaggga gcatggcaca ctgagctgag 13800 tataaggaga gtggagcagg ccactgccag cccagaaaat tttggtcaaa gttgcctgaa 13860 atcttctcag ccttcgattc acagctgctc tctgctgctc tggggccatg cagaccagtt 13920 cagaaaagag ttaatttgtt ggggcagttg gaggcaggtg gactgccagc tttgacacct 13980 tcccagccca caggctgctg cactggggct gaaggcgtgg ctaacccctg cacacctaga 14040 gagtgacaga gatgccagac tgggcagcag gaaggcaaga ggattaagag agagcttcct 14100 ggctgaaagc cacactcggt taaccaggaa aaagcccttg gcacgagaag actcagtggc 14160 ctgagggact gagccttggt tgttgggcat gtgctgcata agccatccat gtgtgacagt 14220 agagtgtagt ccagccactg tgggacatgg gtgctgaaag accacatgga gaggaacagt 14280 gagtgctgac aagggctagc cttgatcact ttggagacac cccctgtgtc ttctagatgt 14340 cagactttcc aaatctgtct gctatcctcc aaacgtgcat tttcaagagc aatggaaaaa 14400 ggattggact tgatggaatg cagcaagagt cctaggtctg ttactaccta cctatgacct 14460 taagaaactc cttcacccct cagaaccctt acagctttct ttctgattct atcatgagtt 14520 actctactcc aagctgagac ttttctgctt agatctatcc cttcctccta aacccccaac 14580 ctccatttct cctggtgtct ttctttacac acccctcagc atacacacac acctagccac 14640 aggaaccaat gagttaatat ttgaggagtt ggttttcttt tgtcctcaat gagatcctgg 14700 tgaggccact tgagctgttc agctcccttg cggtattttg gggatggaac tcagaagcca 14760 acaatataga aaaagagtct ttggccagct ttcccagggg ctccatgcca tagagagtac 14820 tgcacccgtg tgcacagggg gccctgacat gaggactttg aggataacac tattcctcca 14880 actctgcttc agcatctcca tggattttca cacagacact ttaggaaaga aactaagttt 14940 ggggggactt gacctaatcc cacatcccag ccccagtaat acagccctgg aatttatcac 15000 agaaagccta gaatcccatg catatcccat gcatatgcat ccctagtcct atgggttcaa 15060 ggcttggagc tctccctgga tttagctggg aaaagttggc agacagttct tctctgtctt 15120 ctagaaatat ggactagaat cgtgagtgtg agattgcaag taacttttaa aatcatctag 15180 tttaacttca ccccatttca tagaccaaga aactgagacc agagagagaa atggactttc 15240 aagttcaccc tgctagttac tgatggatca caagtcaaat ctcctgattc tagcactgtt 15300 tctcttacac cacaccacct ttgaaagtgt gtcaatcaaa tcttacttta gttgcagagg 15360 atgactttag tttctgaaga taaaattgtg agtcaatcaa gatcagtccc aagacaatag 15420 cctgtttagc ccttataagt tcagggatga aaggttagaa agaaacagga tggaaggagg 15480 actggagaaa aaaacaaaag aggaaggaag gaggaggaag caaacaggaa aaaaaaagaa 15540 tgtgcatagc ttgtcactcc tcagtcattt cctgggagcc catttctagc aaagtgacag 15600 ctgcaactcc ctggccacct gagcatctta gctgatctgt ctctgaaaca ccccctggag 15660 aacagatgaa tcaggcttca tcttcgctta actaagtctt ccctgagacg actccattta 15720 aatgaacaag agcaggattt cctgggcaca ctgagagcac cttccagagg cccctccaga 15780 gccctaaagc ctgtatttct tccagtcggc ctgtttcttt cctggtgatg tcattaaacg 15840 ccctttgaga gtcccacagt gagcagttct gcggtaaaac ccgctgcaat taaagtctga 15900 gtcctttcct gtctcaaagg gcatattcat atagaagaaa ggaaaaggaa ggactggctg 15960 tttgcatttg gttccaggcc tgttgagtag aggtcgtgct cactccaccg aaggtacagg 16020 gtagccttca gcagaacctg gggatttggt tttaagcaag tctttcttag gtgtgggctt 16080 tcagaacact tccttccttg caatattatt tgaaattctc agtgttttag ccgtccccag 16140 aatattggtt cgttaaagct gtgtatttca gatctccaga cagtggtcac tgtttgtata 16200 ttttcaattt caaaccagaa aacaaaagtt cttattgatt acttttttta tttaaaaaat 16260 aaaaagtaag tatcttcgta agaggagctt tgttttaatt ttaaagttta aaatttgatt 16320 gtgaagacag agaaaaactt gatgattgta gatatattcc cctctttggc tattcaatca 16380 gagaactaga aaatcatgag agatttaatg accactgcct gatacacata tgtgttttac 16440 agatgaggaa actgagaccc agagagatga tgaaattggc tgaggatggc ccagctggtc 16500 agtgacagac tcagagccag agctggtgca gggctctttc tattccttcc tgttcccttt 16560 caggaacact caccatcggc tttcctgtga ataatgttga gataaaatcc ttggtgcatt 16620 atgttttcta gtcacaacat tgactaggct gccagagtcc tctgttctcc cagttggttg 16680 gctgtaggtg ttggcagccg ccaggagcat tctacagaac agaggaggag tgagactctc 16740 cttgctcagg aaaggcagac ctatgactta gcaaatgact cctaagagga gagtgtttca 16800 cccaccattc ctcttccttg gctgtggagg caacttagtg gagaggggcc agatgacctg 16860 tgaggaacag tgaagccctg cctaacacaa tgtatggttg tcttgttaca gagtcatcag 16920 ctacgagtgc tgtcctggat atgaaaaggt ccctggggag aagggctgtc cagcaggtga 16980 atgaatcctc cgggccttgc ctgttggtgt gggtggaagg gaatggtggg agagaggagt 17040 acccacataa aaggcagcag agtgtgaatg ggggcagtgg cacaaggaca tggcattctc 17100 cccacgtgcc cactggcccc aggctctatg cgaggggctg aggaatggaa gctggaaaca 17160 gcgcatttcc tgagctgctc ctcctggcct ccttaccaca ctggtggagt agactccaac 17220 tgtggcctgt ccatgccctt cccagcaggc acaggctcag gctcaggctc ttggcctctg 17280 cctctggctg ggagtgattc taaacacatc cagcagggtc agcctgatag cccatcagtt 17340 tccgatcagc tctgctagag agccgatggg atgtgggagg agggggtcac tggtgggctg 17400 gcaaccccaa gccatcccca tctccctctg tgtctaaact tggccctttg gagttcggta 17460 gggagaagag ccataggcca ggtgggctca cccagagtca gcagagagtc ccacaaatgg 17520 ttgcactggg cgaaagacag catggcacct gtgaatttta ttagagcttt tcttttagtg 17580 ctacacacaa gtgactgtac aggggagtta gtattttgtt ttaattttga aatagagtca 17640 tcttttggta tctgcggggg attgattcta ggacccattc taggatgcca tatcctcaga 17700 tgttcaagtc cctgatataa agtggtatag tatttgcatg taatctatgc atattcttcc 17760 atgtacttta aatcatctca agattactta taataccaaa tataatgtaa atcctatgta 17820 agtagttgtt ataccctctt ttaaattttt gtattatctt ttattgtatt tcaaaaaata 17880 tttttggtcc atgtttagtt gaatctgtgg gtgaagaacc cacagatacg aagggccaac 17940 tgtattggct atttttttag ttaagaatgt gagactgagg ccaggcgcag tggctcatgc 18000 ctttgattcc agcactttgg gaggccaaga ggggacgatc acctgagcca agaattcgag 18060 accagcagcc cgtgcaacat agtgagacct tgtctcttaa agattgtgag actgggctgg 18120 gcacggtggc tcacgcctgt aatcctagca ctttgggagg ccaaggcagg tggatcaact 18180 gaggtcagga gtttgagatc agcctggcta acatagtgaa actctgtctc tactaaaaat 18240 acaaaaaaat tagctgggtg tggtggtggg cgcctataat cccagctact caggaggctg 18300 aggcaggaga atcgcttgta tccaggaggc ggaggttgca gtgagctgag atagggccgt 18360 tgcactccag cctgggcaag aagagcaaaa ctccatctca aaaataaata aataaataaa 18420 taaataaatc atgagactga gacataacag gaaggagggc aatttggttg gttccaaggt 18480 tcctagagta tgtgatggga gaggttggtg cgggtggggc catggaggta ctgactcaag 18540 tggagggaca ggtggggaaa tgggatggga aaagaagatt gaccttagaa ggggagctca 18600 acctctgaac cctaatttca gacccttcaa aatgaatatt aagctcattt tggtctaaga 18660 aacaaaaaac aaatgaacat gaaactcatt ttggtcttat aaggtctgag aaaccccttc 18720 taaacttcaa gctgctttaa gaaataacat tttattacct gcaaatacac acagtacttt 18780 ggagatttat aatagtctct tattctaata gaagccatta gggaaccagt ttcaataaac 18840 aggtaaatct gtaagactag tttgtaatta ggatatctgt ttccagtgtc cattcctgcc 18900 tctgttatct aaatgtctgg gaacaagagc tgtgctctgc tgtgtttaaa atgattaaaa 18960 atcaccaatt agttgagttc acgtagacag gcatttgact tattgagttg ttttaagaag 19020 actataacaa gccttaagcc ccccagaaac agcctgtctt tgggctttcc cacatgcctc 19080 ctcgtcctct ccacctgtag atgtaccgtg ctctctgtca gagaagggag ggtgtggttg 19140 ggctggaccc ccagaggcca tccctccttc tgtcttctgc tcctgcagcc ctaccactct 19200 caaaccttta cgagaccctg ggagtcgttg gatccaccac cactcagctg tacacggacc 19260 gcacggagaa gctgaggcct gagatggagg ggcccggcag cttcaccatc ttcgccccta 19320 gcaacgaggc ctgggcctcc ttgccagctg tgagatgacc tccgtctgcc cgggggactc 19380 ttatggggaa ctgccttact tccccgaggg gtgggcatga tgaatgggag tctgcagtca 19440 tttcctactg tttcaggaag ctttctcctt aaccccttag aaaaggctgt ggaacttgag 19500 ctaaaatatg tcttaccagg ttgcgtctaa tgccccccgt tccctactgg gcagaaagac 19560 ttgggtgctt cctgaggagg gatccttggc agaagagagg cctgggctca cgagggctga 19620 gaacatgttt cccagagttg caaggaccca tctcttaaac acagagtctg cagcccctaa 19680 ctgacaccct gtccttcctc ctaggaagtg ctggactccc tggtcagcaa tgtcaacatt 19740 gagctgctca atgccctccg ctaccatatg gtgggcaggc gagtcctgac tgatgagctg 19800 aaacacggca tgaccctcac ctctatgtac cagaattcca acatccagat ccaccactat 19860 cctaatgggg taggggatcc ccagccatac tgcatggccc ttggtgcata atgaacccat 19920 ttctgttcca tgtgtgggct ggtttctggg gtttaagctg tagacaaccc accctctttg 19980 tgcctgcttc tccttgggcc ctctattcca cagcttgtgg aacccacatt ttgctactgt 20040 gtttgaaaac actgttttct cctcccgggg ctttgggact atgcctctgt tgtgttgact 20100 gctcatcctt gctgcttctc tgggcagatt gtaactgtga actgtgcccg gctgctgaaa 20160 gccgaccacc atgcaaccaa cggggtggtg cacctcatcg ataaggtcat ctccaccatc 20220 accaacaaca tccagcagat cattgagatc gaggacacct ttgagaccct tcgggtaagg 20280 gactgccctg ggtggaggcc caggcttggg acacattgcc tcccaagagg ggcctagcag 20340 gaactcttct gcaggagagg tagaggatgg ctcctgtagg ggaacataga gcaggttccc 20400 ctgaatgccc ttgaacatgg agaattcatt gaccagacat tcagcttgac ctaacctgtg 20460 aaattctcca tcttctttat aaagtgttcc cttccttgcc tcccctggaa aggtcagtgg 20520 tgtgtggctg cagcagcaca gtgtcctctg agccctggac ctgcactgtg gcttccagag 20580 gtggcagttc ccacatgggg tactagaata aatggcctat caggctgtgt gtgctttggg 20640 atcacatgtc cccaccctag gaccctggtt ccaaccatac gcatgttctc ttggagccca 20700 gaacagcaga gaagccacca gtgtggacac agaagtcaag ggtctgattt ccagcctggc 20760 ttctgactgc tctggggccg caggaatacg gttccttccc ccatgcccag caggcatttg 20820 tcttacaact ggaggggaag gcatgttcct cttggcaagg actgctcagg aggaagtgga 20880 ggcaggctgc cctgtcaggg tttttgcctt gattcaagga gaacttccta accacaaagg 20940 atacaagtgg gagtgaggcg gaccctccct agagatctcc aacacagaga gacaaacacg 21000 ctggggctgg ctggcactga caggcctcgc aggtgtggat ggctgttagc tgggagcttc 21060 gctgtctaag ctcctctccc atgcttttct tctgggttgc tcgaaggacg ggggtctgca 21120 agaaaatgat gttcccacat agttggcagc acgtgaacag caattgatcc ctttgcatca 21180 cctcctctta ctgtttagat ttggtaaata tttcttcctt ccctcttctg accctccatt 21240 ttgccgatct ttccttctta taacacatac ttactaggta cctgctactt cccgggtggg 21300 cctatgtgcc aggagtatag aggtgaacaa ggaaggcaaa gttctattct cagtagagct 21360 aatactctat ctggagagag acaacaaaca aatcaacaag gtagccaggg gctgtgataa 21420 tttatgtcaa gtgggcaggt aaatcgggag tgacagtagt gcagggagga ttggaaagtc 21480 agggagttct ctctggagga ggtggctttt gatctgcagc ctaaaggatg agaatgggtc 21540 cattatacaa aatgctgggg caagagcaca cccagtagag gggagagtaa tagcaaaggc 21600 tcagggcagg aagggcaagg gagaggccag tgggtgaggt cacatgtgaa gggcatacaa 21660 tgggcaaaga caaggccaga gtggccaggc ccaatcctcc aggacttgca gacctgggaa 21720 agagtgcatc tccatcctgg gagcagcagg aaaccactca ggcctttaga agatccttct 21780 ggcagctgtg tagagaatgg gtggtgtgat ccttccatgc atgggctcat gtacgtgatt 21840 accaataact gtcgagtgac agtgtgagga gggctgcaag ccatgagtgt aggcacagca 21900 gacagactca cctttgtctg gcggtgagat ggggtgggaa gtgtgccaag ttgacctccc 21960 aaagaaatga tattttagtg gaagaatgaa tagaatcaga gaagcaaagt aagagggaag 22020 agcagagagg acagcaggga caaggacttg ggggcaggaa gaggaaaggc aggttaagga 22080 catgaaagat ggccaggctg gctggagctc aggcccagca aggccccctg ggggccatgg 22140 tcatgggtga gcttgggttt ggcttctgtt ttcgtcttgg gcttctgtga aagcctcgag 22200 cccttgcggg gaaccagtga agctgtgtgt gcatcttctg tggggagtgc cagagtcttc 22260 agggagcact ccatcttctc tcctccccac aggctgctgt ggctgcatca gggctcaaca 22320 cgatgcttga aggtaacggc cagtacacgc ttttggcccc gaccaatgag gccttcgaga 22380 agatccctag tgagactttg aaccgtatcc tgggcgaccc agaagccctg agaggtgagc 22440 atcctttggc tcctgctgct gcctcatttg tgcagctaga ttgagcccaa gacctgctct 22500 ggtccaagat gaacatacca cctgccatga ggtgaccctc aggatatcca ctgcagccat 22560 gggctggggt catcctgtcc tgttgcttca gctaaccgtg tctctagcag ccacactact 22620 ctgagggctg actacagaat ccagcagctt ttgtctggga gagctggact gaagagaggc 22680 atagctggag acccatagct ggccctggcc agaaacaggg agagtgaaag gctggaatag 22740 ccaaggccag agcaaggcta ataggtagag caacagctta caggtgtggg ggtggcagat 22800 actggcaccc ttgaaatgga ttcctcatgc ccacgcttca ctattcttct ctgtggctag 22860 gggatttatg gataaaccaa aattacagtt aaaaaccagc cataggccag gcacagtgac 22920 tcacgccttt aatatcagca ctttgggagg acaaggtggg cggatcacct gagatctgga 22980 atttgagacc agcctggcca acatggcgaa accccatctc tactaaaaat acaaaaatta 23040 gctgggcatg gtggtgggca cctgtaatcc cagttactca ggggctgagg caggagaacc 23100 acttgaaccc aggaggtgga ggttgcagtg agccaagctt gcaccactgc actccagcct 23160 gggtgacaca gcgacactcc gtctcaagaa aaaaaaaaaa aaaaacagtt atagtagtca 23220 acttttgact ctccatttca gatttcgtca tgccctcctc aatgagctgc taagttaggc 23280 agtgcattga ttattgctgc aggagaggga aggaaggagc taacgtgttt tcacatgttt 23340 tccttttgga gatgagaaag gaggactctg ccttccccct accctgcccc tttctactcc 23400 aggacctctg aaaggccatg agcacaaagc tgctgcctga gtcccctgaa atgcagggta 23460 cgccccaggt ctctgatgta ccccaccaca cttttcctct caaacatatt ccaggatcac 23520 ttgatttctt ttgaatctat ttaaacccac cgtgtcaatg tgctatataa aatgtctaat 23580 gcatttcaga caccctatac atctatacat ttaaagtgtt ctccttctat ctgtgcaggg 23640 atgggaaagg gcatatttct gaaagcacag atgggaagac gggatttgtt ccgtgtccag 23700 gtgattatgg tacctctatg cgcctggccg gcactgggga cagaggccat gaaaatgaat 23760 acagcacagc ctttgcctcc aagaaactta agacctagta gaaatggcag gctttaaaac 23820 aggttgttgg gatctgattt ggtgagtgca atgacagaga tactcacagc acaaaatggg 23880 gaatgagggc gggcattggg acacacatag ccttaagggg cccaaaggct tttagaactg 23940 tattccctat taaaacatga tttgcacaga gcacattctt tgctttggag acctcagaac 24000 tccttactat aggccgggca tggttataat cccagcactt tgggaagcca aggcgggcag 24060 atcacttgag gctgagagtt caagaccagc ctggccaaca tggtaaaacc ccgtctctac 24120 taaaaataca aaaattagct gggtgtggtg gtggccacct gtaatcccag ctactcagga 24180 ggctgaggta ggagaatcac ttgaacctgg gaggcagaag ttgcaataag cccagatcat 24240 gccactgcac tccagcctgg gcaacaaagc tagactctct caaaagaaaa aaacaaaaca 24300 aaacaaaaca aaacaaaaaa aactccttat tataaactgt aagaaaaaaa aggcccctac 24360 ttcgtccctt ttgcaaatct gccttttcct actcactaac cagctggttc agagcaagga 24420 cactctgttt ggtgccatcg ctgcagactg gaaggaagag gtccttgccc cacacccaac 24480 agtctcctgc tgttaccggc aggttggcag gcaggcaggc gagaagcagc cagggctggt 24540 ggtgtgtcca gtttgaagac tagtttccag ccctggccct gctcaccctc caagtggccc 24600 tggcaggttc ctctaccaca tcgtggactt caccttcctt ctctaagaag ctcaatcccc 24660 aaggcctcat tcccataggc cttctcaccc tttttctttc cctctggctg aatgtggcca 24720 gcacgggctt ccaaggccat caactcgtct gcagcagccc catgccttgc agggcctcag 24780 agcttcctcc tgcctatgac agtgtggttt tggttcccac acttgggatc agattgaaac 24840 tcgcctccgt ggtgagaata tgggacatag agcctcggtg accttggtga gcagcagtcc 24900 aggccacctg ctcagcctgg ggttgggggg gggctcctcc tccttgactg gtccttgcat 24960 ttgcctccat ccagcctgtc tgggctctcc gaggcaatgg agaccagcag gagtcacgat 25020 gggtcaggag ccccctttgg gcctcagccc tgccctgccc cctaaagtag cacttggata 25080 agcaaataaa ttattatact tactatttat gggtgtggtg aatgggatgg caaaggccaa 25140 gtcttactga tcaccaaacc ttaagatata tcctggcagc tagtagaccc ttgggctaaa 25200 tgaacagaaa actggacaaa taaagtgtac acaaataact caaagctgtc atttgtacac 25260 ttttcgtctt ttcctactac agtttacatt tttataaagg tgagtagatt tctaaaatcc 25320 cgtggtaggc tctcttgagt ttttcttgta tccctgaagt tcagctacaa ataagctaat 25380 cactaacatt tgttgagcat ttactctgtt gtcaggcccc gtgccgagtg ctttaggttc 25440 agaatttcat gtcatcccca cagcagccct aggagatgaa tgcaattctt atgtccactt 25500 gactgataag gaagttgagg ttcaaagagg ctaaatgact ctcccagggt cccacagctg 25560 gaaagtggcc acagggcccc agctggtttt ctagggcagc aggcagaagg cgaggaggat 25620 ctgggccctg tggtgcccca gcctcatctg agggtcctca tctgagagaa caggatcctc 25680 acagcatggg caggctgcaa gtggtccctg aggttatcgt ggagtggacc ctgacttgac 25740 ctgagtctgt ttggacccca gacctgctga acaaccacat cttgaagtca gctatgtgtg 25800 ctgaagccat cgttgcgggg ctgtctgtag agaccctgga gggcacgaca ctggaggtgg 25860 gctgcagcgg ggacatgctc actatcaacg ggaaggcgat catctccaat aaagacatcc 25920 tagccaccaa cggggtgatc cactacattg atgagctact catcccagac tcaggtaggc 25980 caggcctccg ggggccttgg ccctgcctgg cccaccatct cttctgccat cctttgtggc 26040 gggggagggg aaattcagag atctttgggc gacttccctg cctggaccca gctcacagct 26100 tctcggccac tgcaaatgtg tgggttgtga ccagactgat gtgtcttgag cttcaggctt 26160 gcaagtgcag tggagaggca gtggggagct attgaagggg tctggggaca gactcaatca 26220 cagaggcctt tcagaagatc tgcctgctgt gcatgggcaa agagggccac ttgctgacct 26280 cagagcatgt gctttctcag tagtgcccaa gctgtcccat ggtcactgac ccagttagaa 26340 tgactgaatg gactttggct tgtgtctcat taggaatcct agccccattc tagtcttcca 26400 gtgagatctg tccatgagtg aaggaatctc acaggaaaaa acaaaatgct tctatgggtg 26460 tggttgctgg ccttatctac accacagaag ccatcacaca gactgtcttt cttcccattg 26520 ttagaatgtg ccctgaccaa gcagcccaca gggcctggga cagaggctga tctctgccta 26580 actgagctca cctctcctcc ctctcctcct gactggttag attttctagg tgactgttcc 26640 cctgatgaca caagcccgct gggccccagc agtgtttaga ggggttgttg actcacgaga 26700 tgacattcct gctgatgtgt gtcatgccct ggggtggatg aatgataaat gaaaacagcg 26760 cttttaactt ttgaacccac tttctccttc cttgtagcca agacactatt tgaattggct 26820 gcagagtctg atgtgtccac agccattgac cttttcagac aagccggcct cggcaatcat 26880 ctctctggaa gtgagcggtt gaccctcctg gctcccctga attctgtatt caaaggtaac 26940 atggggaagg catccctgtt agattgtccc tggaggcagc ttccccaccc ctgtcacctc 27000 cacaacactc tccgatttac agcaccccat gggacattag aacttccact cagctcaacc 27060 aaaagcagat gtgacttcag cagaaacttc agaggctctg ttgtttcatt aggcagtgca 27120 gagaatgcct ttggggagcc gttcctcaga actcaagact tgacatctgg gaggcagccg 27180 ttcctcagaa ctcaagactt gacatctggg agagcagagc attcccttgc ctttctattt 27240 gcagggtcac ttgccaatgt atagtcaaga ggtcagagtg agggtacagc tgagctgcag 27300 ccccaggaag gcagagaagg gggccaagtt gtgtgcgtgc ctgcccttcc ctcttagggc 27360 aaaactccaa acacccttga ttatctggat cttctttaat tctccataga agataccaga 27420 tgttaaggaa tattggcagc ttcacttggt ttctcaatcc ctgtttccaa actcaaggag 27480 ggatgggctt tttcactgta tttatctctc atcactctct tcattgcagg agcacatctc 27540 tctggaccta accatcaccc tttcttgtag atggaacccc tccaattgat gcccatacaa 27600 ggaatttgct tcggaaccac ataattaaag accagctggc ctctaagtat ctgtaccatg 27660 gacagaccct ggaaactctg ggcggcaaaa aactgagagt ttttgtttat cgtaatgtaa 27720 gttctgggtc ctaaatcatg ctcctgggaa gctccttact gtgggacttg tattagtgta 27780 aaaaaaaatg tcctcaataa gcaggagttt gcatgagaac tggttgctga caaggaagga 27840 aataatttct ggaaaatata gataacaaaa tgagatcctg cagaaggatt ggaatctctt 27900 tttctggagg cctttgagaa taaaccacac aattatccaa cctgtattgt gaaggaataa 27960 gtccttcttg aattcaggaa ttaacacctg ggaggaggga tggagttcag actctttctg 28020 agcttatgag aagagaagcc ccctaaacta aaatacagcc ctccttggtc caaaaggtgc 28080 cttctctctt ctgctgtatc ttctttgttt tcaaacccaa cagttaccct ggaaatcaaa 28140 aaggaagtac aactcaacat agctcttgcc tgggaccaac cagcaccatt tggctaaaga 28200 tggttatcat ctgttaaaca aagaaataaa taaatgggtt caacgtattt atttcaacat 28260 tgtcaatgga cctcatgtgt aactgatatt ctcattatgg gacctctgtg tgactttatt 28320 ggggcctctc taaccgttct ttccttaagg aagaccattt attgttttat ttcctggaga 28380 aaatacatca ttttatccca gccttaataa cccatcccag tgtatactcc ttcatcttca 28440 tggataatga ccctgctaca tgctctgaac aaatcaggag gcccctcgtg gaagtataac 28500 cagtcctttc tttctctgtc cctcttctgt gcagagcctc tgcattgaga acagctgcat 28560 cgcggcccac gacaagaggg ggaggtacgg gaccctgttc acgatggacc gggtgctgac 28620 ccccccaatg gggactgtca tggatgtcct gaagggagac aatcgcttta ggtaattagt 28680 tccatccccg ggtggagctt ctgcccagtg gtcatgctgg agtgggatgt ggggccccag 28740 ctatttgtca agctttcttc taccttgggg attcaattaa cactagcagt gcactgctgc 28800 gaccttccag acttgggatg gggaaaaggc aagggtcgcc ttgaaagctt acattgggaa 28860 gaagggttac ttctaagagt gtaatcttca catgcatggg aagcagggag gggggactac 28920 atttttatga ctgaagtgca aggaaaacat caccctctca ttgtaaagct ccaagtgagc 28980 caagagcaca tagtttacag tgcacgatga gcctctcact ctctgcgcag tatctgttta 29040 ttgcaactga agcacccttg tgagtttgtt ttcttgcccg gctatctcca tttctgactt 29100 gctcattcac cttggggtgc tgtcatattg aatgtttccc tgtcactgac ttcagccacc 29160 tgcacaaggg cttggagacc acacccctct gccctcccag aatcatatcc ctggaggctc 29220 agctagtctc tgggtcagcc atacctctgc cctttctttt ccctcctttc tcctgtggcc 29280 tctgacgtct ggccatttaa cagagcttag catttttgct gggtggagag agctggagcc 29340 tggaatcact ccctctttgt gcatacggag ggcatgaaaa ccaaggtgtg tgcattccag 29400 tggcctggac tctactatcc tcagtggtga ggtatttaag gaaaatacct ctcagcgtgg 29460 tgaggtattt aaggaaaata cctgttgaca ggtgacattt tctgtgtgtg tatctacagc 29520 atgctggtag ctgccatcca gtctgcagga ctgacggaga ccctcaaccg ggaaggagtc 29580 tacacagtct ttgctcccac aaatgaagcc ttccgagccc tgccaccaag agaacggagc 29640 agactcttgg gtaaagacca acttaagtac acgtctccat ttttctaaag tagtgatccc 29700 tcagggcccc agcagcaaac agttggcaca tcaaggattg acttgaaggg attttatgac 29760 aagactatta gtgaaagagt gggcgggact aaaggaacta gcaaaggatg aggccaacca 29820 gggactagca accctgggaa gcctttacta cccctaggcc tgggggaatg ggaggatgag 29880 agcaggaacc agggaggtca tgagccttgg acaagggcac agaacagcag ccagagccat 29940 gtgcagccag ccactgtcag aaccatgcaa gggggaccac tcagcgcccc agcctccctc 30000 tcagacagtt gccatctggg tctcttgttg gctgatgcga gagcaggagg gagcccactg 30060 atgcagttca tagagctcag cctcctgggc aggaaaccgg gcagagagga gtagaaaaga 30120 attaagggtg gctgcgacca gcccagtcac tgaggcacgt ttcccactgg agacctatga 30180 gcacagtgat aataaagcca gttacctgca ctgactatcc ctccagacaa aagctttccc 30240 aagaagttag tcatggctct gagagatcta gttgaggatg tttggcaggg gatctagtgg 30300 ttacgggtgg ctaagaaaaa tgaggaaggt aagagtatct tgcagcctgt gttgggagga 30360 ttaaatagga tgccacacac agggccaggc agacagcctg gtcagtaata gccatgacga 30420 tgggggcggg gggagcagga atgggagttg cagtgtttag ctcagatgca tgcctgtgag 30480 agatgcttcc actctcacag aaagatgaga ccaaggaaaa ggaggaggaa gaggaaggac 30540 cttgacaaac cttggggccc acattgtcta cacctccctt cctgctctag agcagaatag 30600 aaagttcagg ttgcaggcag ctctaagttg aattcgtgtc ctgtttaatt ttctttattg 30660 ctaaatgaat gcctgtgtct gtgatgctga cgtatgttcc taaggagagg ggagaagttc 30720 attctgaaca taaacttttc atcctctctc tgtccagcaa gaatggaata ttccccaagt 30780 ggcctgagcc agcttggctt tctttttgtt ttcaattatg tgggagttga ggagggggat 30840 gggaaaagct tcccaaacac accctccccc aggcctgagg cacccctggg ggacagagag 30900 tgttagaggt tggtacaggc gttagagata ttgaaaggac atcccatgca ccccaggggc 30960 tggtgtggct ctgtacttcc aggcaatatt ttgtggaagg ggaaccttgt cagctccagg 31020 ttgtggatgt ttgaaaatca gttggtaccc agtggctcca tcctctggca ggcatgtgga 31080 tttgtcaata accaagtgaa ctctccaaaa taagttaaaa cttcctccct tctcagtttc 31140 aagatgctgg aaatagctgt tcataagccc tggggaaatt tagccctttg gctggtaatg 31200 ggagtatccg agatgagagg gcagctggaa actttcggaa tgacctccca cacttaattt 31260 gggaaatgcc tctgcacctt tatgggcaac cagatgcctg ccccagttgc tggagacact 31320 gatgtgggct gaaaggaatg ctgagacgtg acgaggagag atgctgcgga gggaatatcc 31380 ccctcagccc tgacctcatc ggctccatgg ctcctccaca gtacagctgt ctactctttt 31440 aagttctccc ttcaggaaat agccatctca aacagaatgt gcatttgagg gcagaatgtg 31500 taaatattgc actactgtgt tataaccgtc aggagccatg ctgatgatga aacgtcccag 31560 atgccggtgc tggaaaggtc cctggctttc caagcaaata tttatctcat ggaaacatga 31620 gtcatactca cagaggagta tggattaact ccttctcagc agccagggag cccagcatcc 31680 cagacagcat atttaaccca gaggccaact gactgctggg gcagatttgt ggtcatgaac 31740 atgtgctttg tgtcctctga ccattagaca gattgtgggt cacaacgttg agtatacagt 31800 gggagcttaa taagtgctta ttccctgggc agggagttct tcatttcagg ggtgaccact 31860 tacatcttct cctctgggcc ctccttgacc aggctaatta ccattcttgg gattaactct 31920 atctcctttt cccgcaacct gcaggagatg ccaaggaact tgccaacatc ctgaaatacc 31980 acattggtga tgaaatcctg gttagcggag gcatcggggc cctggtgcgg ctaaagtctc 32040 tccaaggtga caagctggaa gtcagcttgg taagtgtcct gcaaatcaaa ggctggctaa 32100 atttccccag ggcagggctc caggacatat ctcaccccca ggatggaatt atacacacac 32160 aaccttcaag ttgcagcccg aatctctgag tgtaattcgt ccaaagaaaa agagaaaaga 32220 gaagagggtc ttcagggaaa tcaagtgaga tcatagttag acatgagtaa gaacttccag 32280 atttacaagg gaatagagca tctgatttgg catctgagag aggctattag atcttccttc 32340 tcttaaggag gttgtaggca actagttatg tgactgaaga gatcagtctg tactcacacc 32400 atcccacccc ccaaacccag ggcttcactg agttgtacca tgaaccagac catcccaaga 32460 ggctttttga gttctgacac ttgctctgtg agccttccct tgctctgcac attgatgata 32520 taactttgta actgcactaa gagtgttcct aaagcagata gccagccgag ctccagaaat 32580 ctccctggct gcacctgcag aggccactga cccctctgtg gagggaccgc tcttcagtgt 32640 gtggctggct tctactctct gctcctctct cttggtcttc agccatccat tgctcaccag 32700 tttctcacca ggagcatagg aagatatgca tgtagggagg taggcacggg gatgacttgt 32760 ttgactttaa gcaggtcatt caagaatctc ctcgcacctg gtttcagatg ctggggtcct 32820 gtctgtcaca ggcttctgtg cctcctaccc ccttgagttt gtcacatggc ccttcaggaa 32880 ggcctgagat agatttgccc tgggtgggcc tcctatgaga aaatcttaag tgaggcaccc 32940 aggcaaaatg gaaagagcct tttgcccaga gcaggaagcc tgtcttccat ttccagctgt 33000 tccacctact tagcttaaaa gaggcacttc gcctgtcttc agtctcagtc tcagtctcct 33060 cttctgtgga atgggacaat aatatctact ctccttatca tacactgctg tgaggactga 33120 gtggatcaca caaaaaagca ttatgtaaat tgcaaagtgc taaatccaca caggagattt 33180 gaattaatcc accacactga aggtctgtca agggcaggga ctgtttcatt caccagagta 33240 tccccagtct tacacaggac ttggcatatg aaaagtgttc agtaggccgg gtgcagtggc 33300 tcatgcctgt aatcccagca ctttgggagg ccaaagtggg cggatcatct gaggtcagga 33360 gttcaagtcc agcctggcca acgtggtgaa acctcatctc tactaaaaat acaaaattag 33420 ctgggcgtgg tggcacatgc ctgtaatcac agctactctg gaggctgagg caggagaatc 33480 acttgaaccc aggaggcgga ggttgcagtg agtcgagatc atgccactgc actccagcct 33540 gggcgacaag attgaaactc catctcaaaa acaaagaaca aggaaaaaaa cgaaaactgt 33600 tcagtaaaca cttgctgagt gaataaaata aataaataaa tgtataaata aatgctctac 33660 tttcaaccac tactctgttt ttcttttaga aaaacaatgt ggtgagtgtc aacaaggagc 33720 ctgttgccga gcctgacatc atggccacaa atggcgtggt ccatgtcatc accaatgttc 33780 tgcagcctcc aggtaagtgt cgcatcccca ctgactctgc agccagtcct tttctccatg 33840 tggcagttgg tggagagaag aaaaactgtt ctaaacaatg atgagaataa catgtaattg 33900 tgatagttaa actgtgccta tgtgactgat tgcagagtga attgggagct gttggttttg 33960 aatgcaccac actaaggaat gtgaggacac attgctcttt gcggagttgc ccagctatat 34020 tagctcccct cggacacagc ccagttttct gtattcgcgt ggatgctgtc cgcgcgattc 34080 ccagcactcc tcttacagca tctcacctca gtgtatgttc cttgcctcca gtgcagttga 34140 acctcagtcc tgcctctcct catgtgtgca ttcacctttc ttggcgctct ctccccatgg 34200 gccaagttct accatgagtt atgaaacatt atggagaaaa catgtctttg gaaatgtgag 34260 ccagaaagcc caccagtgcc cctcagtcac ggttgttatg aatgacatgc taatggtttc 34320 actctggtca aacctgcctt ttctttcctc ttcagccaac agacctcagg aaagagggga 34380 tgaacttgca gactctgcgc ttgagatctt caaacaagca tcagcgtttt ccagggtaag 34440 atgcctgcta ggtttgcgcc tagcctgagc agcctcaggt cctctgtttg ggccatagag 34500 gagcctctcc agcccctgtc ttccttggct gctccccagg gctctcttaa aacttctccc 34560 cactcccact gaggcatcct cagccccagc ctgtgtcaaa ttcagagtaa agaaccaagg 34620 caactccctg gctttcatgg gccaaagcgc aggctttcac accgaggcct ctgagcctca 34680 gatcatgggg aagtcactgc tggagagaac agacatagct ctggaagcca tctgcccaag 34740 agggcagccc atcccaagtt catcttacag tggccaggcc tgccctgagc cggggcctct 34800 gggtcactct tctgctgtcc atggcattgc ccatcctggg tgaggctggg gctctcctgg 34860 gcactgtatg tattctggat acagggatac tgggctcgct atgtgtgtgg agccatccct 34920 tccttgcccc agccccacct ccctctcaaa ccctctctgg ctctttctga gcttcctttc 34980 ctgctcccca gcttgcccag tgctcagtgc cccacttggc tcttttgcta cttcgggtca 35040 ggtggagcct cttgggaatg tgaagtgcct tacagaaaga ttgcacttca agaggagagg 35100 ctgcagggag ccatcctaaa cccagaggcc tggagcttac tgtgtcactt tacttttgta 35160 cacaggggtc tccttagtgc cctcgagaag gattcttggc cctgagcttc tactcctgag 35220 gccacctctg tgcagcccca gctccctcaa ctctaggctg tagtctcagt gggaaagcct 35280 ggcttggggg tctcctagga atgtccacct gaaggcacac ttgatagggg cttgcacaac 35340 ttatgtctgc caaggccacc tgaggaactc cctggtgcct ataagttcca ccttcccctt 35400 cctcttcctc gccccagcat tttttctgag taggggtggc aatgggcaaa gccattgtca 35460 taagcagttg caggtataac tttcactaga aaacctgaca ccttgtgttt tctttcaggc 35520 ttcccagagg tctgtgcgac taggtgagtc tggtctgggt ttgaagtcat tgcagacctg 35580 tttaggcctt acccccaagc aagcccaagc ctgccatctg ctgtatatag ataagaacat 35640 catggtgcag taaaagaagc ctggcctttg gagtcagaac agcagggtga cttggggtca 35700 gacccagagc accccatttc cttctctgta agatgaggat aataagagta acaacctttt 35760 agggttaagg tgagttttca gcttaggaag tctgggaata ttgcaaaggg cttggcagga 35820 acccatggtg aggatctagt tccaagttga taggtacaga aaaccagaac atcgggcctt 35880 gagtaaagag tgaagtttca caaaccacaa agcacctgct atgtgcagga gagcatggca 35940 gaaggaggct gcttggccct ggtccttgag attctgacag tgtcctagac agacatgggg 36000 agatctgcac ctatttgacg ttaccaactt ctctttttca gcccctgtct atcaaaagtt 36060 attagagagg atgaagcatt agcttgaagc actacaggag gaatgcacca cggcagctct 36120 ccgccaattt ctctcagatt tccacagaga ctgtttgaat gttttcaaaa ccaagtatca 36180 cactttaatg tacatgggcc gcaccataat gagatgtgag ccttgtgcat gtgggggagg 36240 agggagagag atgtactttt taaatcatgt tccccctaaa catggctgtt aacccactgc 36300 atgcagaaac ttggatgtca ctgcctgaca ttcacttcca gagaggacct atcccaaatg 36360 tggaattgac tgcctatgcc aagtccctgg aaaaggagct tcagtattgt ggggctcata 36420 aaacatgaat caagcaatcc agcctcatgg gaagtcctgg cacagttttt gtaaagccct 36480 tgcacagctg gagaaatggc atcattataa gctatgagtt gaaatgttct gtcaaatgtg 36540 tctcacatct acacgtggct tggaggcttt tatggggccc tgtccaggta gaaaagaaat 36600 ggtatgtaga gcttagattt ccctattgtg acagagccat ggtgtgtttg taataataaa 36660 accaaagaaa catacgtcct gtgtgcatgg tacagtgtgc tgacctgagg ccgtcatgct 36720 cctccacacc tcaattctgc tctggagaag ctcagaaagg agccccgagg gatggttttg 36780 gggagattcc agcagccagc cctcagacag ccagacagct catgggggtt tgagcctgtc 36840 tttgccaaac aggtttttat ttcaccctcc tccggtcctg gggtttcaag ttttcagtgt 36900 tgccttcacc ccgcacttta ttcctcttat tacttggaag taccttccct ccagcatggt 36960 gatcccctgc ctgtgtgctg gacttttgag tcctcagcac caacctgtga agtggttgcc 37020 agcataatcc cattatgcag atgaggagac caaggcccag ggaagggaga accaccagca 37080 gcacgtaaaa tagctgagct gggactggaa ctcacacctc ctgactctca gtgaccacca 37140 ctgacaacag cataagtcca ggttttccag gcccatcccc tctgtgccaa cccacattca 37200 gattccttcc ccggctcccg taatctctgg catctagaat atcctcagga ctctgagagg 37260 tgatatcatg tggttgtggt gccattgccc cctacctgtg tggcctgggg ccagtcatgt 37320 gacctcccag ggtctcctct tctgtaatag ggagatgacc gtcacatcta cttcatgggt 37380 ccatcgtgag gatgaaatga gatgatctat ataaaatgct tggtacaaca ttaggtggcc 37440 ttatttttat cctgccgtct gggactgctc aggatcaatg cgccagagag cctttatttg 37500 tgtctttccc acaggtgggc tggcccactt tcctagagaa tgggacagac ctccttccca 37560 cccacaccca tctctgccaa ggctgattca ctccagcagg cggagctcat ttcacttcat 37620 ggaaccaatg acccaaagat atatccccag cactactgct ggtcagtcca ctgctgctgg 37680 gaatacagca atggtagtgg cagacagagg ccctctctta aatagcttcc agtctgagga 37740 aagagagata tgacatcaat ccattaaaat cattcatcca ttggttccac aaatatt 37797 77 683 PRT Homo sapiens 77 Met Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu Ala Leu 1 5 10 15 Gly Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu 20 25 30 Val Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val 35 40 45 Cys Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn 50 55 60 Cys Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile 65 70 75 80 Ser Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly 85 90 95 Cys Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val 100 105 110 Val Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu 115 120 125 Arg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser 130 135 140 Asn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val 145 150 155 160 Ser Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val 165 170 175 Gly Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Leu Thr 180 185 190 Ser Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly 195 200 205 Ile Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala 210 215 220 Thr Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr 225 230 235 240 Asn Asn Ile Gln Gln Ile Ile Glu Ile Glu Asp Thr Phe Glu Thr Leu 245 250 255 Arg Ala Ala Val Ala Ala Ser Gly Leu Asn Thr Met Leu Glu Gly Asn 260 265 270 Gly Gln Tyr Thr Leu Leu Ala Pro Thr Asn Glu Ala Phe Glu Lys Ile 275 280 285 Pro Ser Glu Thr Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg 290 295 300 Asp Leu Leu Asn Asn His Ile Leu Lys Ser Ala Met Cys Ala Glu Ala 305 310 315 320 Ile Val Ala Gly Leu Ser Val Glu Thr Leu Glu Gly Thr Thr Leu Glu 325 330 335 Val Gly Cys Ser Gly Asp Met Leu Thr Ile Asn Gly Lys Ala Ile Ile 340 345 350 Ser Asn Lys Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp 355 360 365 Glu Leu Leu Ile Pro Asp Ser Ala Lys Thr Leu Phe Glu Leu Ala Ala 370 375 380 Glu Ser Asp Val Ser Thr Ala Ile Asp Leu Phe Arg Gln Ala Gly Leu 385 390 395 400 Gly Asn His Leu Ser Gly Ser Glu Arg Leu Thr Leu Leu Ala Pro Leu 405 410 415 Asn Ser Val Phe Lys Asp Gly Thr Pro Pro Ile Asp Ala His Thr Arg 420 425 430 Asn Leu Leu Arg Asn His Ile Ile Lys Asp Gln Leu Ala Ser Lys Tyr 435 440 445 Leu Tyr His Gly Gln Thr Leu Glu Thr Leu Gly Gly Lys Lys Leu Arg 450 455 460 Val Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu Asn Ser Cys Ile Ala 465 470 475 480 Ala His Asp Lys Arg Gly Arg Tyr Gly Thr Leu Phe Thr Met Asp Arg 485 490 495 Val Leu Thr Pro Pro Met Gly Thr Val Met Asp Val Leu Lys Gly Asp 500 505 510 Asn Arg Phe Ser Met Leu Val Ala Ala Ile Gln Ser Ala Gly Leu Thr 515 520 525 Glu Thr Leu Asn Arg Glu Gly Val Tyr Thr Val Phe Ala Pro Thr Asn 530 535 540 Glu Ala Phe Arg Ala Leu Pro Pro Arg Glu Arg Ser Arg Leu Leu Gly 545 550 555 560 Asp Ala Lys Glu Leu Ala Asn Ile Leu Lys Tyr His Ile Gly Asp Glu 565 570 575 Ile Leu Val Ser Gly Gly Ile Gly Ala Leu Val Arg Leu Lys Ser Leu 580 585 590 Gln Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser Val 595 600 605 Asn Lys Glu Pro Val Ala Glu Pro Asp Ile Met Ala Thr Asn Gly Val 610 615 620 Val His Val Ile Thr Asn Val Leu Gln Pro Pro Ala Asn Arg Pro Gln 625 630 635 640 Glu Arg Gly Asp Glu Leu Ala Asp Ser Ala Leu Glu Ile Phe Lys Gln 645 650 655 Ala Ser Ala Phe Ser Arg Ala Ser Gln Arg Ser Val Arg Leu Ala Pro 660 665 670 Val Tyr Gln Lys Leu Leu Glu Arg Met Lys His 675 680 78 660 DNA Homo sapiens 78 aaaaaacagc ccggagcctg cagcccagcc ccacccagac ccatggctgg acctgccacc 60 cagagcccca tgaagctgat ggccctgcag ctgctgctgt ggcacagtgc actctggaca 120 gtgcaggaag ccacccccct gggccctgcc agctccctgc cccagagctt cctgctcaag 180 tgcttagagc aagtgaggaa gatccagggc gatggcgcag cgctccagga gaagctgtgt 240 gccacctaca agctgtgcca ccccgaggag ctggtgctgc tcggacactc tctgggcatc 300 ccctgggctc ccctgagcag ctgccccagc caggccctgc agctggcagg ctgcttgagc 360 caactccata gcggcctttt cctctaccag gggctcctgc aggccctgga agggatctcc 420 cccgagttgg gtcccacctt ggacacactg cagctggacg tcgccgactt tgccaccacc 480 atctggcagc agatggaaga actgggaatg gcccctgccc tgcagcccac ccagggtgcc 540 atgccggcct tcgcctctgc tttccagcgc cgggcaggag gggtcctagt tgcctcccat 600 ctgcagagct tcctggaggt gtcgtaccgc gttctacgcc accttgccca gccctgagcc 660 79 204 PRT Homo sapiens 79 Met Ala Gly Pro Ala Thr Gln Ser Pro Met Lys Leu Met Ala Leu Gln 1 5 10 15 Leu Leu Leu Trp His Ser Ala Leu Trp Thr Val Gln Glu Ala Thr Pro 20 25 30 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu 35 40 45 Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys 50 55 60 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 65 70 75 80 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 85 90 95 Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu 100 105 110 Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu 115 120 125 Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala 130 135 140 Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu 145 150 155 160 Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg 165 170 175 Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu 180 185 190 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro 195 200 80 2475 DNA Homo sapiens 80 agccgctctc cgcatcccag gacagcggtg cggccctcgg ccggggcgcc cactccgcag 60 cacccagcga gcgagcgagc gagcgagggc ggccgacgcg cccggccggg acccagctgc 120 ccgtatgacc gcgccgggcg ccgccgggcg ctgccctccc acgacatggc tgggctccct 180 gctgttgttg gtctgtctcc tggcgagcag gagtatcacc gaggaggtgt cggagtactg 240 tagccacatg attgggagtg gacacctgca gtctctgcag cggctgattg acagtcagat 300 ggagacctcg tgccaaatta catttgagtt tgtagaccag gaacagttga aagatccagt 360 gtgctacctt aagaaggcat ttctcctggt acaagacata atggaggaca ccatgcgctt 420 cagagataac acccccaatg ccatcgccat tgtgcagctg caggaactct ctttgaggct 480 gaagagctgc ttcaccaagg attatgaaga gcatgacaag gcctgcgtcc gaactttcta 540 tgagacacct ctccagttgc tggagaaggt caagaatgtc tttaatgaaa caaagaatct 600 ccttgacaag gactggaata ttttcagcaa gaactgcaac aacagctttg ctgaatgctc 660 cagccaagat gtggtgacca agcctgattg caactgcctg taccccaaag ccatccctag 720 cagtgacccg gcctctgtct cccctcatca gcccctcgcc ccctccatgg cccctgtggc 780 tggcttgacc tgggaggact ctgagggaac tgagggcagc tccctcttgc ctggtgagca 840 gcccctgcac acagtggatc caggcagtgc caagcagcgg ccacccagga gcacctgcca 900 gagctttgag ccgccagaga ccccagttgt caaggacagc accatcggtg gctcaccaca 960 gcctcgcccc tctgtcgggg ccttcaaccc cgggatggag gatattcttg actctgcaat 1020 gggcactaat tgggtcccag aagaagcctc tggagaggcc agtgagattc ccgtacccca 1080 agggacagag ctttccccct ccaggccagg agggggcagc atgcagacag agcccgccag 1140 acccagcaac ttcctctcag catcttctcc actccctgca tcagcaaagg gccaacagcc 1200 ggcagatgta actggtaccg ccttgcccag ggtgggcccc gtgaggccca ctggccagga 1260 ctggaatcac accccccaga agacagacca tccatctgcc ctgctcagag accccccgga 1320 gccaggctct cccaggatct catcaccgcg cccccagggc ctcagcaacc cctccaccct 1380 ctctgctcag ccacagcttt ccagaagcca ctcctcgggc agcgtgctgc cccttgggga 1440 gctggagggc aggaggagca ccagggatcg gaggagcccc gcagagccag aaggaggacc 1500 agcaagtgaa ggggcagcca ggcccctgcc ccgttttaac tccgttcctt tgactgacac 1560 acatgagagg cagtccgagg gatcctccag cccgcagctc caggagtctg tcttccacct 1620 gctggtgccc agtgtcatcc tggtcttgct ggccgtcgga ggcctcttgt tctacaggtg 1680 gaggcggcgg agccatcaag agcctcagag agcggattct cccttggagc aaccagaggg 1740 cagccccctc actcaggatg acagacaggt ggaactgcca gtgtagaggg aattctaaga 1800 cccctcacca tcctggacac tctcgtttgt caatgtccct ctgaaaatgt gacgcccagc 1860 cccggacaca gtactccaga tgttgtctga ccagctcaga gagagtacag tgggactgtt 1920 accttccttg atatggacag tattcttcta tttgtgcaga ttaagattgc attagttttt 1980 ttcttaacaa ctgcatcata ctgttgtcat atgttgagcc tgtggtctat aaaaccccta 2040 gttccatttc ccataaactt ctgtcaagcc agaccatctc taccctgtac ttggacaact 2100 taactttttt aaccaaagtg cagtttatgt tcacctttgt taaagccacc ttgtggtttc 2160 tgcccatcac ctgaacctac tgaagttgtg tgaaatccta attctgtcat ctccgtagcc 2220 ctcccagttg tgcctcctgc acattgatga gtgcctgctg ttgtctttgc ccatgttgtt 2280 gatgtagctg tgaccctatt gttcctcacc cctgcccccc gccaacccca gctggcccac 2340 ctcttccccc tcccacccaa gcccacagcc agcccatcag gaagccttcc tggcttctcc 2400 acaaccttct gactgtcttt tcagtcatgc cccctgctct tttgtatttg gctaatagta 2460 tatcaatttg cactt 2475 81 553 PRT Homo sapiens 81 Met Thr Ala Pro Gly Ala Ala Gly Arg Cys Pro Pro Thr Thr Trp Leu 1 5 10 15 Gly Ser Leu Leu Leu Leu Val Cys Leu Leu Ala Ser Arg Ser Ile Thr 20 25 30 Glu Glu Val Ser Glu Tyr Cys Ser His Met Ile Gly Ser Gly His Leu 35 40 45 Gln Ser Leu Gln Arg Leu Ile Asp Ser Gln Met Glu Thr Ser Cys Gln 50 55 60 Ile Thr Phe Glu Phe Val Asp Gln Glu Gln Leu Lys Asp Pro Val Cys 65 70 75 80 Tyr Leu Lys Lys Ala Phe Leu Leu Val Gln Asp Ile Met Glu Asp Thr 85 90 95 Met Arg Phe Arg Asp Asn Thr Pro Asn Ala Ile Ala Ile Val Gln Leu 100 105 110 Gln Glu Leu Ser Leu Arg Leu Lys Ser Cys Phe Thr Lys Asp Tyr Glu 115 120 125 Glu His Asp Lys Ala Cys Val Arg Thr Phe Tyr Glu Thr Pro Leu Gln 130 135 140 Leu Leu Glu Lys Val Lys Asn Val Phe Asn Glu Thr Lys Asn Leu Leu 145 150 155 160 Asp Lys Asp Trp Asn Ile Phe Ser Lys Asn Cys Asn Asn Ser Phe Ala 165 170 175 Glu Cys Ser Ser Gln Asp Val Val Thr Lys Pro Asp Cys Asn Cys Leu 180 185 190 Tyr Pro Lys Ala Ile Pro Ser Ser Asp Pro Ala Ser Val Ser Pro His 195 200 205 Gln Pro Leu Ala Pro Ser Met Ala Pro Val Ala Gly Leu Thr Trp Glu 210 215 220 Asp Ser Glu Gly Thr Glu Gly Ser Ser Leu Leu Pro Gly Glu Gln Pro 225 230 235 240 Leu His Thr Val Asp Pro Gly Ser Ala Lys Gln Arg Pro Pro Arg Ser 245 250 255 Thr Cys Gln Ser Phe Glu Pro Pro Glu Thr Pro Val Val Lys Asp Ser 260 265 270 Thr Ile Gly Gly Ser Pro Gln Pro Arg Pro Ser Val Gly Ala Phe Asn 275 280 285 Pro Gly Met Glu Asp Ile Leu Asp Ser Ala Met Gly Thr Asn Trp Val 290 295 300 Pro Glu Glu Ala Ser Gly Glu Ala Ser Glu Ile Pro Val Pro Gln Gly 305 310 315 320 Thr Glu Leu Ser Pro Ser Arg Pro Gly Gly Gly Ser Met Gln Thr Glu 325 330 335 Pro Ala Arg Pro Ser Asn Phe Leu Ser Ala Ser Ser Pro Leu Pro Ala 340 345 350 Ser Ala Lys Gly Gln Gln Pro Ala Asp Val Thr Gly Thr Ala Leu Pro 355 360 365 Arg Val Gly Pro Val Arg Pro Thr Gly Gln Asp Trp Asn His Thr Pro 370 375 380 Gln Lys Thr Asp His Pro Ser Ala Leu Leu Arg Asp Pro Pro Glu Pro 385 390 395 400 Gly Ser Pro Arg Ile Ser Ser Pro Arg Pro Gln Gly Leu Ser Asn Pro 405 410 415 Ser Thr Leu Ser Ala Gln Pro Gln Leu Ser Arg Ser His Ser Ser Gly 420 425 430 Ser Val Leu Pro Leu Gly Glu Leu Glu Gly Arg Arg Ser Thr Arg Asp 435 440 445 Arg Arg Ser Pro Ala Glu Pro Glu Gly Gly Pro Ala Ser Glu Gly Ala 450 455 460 Ala Arg Pro Leu Pro Arg Phe Asn Ser Val Pro Leu Thr Asp Thr His 465 470 475 480 Glu Arg Gln Ser Glu Gly Ser Ser Ser Pro Gln Leu Gln Glu Ser Val 485 490 495 Phe His Leu Leu Val Pro Ser Val Ile Leu Val Leu Leu Ala Val Gly 500 505 510 Gly Leu Leu Phe Tyr Arg Trp Arg Arg Arg Ser His Gln Glu Pro Gln 515 520 525 Arg Ala Asp Ser Pro Leu Glu Gln Pro Glu Gly Ser Pro Leu Thr Gln 530 535 540 Asp Asp Arg Gln Val Glu Leu Pro Val 545 550 82 505 DNA Homo sapiens 82 aaagttctct ggaggatgtg gctgcagagc ctgctgctct tgggcactgt ggcctgcagc 60 atctctgcac ccgcccgctc gcccagcccc agcacacagc cctgggagca tgtgaatgcc 120 atccaggagg cccggcgtct cctgaacctg agtagagaca ctgctgctga gatgaatgaa 180 acagtagaag tcatctcaga aatgtttgac ctccaggagc cgacctgcct acagacccgc 240 ctggagctgt acaagcaggg cctgcggggc agcctcacca agctcaaggg ccccttgacc 300 atgatggcca gccactacaa acagcactgc cctccaaccc cggaaacttc ctgtgcaacc 360 cagattatca cctttgaaag tttcaaagag aacctgaagg actttctgct tgtcatcccc 420 tttgactgct gggagccagt ccaggagtga gaccggccag atgaggctgg ccaagccggg 480 gagctgctct ctcatgaaac aagag 505 83 144 PRT Homo sapiens 83 Met Trp Leu Gln Ser Leu Leu Leu Leu Gly Thr Val Ala Cys Ser Ile 1 5 10 15 Ser Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp Glu His 20 25 30 Val Asn Ala Ile Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp 35 40 45 Thr Ala Ala Glu Met Asn Glu Thr Val Glu Val Ile Ser Glu Met Phe 50 55 60 Asp Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys 65 70 75 80 Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met 85 90 95 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser 100 105 110 Cys Ala Thr Gln Ile Ile Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys 115 120 125 Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu 130 135 140 84 1080 DNA Homo sapiens 84 ccggggggca tgagggtccg agacttgttc ttctgtccct tccaagaccc ggcgacagga 60 ggcatgaggg gcccccggcc gaaatgacag tgctggcgcc agcctggagc ccaacaacct 120 atctcctcct gctgctgctg ctgagctcgg gactcagtgg gacccaggac tgctccttcc 180 aacacagccc catctcctcc gacttcgctg tcaaaatccg tgagctgtct gactacctgc 240 ttcaagatta cccagtcacc gtggcctcca acctgcagga cgaggagctc tgcgggggcc 300 tctggcggct ggtcctggca cagcgctgga tggagcggct caagactgtc gctgggtcca 360 agatgcaagg cttgctggag cgcgtgaaca cggagataca ctttgtcacc aaatgtgcct 420 ttcagccccc ccccagctgt cttcgcttcg tccagaccaa catctcccgc ctcctgcagg 480 agacctccga gcagctggtg gcgctgaagc cctggatcac tcgccagaac ttctcccggt 540 gcctggagct gcagtgtcag cccgactcct caaccctgcc acccccatgg agtccccggc 600 ccctggaggc cacagccccg acagccccgc agccccctct gctcctccta ctgctgctgc 660 ccgtgggcct cctgctgctg gccgctgcct ggtgcctgca ctggcagagg acgcggcgga 720 ggacaccccg ccctggggag caggtgcccc ccgtccccag tccccaggac ctgctgcttg 780 tggagcactg acctggccaa ggcctcatcc tgcggagcct taaacaacgc agtgagacag 840 acatctatca tcccatttta caggggagga tactgaggca cacagagggg agtcaccagc 900 cagaggatgt atagcctgga cacagaggaa gttggctaga ggccggtccc ttccttgggc 960 ccctctcatt ccctccccag aatggaggca acgccagaat ccagcaccgg ccccatttac 1020 ccaactctga acaaagccct tgcccccatg aaattgttta taaatcatcc ttttctccca 1080 85 235 PRT Homo sapiens 85 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu 1 5 10 15 Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe 20 25 30 Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu 35 40 45 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 50 55 60 Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln 65 70 75 80 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly 85 90 95 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala 100 105 110 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser 115 120 125 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp 130 135 140 Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro 145 150 155 160 Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala 165 170 175 Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu Leu Leu Leu Leu Leu Leu 180 185 190 Pro Val Gly Leu Leu Leu Leu Ala Ala Ala Trp Cys Leu His Trp Gln 195 200 205 Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly Glu Gln Val Pro Pro Val 210 215 220 Pro Ser Pro Gln Asp Leu Leu Leu Val Glu His 225 230 235 86 1321 DNA Homo sapiens 86 ccgcctcgcg ccgagactag aagcgctgcg ggaagcaggg acagtggaga gggcgctgcg 60 ctcgggctac ccaatgcgtg gactatctgc cgccgctgtt cgtgcaatat gctggagctc 120 cagaacagct aaacggagtc gccacaccac tgtttgtgct ggatcgcagc gctgcctttc 180 cttatgaaga agacacaaac ttggattctc acttgcattt atcttcagct gctcctattt 240 aatcctctcg tcaaaactga agggatctgc aggaatcgtg tgactaataa tgtaaaagac 300 gtcactaaat tggtggcaaa tcttccaaaa gactacatga taaccctcaa atatgtcccc 360 gggatggatg ttttgccaag tcattgttgg ataagcgaga tggtagtaca attgtcagac 420 agcttgactg atcttctgga caagttttca aatatttctg aaggcttgag taattattcc 480 atcatagaca aacttgtgaa tatagtcgat gaccttgtgg agtgcgtcaa agaaaactca 540 tctaaggatc taaaaaaatc attcaagagc ccagaaccca ggctctttac tcctgaagaa 600 ttctttagaa tttttaatag atccattgat gccttcaagg actttgtagt ggcatctgaa 660 actagtgatt gtgtggtttc ttcaacatta agtcctgaga aagggaaggc caaaaatccc 720 cctggagact ccagcctaca ctgggcagcc atggcattgc cagcattgtt ttctcttata 780 attggctttg cttttggagc cttatactgg aagaagagac agccaagtct tacaagggca 840 gttgaaaata tacaaattaa tgaagaggat aatgagataa gtatgttgca agagaaagag 900 agagagtttc aagaagtgta aattgtggct tgtatcaaca ctgttacttt cgtacattgg 960 ctggtaacag ttcatgtttg cttcataaat gaagcagctt taaacaaatt catattctgt 1020 ctggagtgac agaccacatc tttatctgtt cttgctaccc atgactttat atggatgatt 1080 cagaaattgg aacagaatgt tttactgtga aactggcact gaattaatca tctataaaga 1140 agaacttgca tggagcagga ctctatttta aggactgcgg gacttgggtc tcatttagaa 1200 cttgcagctg atgttggaag agaaagcacg tgtctcagac tgcatgtacc atttgcatgg 1260 ctccagaaat gtctaaatgc tgaaaaaaca cctagcttta ttcttcagat acaaactgca 1320 g 1321 87 245 PRT Homo sapiens 87 Met Lys Lys Thr Gln Thr Trp Ile Leu Thr Cys Ile Tyr Leu Gln Leu 1 5 10 15 Leu Leu Phe Asn Pro Leu Val Lys Thr Glu Gly Ile Cys Arg Asn Arg 20 25 30 Val Thr Asn Asn Val Lys Asp Val Thr Lys Leu Val Ala Asn Leu Pro 35 40 45 Lys Asp Tyr Met Ile Thr Leu Lys Tyr Val Pro Gly Met Asp Val Leu 50 55 60 Pro Ser His Cys Trp Ile Ser Glu Met Val Val Gln Leu Ser Asp Ser 65 70 75 80 Leu Thr Asp Leu Leu Asp Lys Phe Ser Asn Ile Ser Glu Gly Leu Ser 85 90 95 Asn Tyr Ser Ile Ile Asp Lys Leu Val Asn Ile Val Asp Asp Leu Val 100 105 110 Glu Cys Val Lys Glu Asn Ser Ser Lys Asp Leu Lys Lys Ser Phe Lys 115 120 125 Ser Pro Glu Pro Arg Leu Phe Thr Pro Glu Glu Phe Phe Arg Ile Phe 130 135 140 Asn Arg Ser Ile Asp Ala Phe Lys Asp Phe Val Val Ala Ser Glu Thr 145 150 155 160 Ser Asp Cys Val Val Ser Ser Thr Leu Ser Pro Glu Lys Gly Lys Ala 165 170 175 Lys Asn Pro Pro Gly Asp Ser Ser Leu His Trp Ala Ala Met Ala Leu 180 185 190 Pro Ala Leu Phe Ser Leu Ile Ile Gly Phe Ala Phe Gly Ala Leu Tyr 195 200 205 Trp Lys Lys Arg Gln Pro Ser Leu Thr Arg Ala Val Glu Asn Ile Gln 210 215 220 Ile Asn Glu Glu Asp Asn Glu Ile Ser Met Leu Gln Glu Lys Glu Arg 225 230 235 240 Glu Phe Gln Glu Val 245 

What is claimed is:
 1. A method of inhibiting or treating a tumor or infectious lesion in a subject, comprising: administering into or near a site of a tumor or infectious lesion in a subject an effective amount of an antigen presenting cell and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine.
 2. The method of claim 1, wherein the antigen presenting cell is a dendritic cell.
 3. The method of claim 2, wherein the dendritic cell is selected from the group consisting of a CD34+-derived dendritic cell, a bone marrow-derived dendritic cell, a monocyte-derived dendritic cell, a splenocyte derived dendritic cell, a skin-derived dendritic cell, a follicular dendritic cell, and a germinal center dendritic cell.
 4. The method of claim 1, wherein the dendritic cell is a CD34+-derived dendritic cell cultured in the presence of at least one factor selected from the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulatory factor, tumor necrosis factor alpha, interleukin 4, the Flt-3 ligand, and the kit ligand.
 5. The method of claim 1, wherein the antigen presenting cell is selected from a group consisting of a Langherhans' cell, an interdigitating cell, a B cell, and a macrophage.
 6. The method of claim 1, wherein the immunostimulatory cytokine is selected from the group consisting of interleukin-1 a, interleukin-1 P, interleukin-2, interleukin-3, interleukin-4, interleukin-6, interleukin-8, interleukin-9, interleukin-10, interleukin-12, interleukin-18, interleukin-19, interleukin-20, interleukin-23, interleukin-27, interleukin-1f3, interleukin-1f5, interleukin-1f6, interleukin-1f7, interleukin-1f8, interleukin-1f9, interleukin-1f10, interferon-α, interferon-β, interferon-γ, tumor necrosis factor α, transforming growth factor, granulocyte colony stimulating factor, macrophage colony stimulating factor, granulocyte-macrophage colony stimulating factor, the Flt-3 ligand, and the kit ligand.
 7. The method of claim 1, wherein the expression vector is a viral vector.
 8. The method of claim 2, wherein the expression vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a lentiviral vector, a herpes viral vector, and a vaccinia viral vector.
 9. The method of claim 1, wherein the subject has a tumor selected from the group consisting of melanoma, hepatoma, adenocarcinoma, colorectal cancer, basal cell cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, bladder cancer, head and neck cancer, renal cell cancer, pancreatic cancer, pulmonary cancer, cervical cancer, ovarian cancer, esophageal cancer, gastric cancer, prostate cancer, testicular cancer, and breast cancer.
 10. The method of claim 1, wherein the size of the tumor or infectious lesion is decreased.
 11. The method of claim 1, wherein said administering step comprises injecting into the tumor or infectious lesion.
 12. The method of claim 1, wherein said administering step comprises injecting the subject within the same organ as the tumor or infectious lesion.
 13. A method of inhibiting or treating metastasis of a tumor in a subject, comprising: administer into or near a site of a tumor in a subject an effective amount of an antigen presenting cell and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine.
 14. The method of claim 13, wherein the antigen presenting cell is a dendritic cell.
 15. The method of claim 14, wherein the dendritic cell is selected from the group consisting of a CD34+-derived dendritic cell, a bone marrow-derived dendritic cell, a monocyte-derived dendritic cell, a splenocyte derived dendritic cell, a skin-derived dendritic cell, a follicular dendritic cell, and a germinal center dendritic cell.
 16. The method of claim 13, wherein the dendritic cell is a CD34+-derived dendritic cell cultured in the presence of at least one factor selected from the group consisting of granulocyte colony stimulating factor, granulocyte macrophage colony stimulatory factor, tumor necrosis factor alpha, interleukin 4, the Flt-3 ligand, and the kit ligand.
 17. The method of claim 13, wherein the antigen presenting cell is selected from a group consisting of a Langherhans' cell, an interdigitating cell, a B cell, and a macrophage.
 18. The method of claim 13, wherein the immunostimulatory cytokine is selected from the group consisting of interleukin-1α, interleukin-1β, interleukin-2, interleukin-3, interleukin-4, interleukin-6, interleukin-8, interleukin-9, interleukin-10, interleukin-12, interleukin-18, interleukin-19, interleukin-20, interleukin-23, interleukin-27, interleukin-1f3, interleukin-1f5, interleukin-1f6, interleukin-1f7, interleukin-1f8, interleukin-1f9, interleukin-1f10, interferon-α, interferon-β, interferon-γ, tumor necrosis factor α, transforming growth factor-β, granulocyte colony stimulating factor, macrophage colony stimulating factor, granulocyte-macrophage colony stimulating factor, the Flt-3 ligand, and the kit ligand.
 19. The method of claim 13, wherein the expression vector is a viral vector.
 20. The method of claim 13, wherein the expression vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a retroviral vector, a lentiviral vector, a herpes viral vector, and a vaccinia viral vector.
 21. The method of claim 13, wherein the subject has a tumor selected from the group consisting of melanoma, hepatoma, adenocarcinoma, colorectal cancer, basal cell cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, bladder cancer, head and neck cancer, renal cell cancer, pancreatic cancer, pulmonary cancer, cervical cancer, ovarian cancer, esophageal cancer, gastric cancer, prostate cancer, testicular cancer, and breast cancer.
 22. The method of claim 13, wherein the size of the tumor or infectious lesion is decreased.
 23. The method of claim 13, wherein the size of the metastasis is decreased.
 24. The method of claim 13, wherein the number of the metastases is decreased.
 25. The method of claim 13, wherein said administering step comprises injecting into the tumor or infectious lesion.
 26. The method of claim 13, wherein said administering step comprises injecting the subject within the same organ as the tumor or infectious lesion.
 27. A therapeutic composition comprising an antigen presenting cell and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine. 